gene	variant	disease	drugs	drug_interaction_type	evidence_type	evidence_direction	evidence_level	clinical_significance	citation_id	evidence_status
MAP2K1	P124S	Melanoma	Selumetinib		Predictive	Supports	D	Resistance	19915144	accepted
MAP2K1	Q56P	Melanoma	Selumetinib		Predictive	Supports	D	Resistance	19915144	accepted
NRAS	Q61	Melanoma	Vemurafenib		Predictive	Supports	B	Resistance	23569304	accepted
PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Resistance	15928335	accepted
PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Resistance	16954519	accepted
ARAF	S214C	Lung Non-small Cell Carcinoma	Sorafenib		Predictive	Supports	C	Sensitivity/Response	24569458	accepted
DNMT3A	R882	Acute Myeloid Leukemia	Idarubicin		Predictive	Supports	B	Sensitivity/Response	22081665	accepted
JAK2	V617F	Polycythemia Vera	Fedratinib		Predictive	Supports	D	Sensitivity/Response	18394554	accepted
NRAS	G13D	Melanoma	Tanespimycin		Predictive	Supports	C	Sensitivity/Response	18375819	accepted
NRAS	Q61L	Melanoma	Temozolomide		Predictive	Supports	C	Sensitivity/Response	21576590	accepted
NRAS	Q61R	Melanoma	Temozolomide		Predictive	Supports	C	Sensitivity/Response	21576590	accepted
ALK	F1174L	Inflammatory Myofibroblastic Tumor	Crizotinib		Predictive	Supports	D	Resistance	21030459	accepted
ALK	F1174L	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	21030459	accepted
KIT	L576P	Melanoma	Nilotinib,Imatinib,Sorafenib	Substitutes	Predictive	Supports	D	Resistance	19671763	accepted
KRAS	G12/G13	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	15696205	accepted
NRAS	Q61	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	20619739	accepted
ALK	F1174L	Neuroblastoma	Alectinib		Predictive	Supports	D	Sensitivity/Response	21575866	accepted
ALK	F1174L	Neuroblastoma	Crizotinib		Predictive	Supports	D	Sensitivity/Response	21948233	accepted
ALK	R1275Q	Neuroblastoma	TAE684		Predictive	Supports	D	Sensitivity/Response	18923525	accepted
ARAF	S214C	Lung Non-small Cell Carcinoma	Sorafenib		Predictive	Supports	D	Sensitivity/Response	24569458	accepted
ARAF	S214C	Lung Non-small Cell Carcinoma	Trametinib		Predictive	Supports	D	Sensitivity/Response	24569458	accepted
KIT	L576P	Melanoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	19671763	accepted
PDGFRA	D842I	Gastrointestinal Stromal Tumor	Crenolanib		Predictive	Supports	D	Sensitivity/Response	22745105	accepted
PDGFRA	D842V	Gastrointestinal Stromal Tumor	Crenolanib		Predictive	Supports	D	Sensitivity/Response	22745105	accepted
PDGFRA	D842Y	Gastrointestinal Stromal Tumor	Crenolanib		Predictive	Supports	D	Sensitivity/Response	22745105	accepted
PDGFRA	I843DEL	Gastrointestinal Stromal Tumor	Crenolanib		Predictive	Supports	D	Sensitivity/Response	22745105	accepted
PDGFRA	D842_I843delinsVM	Gastrointestinal Stromal Tumor	Crenolanib		Predictive	Supports	D	Sensitivity/Response	22745105	accepted
ALK	R1275Q	Neuroblastoma	TAE684		Predictive	Supports	D	Resistance	18923525	accepted
KIT	EXON 11 MUTATION	Melanoma	Imatinib		Predictive	Supports	B	Sensitivity/Response	23775962	accepted
BRAF	V600E and V600M	Melanoma	Dabrafenib		Predictive	Supports	C	Sensitivity/Response	23031422	accepted
RET	C634W	Thyroid Gland Medullary Carcinoma	Motesanib		Predictive	Supports	D	Resistance	21422803	accepted
RET	M918T	Thyroid Gland Medullary Carcinoma	Motesanib		Predictive	Supports	D	Resistance	21422803	accepted
RET	M918T	Thyroid Gland Medullary Carcinoma	JAK2 Inhibitor AZD1480		Predictive	Supports	D	Sensitivity/Response	23056499	accepted
BRAF	V600	Colorectal Cancer	Panitumumab		Predictive	Supports	B	Resistance	23325582	accepted
BRAF	V600E	Colorectal Cancer	Panitumumab,Sorafenib	Combination	Predictive	Supports	D	Sensitivity/Response	19001320	accepted
BRAF	V600E	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24576830	accepted
BRAF	V600E	Lung Non-small Cell Carcinoma	Dabrafenib		Predictive	Supports	C	Resistance	23524406	accepted
BRAF	V600E and AMPLIFICATION	Colorectal Cancer	Selumetinib		Predictive	Supports	E	Resistance	21098728	accepted
BRAF	V600	Melanoma	Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	23020132	accepted
BRAF	V600D	Melanoma	Dabrafenib		Predictive	Supports	B	Sensitivity/Response	23463675	accepted
BRAF	V600E	Melanoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	24583796	accepted
BRAF	V600E	Colorectal Cancer	Pictilisib Bismesylate,PLX4720	Combination	Predictive	Supports	D	Sensitivity/Response	23845441	accepted
BRAF	V600E	Colorectal Cancer	PLX4720,Nutlin-3	Combination	Predictive	Supports	D	Sensitivity/Response	23812671	accepted
BRAF	V600E	Colorectal Cancer	Capecitabine,Bevacizumab,Vemurafenib	Combination	Predictive	Supports	D	Sensitivity/Response	22180495	accepted
BRAF	V600E	Colorectal Cancer	Vemurafenib		Predictive	Supports	D	Sensitivity/Response	22180495	accepted
ALK	F1174L	Neuroblastoma	Crizotinib		Predictive	Supports	D	Resistance	22072639	accepted
BRAF	V600E	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	20619739	accepted
FLT3	ITD	Acute Myeloid Leukemia	Tretinoin		Predictive	Supports	B	Resistance	19965647	accepted
FLT3	ITD	Acute Myeloid Leukemia	Daunorubicin		Predictive	Supports	D	Resistance	15626738	accepted
FLT3	ITD	Acute Myeloid Leukemia	SU5614		Predictive	Supports	D	Resistance	15626738	accepted
KRAS	G12/G13	Colorectal Cancer	Chemotherapy,Cetuximab	Combination	Predictive	Supports	B	Resistance	20619739	accepted
KRAS	G12/G13	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	18202412	accepted
KRAS	G12V	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	20978259	accepted
NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Tretinoin		Predictive	Supports	B	Resistance	19965647	accepted
PIK3CA	EXON 21 MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	20619739	accepted
WT1	EXON 7 MUTATION	Acute Myeloid Leukemia	Cytarabine,Daunorubicin	Combination	Predictive	Supports	B	Resistance	18591546	accepted
ALK	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	D	Sensitivity/Response	21575866	accepted
ALK	F1174L	Neuroblastoma	TAE684		Predictive	Supports	D	Sensitivity/Response	18923525	accepted
ALK	R1275Q	Neuroblastoma	Crizotinib		Predictive	Supports	D	Sensitivity/Response	22072639	accepted
FGFR3	FGFR3-BAIAP2L1	Bladder Carcinoma	PD173074		Predictive	Supports	D	Sensitivity/Response	23558953	accepted
KRAS	G13D	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Sensitivity/Response	20978259	accepted
NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Tretinoin		Predictive	Supports	B	Sensitivity/Response	19059939	accepted
NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Daunorubicin		Predictive	Supports	B	Sensitivity/Response	22417203	accepted
NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Valproic Acid		Predictive	Supports	B	Sensitivity/Response	24797300	accepted
NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Tretinoin,NSC348884	Combination	Predictive	Supports	D	Sensitivity/Response	21719597	accepted
NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Anti-CD33,Anti-CD123	Combination	Predictive	Supports	E	Sensitivity/Response	24927407	accepted
NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Anti-CD33		Predictive	Supports	E	Sensitivity/Response	24927407	accepted
NPM1	W288FS	Acute Myeloid Leukemia	NSC348884		Predictive	Supports	D	Sensitivity/Response	21719597	accepted
NPM1	W288FS	Acute Myeloid Leukemia	Induction Therapy		Predictive	Supports	E	Sensitivity/Response	15659725	accepted
TSC1	FRAMESHIFT TRUNCATION	Lung Non-small Cell Carcinoma	Sirolimus		Predictive	Supports	D	Sensitivity/Response	19966866	accepted
TSC1	LOSS-OF-FUNCTION	Bladder Carcinoma	Everolimus		Predictive	Supports	B	Sensitivity/Response	22923433	accepted
BRCA1	LOSS-OF-FUNCTION	Ovarian Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	23346317	accepted
BRCA2	LOSS-OF-FUNCTION	Ovarian Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	23346317	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	24736073	accepted
ABL1	BCR-ABL	Acute Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	12476305	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	15194504	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	B	Resistance	20537386	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	15194504	accepted
ALK	EML4-ALK C1156Y and L1196M	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	20979473	accepted
ALK	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Resistance	20979473	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	A	Resistance	25668228	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Resistance	15728811	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Dacomitinib		Predictive	Supports	B	Resistance	21430269	accepted
ERBB2	L755S	Breast Cancer	Lapatinib		Predictive	Supports	D	Resistance	23220880	accepted
ESR1	L536Q	Breast Cancer	Hormone Therapy		Predictive	Supports	D	Resistance	24185512	accepted
ESR1	D538G	Breast Cancer	Hormone Therapy		Predictive	Supports	D	Resistance	24185512	accepted
ESR1	Y537C	Breast Cancer	Hormone Therapy		Predictive	Supports	D	Resistance	24185512	accepted
ESR1	Y537N	Breast Cancer	Hormone Therapy		Predictive	Supports	D	Resistance	24185512	accepted
ESR1	Y537S	Breast Cancer	Hormone Therapy		Predictive	Supports	D	Resistance	24185512	accepted
FLT3	TKD MUTATION	Acute Myeloid Leukemia	Sorafenib		Predictive	Supports	B	Resistance	22368270	accepted
FLT3	TKD MUTATION	Acute Myeloid Leukemia	Sorafenib		Predictive	Supports	B	Resistance	18230792	accepted
KIT	V654A	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	D	Resistance	16954519	accepted
KRAS	EXON 2 MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	16618717	accepted
KRAS	G12A	Lung Adenocarcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	19794967	accepted
PIK3CA	E542K	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	19223544	accepted
ABL1	BCR-ABL	Acute Myeloid Leukemia	Imatinib		Predictive	Supports	A	Sensitivity/Response	12476305	accepted
ABL1	BCR-ABL	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	A	Sensitivity/Response	20537386	accepted
ABL1	BCR-ABL	Chronic Myeloid Leukemia	Dasatinib,Nilotinib	Substitutes	Predictive	Supports	A	Sensitivity/Response	20537386	accepted
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	20979473	accepted
CCND3	LOSS	T-cell Lymphoblastic Leukemia/lymphoma	Palbociclib		Predictive	Supports	D	Sensitivity/Response	23079656	accepted
CDK4	EXPRESSION	Estrogen-receptor Positive Breast Cancer	Alpelisib		Predictive	Supports	D	Sensitivity/Response	25002028	accepted
DDR2	G253C	Lung Non-small Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	22328973	accepted
DDR2	G505S	Lung Non-small Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	22328973	accepted
DDR2	G774V	Lung Non-small Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	22328973	accepted
DDR2	I638F	Lung Non-small Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	22328973	accepted
DDR2	L239R	Lung Non-small Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	22328973	accepted
DDR2	L63V	Lung Non-small Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	22328973	accepted
DDR2	S768R	Lung Non-small Cell Carcinoma	Dasatinib,Erlotinib	Combination	Predictive	Supports	C	Sensitivity/Response	22328973	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	D	Sensitivity/Response	16730237	accepted
EGFR	G719S	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	D	Sensitivity/Response	15118125	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	24457318	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	D	Sensitivity/Response	15118125	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Pemetrexed,Erlotinib	Combination	Predictive	Supports	C	Sensitivity/Response	24636847	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Staurosporine		Predictive	Supports	E	Sensitivity/Response	24658966	accepted
ERBB2	D769H	Breast Cancer	Neratinib,Lapatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	D769Y	Breast Cancer	Neratinib		Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	DEL 755-759	Breast Cancer	Neratinib,Lapatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	G309A	Breast Cancer	Neratinib		Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	L755S	Breast Cancer	Neratinib		Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	L755W	Breast Cancer	Neratinib		Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	P780INS	Breast Cancer	Neratinib		Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	R678Q	Breast Cancer	Lapatinib,Neratinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	R896C	Breast Cancer	Neratinib		Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	V777L	Breast Cancer	Neratinib		Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ERBB2	V842I	Breast Cancer	Neratinib		Predictive	Supports	D	Sensitivity/Response	23220880	accepted
ESR1	L536Q	Breast Cancer	Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	24185510	accepted
ESR1	D538G	Breast Cancer	Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	24185510	accepted
ESR1	Y537C	Breast Cancer	Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	24185510	accepted
ESR1	Y537N	Breast Cancer	Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	24185510	accepted
ESR1	Y537S	Breast Cancer	Fulvestrant,Tamoxifen	Substitutes	Predictive	Supports	D	Sensitivity/Response	24185510	accepted
FGFR2	FGFR2-MGEA5	Cholangiocarcinoma	Ponatinib		Predictive	Supports	C	Sensitivity/Response	24550739	accepted
FGFR2	FGFR2-TACC3	Cholangiocarcinoma	Ponatinib,Pazopanib	Sequential	Predictive	Supports	C	Sensitivity/Response	24550739	accepted
FLT3	ITD	Acute Myeloid Leukemia	Lestaurtinib		Predictive	Supports	B	Sensitivity/Response	14726387	accepted
FLT3	ITD	Acute Myeloid Leukemia	Sorafenib		Predictive	Supports	B	Sensitivity/Response	18230792	accepted
FLT3	ITD	Acute Myeloid Leukemia	Tyrphostin AG 1296		Predictive	Supports	D	Sensitivity/Response	12357354	accepted
GATA2	EXPRESSION	Lung Adenocarcinoma	Bortezomib,Fasudil	Combination	Predictive	Supports	D	Sensitivity/Response	22541434	accepted
KIT	INTERNAL DUPLICATION	Malignant Anus Melanoma	Imatinib		Predictive	Supports	C	Sensitivity/Response	18421059	accepted
KIT	L576P	Lung Non-small Cell Carcinoma	Dasatinib,Nilotinib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	17372901	accepted
KIT	V654A	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	B	Sensitivity/Response	16638875	accepted
KRAS	G12D	Lung Non-small Cell Carcinoma	Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	19029981	accepted
KRAS	G13D	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Sensitivity/Response	20978259	accepted
MGMT	PROMOTER METHYLATION	Glioblastoma Multiforme	Temozolomide		Predictive	Supports	A	Sensitivity/Response	15758010	accepted
MGMT	PROMOTER METHYLATION	Glioblastoma Multiforme	Carmustine		Predictive	Supports	B	Sensitivity/Response	11070098	accepted
MGMT	PROMOTER METHYLATION	Glioblastoma Multiforme	O6-Benzylguanine		Predictive	Supports	E	Sensitivity/Response	11070098	accepted
PIK3CA	E542K	Breast Cancer	PI3K-alpha Inhibitor MEN1611		Predictive	Supports	D	Sensitivity/Response	21558396	accepted
PIK3CA	E542K	Breast Cancer	Sirolimus		Predictive	Supports	D	Sensitivity/Response	15647370	accepted
PIK3CA	H1047R	Breast Cancer	PI3K-alpha Inhibitor MEN1611		Predictive	Supports	D	Sensitivity/Response	21558396	accepted
PML	PML-RARA	Acute Promyelocytic Leukemia	Tretinoin		Predictive	Supports	B	Sensitivity/Response	8674046	accepted
PTEN	R233*	Breast Cancer	MTOR Inhibitor		Predictive	Supports	D	Sensitivity/Response	20085938	accepted
TP53	R175H	Breast Cancer	Doxorubicin		Predictive	Supports	D	Sensitivity/Response	22698404	accepted
TSC1	FRAMESHIFT TRUNCATION	Invasive Bladder Transitional Cell Carcinoma	Everolimus		Predictive	Supports	B	Sensitivity/Response	22923433	accepted
ABL1	BCR-ABL	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	A	Sensitivity/Response	20537386	accepted
PIK3CA	E545K	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	C	Resistance	19223544	accepted
PIK3CA	H1047R	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	C	Resistance	19223544	accepted
TP53	R249	Breast Cancer	Doxorubicin		Predictive	Supports	B	Sensitivity/Response	9569050	accepted
CSF1R	MEF2D-CSF1R	Acute Lymphoblastic Leukemia	GW-2580,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24186003	accepted
RUNX1	MUTATION	Acute Myeloid Leukemia	Cytarabine		Predictive	Supports	B	Resistance	21343560	accepted
IGF2	OVEREXPRESSION	Prostate Cancer	Linsitinib		Predictive	Supports	D	N/A	25670080	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	16818686	accepted
IGF2	OVEREXPRESSION	Prostate Cancer	Linsitinib,Docetaxel,Cabazitaxel	Substitutes	Predictive	Supports	D	Sensitivity/Response	25670080	accepted
BTK	C481S	Chronic Lymphocytic Leukemia	Ibrutinib		Predictive	Supports	B	Resistance	24869598	accepted
AKT1	Q79K	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265152	accepted
ALK	EML4-ALK and AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	22277784	accepted
ALK	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	22277784	accepted
ALK	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	22277784	accepted
ALK	EML4-ALK S1206Y	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	22277784	accepted
ALK	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	22277784	accepted
APC	MUTATION	Colon Carcinoma	JW55		Predictive	Supports	D	Sensitivity/Response	22440753	accepted
APC	MUTATION	Colorectal Cancer	G007-LK		Predictive	Supports	D	Sensitivity/Response	23539443	accepted
AR	F877L	Prostate Cancer	Apalutamide,Enzalutamide	Substitutes	Predictive	Supports	D	Resistance	23779130	accepted
AR	W742	Prostate Carcinoma	Bicalutamide		Predictive	Supports	D	Resistance	12517791	accepted
ATM	MUTATION	Glioblastoma Multiforme	Temozolomide		Predictive	Supports	D	Sensitivity/Response	23960094	accepted
ATM	MUTATION	Melanoma	Temozolomide		Predictive	Supports	D	Sensitivity/Response	23960094	accepted
ATM	UNDEREXPRESSION	Cancer	KU-0060648,NU7441	Substitutes	Predictive	Supports	D	Sensitivity/Response	23761041	accepted
ATM	MUTATION	Hematologic Cancer	Olaparib		Predictive	Supports	D	Sensitivity/Response	20739657	accepted
AURKA	AMPLIFICATION	Esophagus Adenocarcinoma	Cisplatin,Alisertib	Combination	Predictive	Supports	E	Sensitivity/Response	22302096	accepted
AURKA	OVEREXPRESSION	Cervical Adenocarcinoma	Paclitaxel		Predictive	Supports	D	Resistance	12559175	accepted
KIT	V560DEL	Thymic Carcinoma	Imatinib		Predictive	Supports	C	Sensitivity/Response	15201427	accepted
PTEN	LOSS	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	21163703	accepted
PTEN	LOSS	Prostate Cancer	Temsirolimus		Predictive	Supports	D	Sensitivity/Response	11504908	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	B	Sensitivity/Response	11248153	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	B	Sensitivity/Response	15911866	accepted
KRAS	G12/G13	Pancreatic Adenocarcinoma	Gemcitabine,Trametinib	Combination	Predictive	Supports	B	Resistance	24915778	accepted
CDK12	LOSS-OF-FUNCTION	Ovarian Serous Carcinoma	Olaparib		Predictive	Supports	D	Sensitivity/Response	24240700	accepted
NT5C2	R367Q	T-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	23377281	accepted
NT5C2	K359Q	T-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	23377281	accepted
NT5C2	D407A	T-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	23377281	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	B	Resistance	18818391	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Ponatinib		Predictive	Supports	D	Sensitivity/Response	24236021	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Ponatinib		Predictive	Supports	B	Sensitivity/Response	25349473	accepted
EGFR	T790M	Lung Cancer	Multikinase Inhibitor AEE788,Gefitinib	Sequential	Predictive	Supports	D	Resistance	18227510	accepted
PTEN	LOSS	Bladder Carcinoma	Everolimus		Predictive	Supports	B	Resistance	23989949	accepted
PTEN	LOSS	Breast Cancer	Trastuzumab		Predictive	Supports	B	Resistance	24387334	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Rociletinib		Predictive	Supports	B	Sensitivity/Response	25923550	accepted
ATM	V2288FS*1	Prostate Cancer	Olaparib		Predictive	Supports	C	Sensitivity/Response	26510020	accepted
ATM	N2875H	Prostate Cancer	Olaparib		Predictive	Supports	C	Sensitivity/Response	26510020	accepted
NF2	Y177FS	Peritoneal Mesothelioma	Cisplatin,Carboplatin	Substitutes	Predictive	Supports	C	Resistance	25798586	accepted
BRCA2	LOSS-OF-FUNCTION	Prostate Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	26510020	accepted
PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	D	Resistance	12949711	accepted
PDGFRA	V561A	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	D	Sensitivity/Response	12949711	accepted
KIT	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Sensitivity/Response	14645423	accepted
XRCC1	R194W	Lung Non-small Cell Carcinoma	Docetaxel,Gemcitabine,Vinorelbine	Substitutes	Predictive	Supports	B	Sensitivity/Response	19157633	accepted
GSTP1	DELETION	Ovarian Carcinoma	Cisplatin,Carboplatin,Paclitaxel	Substitutes	Predictive	Supports	D	Sensitivity/Response	25010864	accepted
BIRC7	AMPLIFICATION	Colon Cancer	Cisplatin		Predictive	Supports	D	Resistance	23188704	accepted
EGFR	EXON 4 DELETION	Epithelial Ovarian Cancer	Cisplatin		Predictive	Supports	D	Resistance	23764753	accepted
KRAS	RS61764370	Epithelial Ovarian Cancer	Carboplatin,Paclitaxel	Substitutes	Predictive	Supports	B	Resistance	22139083	accepted
MTHFR	A222V	Stomach Cancer	Fluorouracil		Predictive	Supports	B	Sensitivity/Response	18704422	accepted
GSTP1	I105V	Colorectal Cancer	FOLFOX Regimen		Predictive	Supports	B	Sensitivity/Response	19922504	accepted
XRCC1	Q399R	Cervical Cancer	Carboplatin,Cisplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	16875718	accepted
ABCB1	S893T	Ovarian Cancer	Paclitaxel		Predictive	Supports	B	Sensitivity/Response	16467099	accepted
ABCB1	I1145I	Lung Non-small Cell Carcinoma	Cisplatin,Carboplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	22296372	accepted
ERCC2	K751Q	Osteosarcoma	Cisplatin		Predictive	Supports	B	Resistance	19434073	accepted
ERCC2	K751Q	Lung Non-small Cell Carcinoma	Carboplatin,Paclitaxel	Combination	Predictive	Supports	B	Sensitivity/Response	19470925	accepted
TYMS	5' TANDEM REPEAT	Colorectal Cancer	Fluorouracil,Irinotecan	Combination	Predictive	Supports	B	Resistance	20628391	accepted
LRP1B	EXON 12-22 DELETION	Ovarian Cancer	Doxorubicin		Predictive	Supports	D	Resistance	22896685	accepted
FGFR1	AMPLIFICATION	Lung Squamous Cell Carcinoma	PD173074		Predictive	Supports	D	Sensitivity/Response	21160078	accepted
FGFR1	EXPRESSION	Lung Cancer	Ponatinib		Predictive	Supports	D	Sensitivity/Response	24771645	accepted
FGFR1	AMPLIFICATION	Lung Non-small Cell Carcinoma	PD173074		Predictive	Supports	D	Sensitivity/Response	21666749	accepted
ROS1	REARRANGEMENT	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	25264305	accepted
MET	AMPLIFICATION	Gastric Adenocarcinoma	Onartuzumab		Predictive	Supports	C	Sensitivity/Response	22389872	accepted
EGFR	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	22056021	accepted
CDKN2A	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	Panitumumab		Predictive	Supports	B	Resistance	23746666	accepted
RET	KIF5B-RET	Lung Adenocarcinoma	Vandetanib		Predictive	Supports	C	Sensitivity/Response	23584301	accepted
HRAS	G13D	Colorectal Cancer	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	C	Resistance	26561417	accepted
HRAS	MUTATION	Cancer	Binimetinib,MTOR Kinase Inhibitor AZD8055,Selumetinib,MEK Inhibitor PD0325901,Everolimus	Substitutes	Predictive	Supports	D	Sensitivity/Response	26544513	accepted
CD274	EXPRESSION	Melanoma	Nivolumab,Pembrolizumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	26086854	accepted
MTOR	MUTATION	Bladder Carcinoma	Pazopanib,Everolimus	Combination	Predictive	Supports	C	Sensitivity/Response	24625776	accepted
AKT2	EXPRESSION	Breast Cancer	Trastuzumab		Predictive	Supports	B	Sensitivity/Response	22842582	accepted
AKT1	E17K	Melanoma	Uprosertib		Predictive	Supports	D	Sensitivity/Response	24735930	accepted
PTEN	LOSS	Melanoma	Uprosertib		Predictive	Supports	D	Sensitivity/Response	24735930	accepted
AKT1	E17K	Breast Cancer	Capivasertib		Predictive	Supports	C	Sensitivity/Response	26351323	accepted
PIK3CA	E545K	Breast Cancer	Pictilisib,Akt Inhibitor MK2206	Substitutes	Predictive	Supports	D	Sensitivity/Response	23888070	accepted
PTEN	LOSS	Breast Cancer	PI3Kbeta Inhibitor AZD8186		Predictive	Supports	D	Sensitivity/Response	25398829	accepted
MTOR	H1968Y	Melanoma	Capivasertib,PI3K/BET Inhibitor LY294002	Substitutes	Predictive	Supports	D	Sensitivity/Response	26490311	accepted
PTEN	LOSS	Cancer	Carboplatin,Buparlisib,Paclitaxel	Combination	Predictive	Supports	B	Sensitivity/Response	25672916	accepted
NF2	K159FS*16	Breast Cancer	Temsirolimus		Predictive	Supports	C	Sensitivity/Response	25878190	accepted
PTEN	LOSS	Breast Cancer	Alpelisib		Predictive	Supports	D	Resistance	25409150	accepted
EGFR	S492R	Colorectal Cancer	Cetuximab		Predictive	Supports	C	Resistance	22270724	accepted
FBXW7	MUTATION	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	26508446	accepted
SMAD4	MUTATION	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	26508446	accepted
SMAD4	UNDEREXPRESSION	Head And Neck Squamous Cell Carcinoma	Cetuximab		Predictive	Supports	D	Resistance	26046389	accepted
MTOR	P2213S	Melanoma	PI3K/BET Inhibitor LY294002,Capivasertib	Combination	Predictive	Supports	D	Sensitivity/Response	26490311	accepted
BRAF	AGK-BRAF	Melanoma	Sorafenib		Predictive	Supports	C	Sensitivity/Response	23890088	accepted
BRAF	AGK-BRAF	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	23890088	accepted
BRAF	PAPSS1-BRAF	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24345920	accepted
BRAF	PAPSS1-BRAF	Melanoma	Trametinib		Predictive	Supports	D	Sensitivity/Response	24345920	accepted
BRAF	TRIM24-BRAF	Melanoma	Trametinib		Predictive	Supports	D	Sensitivity/Response	24345920	accepted
BRAF	L597R	Melanoma	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	23715574	accepted
ERBB3	OVEREXPRESSION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	25520391	accepted
NT5E	OVEREXPRESSION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Sensitivity/Response	25520391	accepted
IDH1	R132C	Acute Myeloid Leukemia	GSK321		Predictive	Supports	D	Sensitivity/Response	26436839	accepted
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	D	Resistance	17463250	accepted
MYD88	OVEREXPRESSION	Breast Cancer	Paclitaxel		Predictive	Supports	D	Resistance	26596839	accepted
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	21623265	accepted
MET	EXON 14 SKIPPING MUTATION	Cancer	Crizotinib		Predictive	Supports	D	Sensitivity/Response	26547802	accepted
EGFR	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	26439803	accepted
PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Resistance	26130666	accepted
PIK3CA	P471L	Merkel Cell Carcinoma	Idelalisib		Predictive	Supports	C	Sensitivity/Response	26466009	accepted
RET	EXPRESSION	Breast Cancer	Vandetanib		Predictive	Supports	D	Sensitivity/Response	26686064	accepted
RIT1	MUTATION	Lung Adenocarcinoma	Pictilisib,Selumetinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24469055	accepted
CD274	EXPRESSION	Lung Non-small Cell Carcinoma	Nivolumab,Pembrolizumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	26086854	accepted
MYCN	AMPLIFICATION	Neuroblastoma	FACT Complex-targeting Curaxin CBL0137		Predictive	Supports	D	Sensitivity/Response	26537256	accepted
SMO	D473H	Brain Medulloblastoma	Vismodegib		Predictive	Supports	C	Resistance	19726788	accepted
SMO	MUTATION	Basal Cell Carcinoma	Vismodegib		Predictive	Supports	B	Resistance	25759020	accepted
SMO	MUTATION	Basal Cell Carcinoma	PSI,Arsenic Trioxide	Substitutes	Predictive	Supports	D	Sensitivity/Response	25759020	accepted
PTCH1	MUTATION	Brain Medulloblastoma	Sonidegib		Predictive	Supports	B	Sensitivity/Response	24651015	accepted
PTCH1	LOH	Brain Medulloblastoma	Vismodegib		Predictive	Supports	B	Sensitivity/Response	26169613	accepted
STK11	UNDEREXPRESSION	Prostate Cancer	SB202190		Predictive	Supports	D	Sensitivity/Response	26391455	accepted
SYK	OVEREXPRESSION	Ovarian Cancer	Paclitaxel		Predictive	Supports	D	Resistance	26096845	accepted
CDKN2A	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	Panitumumab		Predictive	Supports	B	Sensitivity/Response	23746666	accepted
SMO	D473H	Basal Cell Carcinoma	Vismodegib		Predictive	Supports	D	Resistance	25759020	accepted
PIK3CA	AMPLIFICATION	Epithelial Ovarian Cancer	Pictilisib		Predictive	Supports	C	Sensitivity/Response	25370471	accepted
BRAF	V600E	Melanoma	Pictilisib		Predictive	Supports	C	Sensitivity/Response	25370471	accepted
ERBB2	AMPLIFICATION	Breast Cancer	AKTi-1/2		Predictive	Supports	D	Sensitivity/Response	18725974	accepted
ERBB2	AMPLIFICATION	Breast Cancer	Neratinib		Predictive	Supports	B	Sensitivity/Response	20142587	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Rociletinib		Predictive	Supports	D	Sensitivity/Response	24065731	accepted
ALK	EML4-ALK L1152R	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	21791641	accepted
ALK	EML4-ALK G1269A	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	22235099	accepted
ALK	EML4-ALK G1269A	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	23344087	accepted
ALK	EML4-ALK and AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	22235099	accepted
ALK	EML4-ALK and AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	23344087	accepted
ERBB4	MUTATION	Melanoma	Lapatinib		Predictive	Supports	D	Sensitivity/Response	19718025	accepted
PIK3CA	MUTATION	Colorectal Cancer	Cabozantinib		Predictive	Supports	D	Sensitivity/Response	25242168	accepted
EGFR	VIII	Glioblastoma Multiforme	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	16282176	accepted
EGFR	VIII	Glioblastoma Multiforme	Afatinib		Predictive	Supports	C	Sensitivity/Response	26423602	accepted
PTEN	EXPRESSION	Glioblastoma Multiforme	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	16282176	accepted
PTEN	EXPRESSION	Glioblastoma Multiforme	Dacomitinib		Predictive	Supports	D	Sensitivity/Response	25939761	accepted
NRG1	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Lapatinib		Predictive	Supports	D	Sensitivity/Response	21840482	accepted
NRG1	EXPRESSION	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	21900593	accepted
NRG1	EXPRESSION	Ovarian Cancer	Seribantumab		Predictive	Supports	D	Sensitivity/Response	20227043	accepted
NRG1	EXPRESSION	Lung Non-small Cell Carcinoma	Cisplatin,Gemcitabine,Carboplatin,Paclitaxel	Substitutes	Predictive	Supports	D	Sensitivity/Response	23390248	accepted
AREG	EXPRESSION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	21791641	accepted
AREG	EXPRESSION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Resistance	23344087	accepted
EGFR	G724S	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Sensitivity/Response	24894453	accepted
EGFR	G719S	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Sensitivity/Response	24894453	accepted
AREG	EXPRESSION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Sensitivity/Response	23374602	accepted
EREG	EXPRESSION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Sensitivity/Response	23374602	accepted
MAPK1	E322K	Head And Neck Squamous Cell Carcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	26181029	accepted
MAPK1	AMPLIFICATION	Lung Non-small Cell Carcinoma	WZ4002		Predictive	Supports	D	Resistance	22961667	accepted
KRAS	A146V	Lung Non-small Cell Carcinoma	Abemaciclib		Predictive	Supports	C	Sensitivity/Response	24836576	accepted
KRAS	G12V	Lung Non-small Cell Carcinoma	Palbociclib		Predictive	Supports	D	Sensitivity/Response	20609353	accepted
MET	MUTATION	Papillary Renal Cell Carcinoma	Foretinib		Predictive	Supports	B	Sensitivity/Response	23213094	accepted
MET	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25971939	accepted
FGFR1	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Infigratinib		Predictive	Supports	D	Sensitivity/Response	26015511	accepted
FGFR1	EXPRESSION	Gastric Adenocarcinoma	Infigratinib		Predictive	Supports	D	Sensitivity/Response	26637881	accepted
FGFR1	EXPRESSION	Bladder Carcinoma	Dovitinib,PD173074	Substitutes	Predictive	Supports	D	Sensitivity/Response	21119661	accepted
FGFR3	EXPRESSION	Bladder Carcinoma	Dovitinib,Tyrosine Kinase Inhibitor SU5402,PD173074	Substitutes	Predictive	Supports	D	Sensitivity/Response	21119661	accepted
CBLC	EXPRESSION	Cancer	Olaparib		Predictive	Supports	D	Resistance	25883215	accepted
PTPRD	MUTATION	Head And Neck Carcinoma	JSI-124		Predictive	Supports	D	Sensitivity/Response	26267899	accepted
DEFA1	EXPRESSION	Prostate Cancer	Docetaxel		Predictive	Supports	B	Sensitivity/Response	26261420	accepted
NOTCH1	AMPLIFICATION	Colorectal Cancer	NOTCH1 Antibody (PF-06293622)		Predictive	Supports	D	Sensitivity/Response	26152787	accepted
NRG1	EXPRESSION	Lung Non-small Cell Carcinoma	Patritumab		Predictive	Supports	B	Sensitivity/Response	26137564	accepted
WEE1	RS3910384	Lung Non-small Cell Carcinoma	Gemcitabine,Platinum Compound	Combination	Predictive	Supports	B	Sensitivity/Response	26057002	accepted
FNTB	RS11623866	Ovarian Cancer	Lonafarnib		Predictive	Supports	B	Resistance	26033044	accepted
PTPRT	PROMOTER HYPERMETHYLATION	Head And Neck Squamous Cell Carcinoma	JSI-124,Stattic	Substitutes	Predictive	Supports	D	Sensitivity/Response	25982282	accepted
VEGFA	UNDEREXPRESSION	Colorectal Cancer	Bevacizumab,Fluorouracil,Levoleucovorin,Irinotecan	Combination	Predictive	Supports	B	Sensitivity/Response	25973082	accepted
DNMT1	EXPRESSION	Ovarian Cancer	Decitabine		Predictive	Supports	D	Sensitivity/Response	25968887	accepted
KRAS	MUTATION	Ovarian Cancer	Decitabine		Predictive	Supports	D	Sensitivity/Response	25968887	accepted
PDCD4	EXPRESSION	Lung Cancer	Paclitaxel		Predictive	Supports	B	Sensitivity/Response	25928036	accepted
MGMT	RS16906252	Glioblastoma Multiforme	Temozolomide		Predictive	Supports	B	Sensitivity/Response	25910840	accepted
TFF3	EXPRESSION	Breast Cancer	Aminoglutethimide,Tamoxifen	Substitutes	Predictive	Supports	B	Sensitivity/Response	25900183	accepted
DKK1	NUCLEAR EXPRESSION	Colorectal Cancer	Oxaliplatin,Fluorouracil,Levoleucovorin,Irinotecan	Combination	Predictive	Supports	B	Resistance	25788273	accepted
CD44	ISOFORM EXPRESSION	Cancer	RG7356		Predictive	Supports	D	Sensitivity/Response	25762343	accepted
EGF	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Cetuximab		Predictive	Supports	D	Resistance	25677871	accepted
MDM2	EXPRESSION	Malignant Pleural Mesothelioma	Cisplatin,Pemetrexed	Combination	Predictive	Supports	B	Resistance	25668009	accepted
HMOX1	EXPRESSION	Renal Cell Carcinoma	Sunitinib,Sorafenib	Substitutes	Predictive	Supports	B	Resistance	26309414	accepted
CASP8	EXPRESSION	Ewing Sarcoma Of Bone	Conatumumab		Predictive	Supports	D	Sensitivity/Response	26291055	accepted
TYMS	EXPRESSION	Lung Non-small Cell Carcinoma	Pemetrexed		Predictive	Supports	B	Resistance	26502926	accepted
PBK	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	D	Resistance	26745678	accepted
MET	AMPLIFICATION	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26724472	accepted
SMARCA4	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Cisplatin,Vinorelbine	Combination	Predictive	Supports	B	Sensitivity/Response	26671993	accepted
ALK	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	Ceritinib,Luminespib,Crizotinib	Sequential	Predictive	Supports	C	Resistance	26698910	accepted
ALK	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	Lorlatinib		Predictive	Supports	C	Sensitivity/Response	26698910	accepted
ALK	EML4-ALK C1156Y-L1198F	Lung Non-small Cell Carcinoma	Lorlatinib		Predictive	Supports	C	Resistance	26698910	accepted
ALK	EML4-ALK C1156Y-L1198F	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26698910	accepted
BRCA1	LOSS-OF-FUNCTION	Prostate Cancer	Olaparib		Predictive	Supports	C	Sensitivity/Response	26510020	accepted
AREG	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Docetaxel,Cetuximab	Combination	Predictive	Supports	B	Resistance	21653686	accepted
EGFR	VIII	Head And Neck Squamous Cell Carcinoma	Docetaxel,Cetuximab	Combination	Predictive	Supports	B	Resistance	21653686	accepted
TP53	MUTATION	Gastric Adenocarcinoma	Chemotherapy		Predictive	Supports	B	Sensitivity/Response	24740294	accepted
TP53	MUTATION	Breast Cancer	Doxorubicin		Predictive	Supports	D	Sensitivity/Response	22698404	accepted
CDKN1A	EXPRESSION	Colorectal Cancer	Fluorouracil		Predictive	Supports	B	Resistance	24708484	accepted
ALCAM	EXPRESSION	Colorectal Cancer	Fluorouracil		Predictive	Supports	B	Resistance	24708484	accepted
EGFR	AMPLIFICATION	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Sensitivity/Response	24653627	accepted
STMN1	EXPRESSION	Endometrial Carcinoma	Paclitaxel		Predictive	Supports	B	Resistance	24587245	accepted
CCND1	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Tamoxifen		Predictive	Supports	B	Resistance	15138475	accepted
RSF1	AMPLIFICATION	Breast Cancer	Tamoxifen		Predictive	Supports	B	Resistance	24367492	accepted
AR	OVEREXPRESSION	Breast Cancer	Dactolisib		Predictive	Supports	D	Sensitivity/Response	24356815	accepted
CDKN1B	CYTOPLASMIC MISLOCALIZATION	Breast Cancer	Lapatinib		Predictive	Supports	D	Resistance	25587029	accepted
NRG1	EXPRESSION	Cancer	Anti-ErbB3 Monoclonal Antibody AV-203		Predictive	Supports	D	Sensitivity/Response	25542901	accepted
AR	SPLICE VARIANT 7	Prostate Cancer	Enzalutamide,Abiraterone	Substitutes	Predictive	Supports	B	Resistance	25184630	accepted
PTEN	LOSS	Gastric Adenocarcinoma	Lapatinib,Trastuzumab	Substitutes	Predictive	Supports	B	Resistance	25300346	accepted
ERBB3	EXPRESSION	Pancreatic Ductal Adenocarcinoma	Pertuzumab,9F7-F11	Combination	Predictive	Supports	D	Sensitivity/Response	25216528	accepted
UGT1A	EXPRESSION	Colorectal Cancer	Ganetespib		Predictive	Supports	D	Resistance	25210794	accepted
ERBB4	NUCLEAR TRANSLOCATION	Breast Cancer	Trastuzumab		Predictive	Supports	D	Resistance	25153719	accepted
ERBB4	EXPRESSION	Breast Cancer	Trastuzumab		Predictive	Supports	D	Resistance	25153719	accepted
ERBB4	EXPRESSION	Breast Cancer	Lapatinib		Predictive	Supports	D	Resistance	25590338	accepted
SLFN11	EXPRESSION	Colorectal Cancer	7-Ethyl-10-Hydroxycamptothecin		Predictive	Supports	D	Sensitivity/Response	25089570	accepted
AURKA	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Cisplatin		Predictive	Supports	B	Resistance	25082261	accepted
KRAS	RS61764370	Head And Neck Squamous Cell Carcinoma	Cisplatin		Predictive	Supports	B	Resistance	25081901	accepted
RAC1	P29S	Melanoma	Vemurafenib,Dabrafenib	Substitutes	Predictive	Supports	D	Resistance	25056119	accepted
BIRC5	NUCLEAR EXPRESSION	Lung Non-small Cell Carcinoma	Taxane Compound,Platinum Compound	Combination	Predictive	Supports	B	Sensitivity/Response	24961465	accepted
TP53	WILD TYPE	Colorectal Cancer	Capecitabine,Cetuximab,Oxaliplatin	Combination	Predictive	Supports	B	Sensitivity/Response	24957073	accepted
MRE11	LOSS	Endometrial Cancer	Talazoparib		Predictive	Supports	D	Sensitivity/Response	24927325	accepted
ATM	UNDEREXPRESSION	Gastric Adenocarcinoma	Olaparib		Predictive	Supports	D	Sensitivity/Response	24841718	accepted
EGFR	L858R	Lung Adenocarcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	23816960	accepted
EGFR	EXON 19 DELETION	Lung Adenocarcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	23816960	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	25862853	accepted
EGFR	EXON 19 DELETION	Lung Adenocarcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	22452895	accepted
EGFR	L858R	Lung Adenocarcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	22452895	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	B	Sensitivity/Response	22285168	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	B	Sensitivity/Response	22285168	accepted
ERBB2	AMPLIFICATION	Uterine Corpus Endometrial Carcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	25268372	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib,Lapatinib,Trastuzumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	25537159	accepted
TOP1	AMPLIFICATION	Colorectal Cancer	Irinotecan		Predictive	Supports	B	Sensitivity/Response	24256029	accepted
CDKN1B	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Cisplatin,Fluorouracil	Combination	Predictive	Supports	B	Sensitivity/Response	24239278	accepted
MET	AMPLIFICATION	Lung Squamous Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	24192513	accepted
AGR2	EXPRESSION	Breast Cancer	Tamoxifen		Predictive	Supports	B	Resistance	24167368	accepted
FGFR1	EXPRESSION	Colorectal Cancer	Infigratinib		Predictive	Supports	D	Sensitivity/Response	24135816	accepted
NAPRT	PROMOTER HYPERMETHYLATION	Cancer	GNE-617		Predictive	Supports	D	Sensitivity/Response	24097869	accepted
EGFR	EXON 18 OVEREXPRESSION	Lung Non-small Cell Carcinoma	Erlotinib,Bevacizumab	Combination	Predictive	Supports	B	Sensitivity/Response	24039832	accepted
ZEB1	EXPRESSION	Mantle Cell Lymphoma	Gemcitabine,Cytarabine,Doxorubicin	Substitutes	Predictive	Supports	D	Resistance	24013721	accepted
ZEB1	EXPRESSION	Mantle Cell Lymphoma	Doxorubicin,Salinomycin	Combination	Predictive	Supports	D	Sensitivity/Response	24013721	accepted
TIMP1	OVEREXPRESSION	Breast Cancer	Fulvestrant		Predictive	Supports	D	Resistance	23881388	accepted
PTP4A3	OVEREXPRESSION	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Sensitivity/Response	23867504	accepted
TYMS	AMPLIFICATION	Lung Adenocarcinoma	Pemetrexed		Predictive	Supports	B	Resistance	23645741	accepted
IGF1R	EXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	D	Resistance	23619944	accepted
EPHB4	EXPRESSION	Colorectal Cancer	Bevacizumab		Predictive	Supports	B	Resistance	23579861	accepted
TP53	WILD TYPE	Esophageal Carcinoma	Chemotherapy		Predictive	Supports	B	Sensitivity/Response	23515910	accepted
TYMS	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Pemetrexed		Predictive	Supports	B	Sensitivity/Response	21367480	accepted
TYMS	UNDEREXPRESSION	Prostate Cancer	Pemetrexed		Predictive	Supports	C	Sensitivity/Response	24782778	accepted
TOP2A	EXPRESSION	Breast Cancer	Doxorubicin		Predictive	Supports	B	Sensitivity/Response	15486187	accepted
TOP1	EXPRESSION	Ovarian Cancer	Carboplatin,Topotecan,Cyclophosphamide	Combination	Predictive	Supports	B	Sensitivity/Response	19648970	accepted
EGFR	AMPLIFICATION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Sensitivity/Response	18794099	accepted
TOP1	EXPRESSION	Colorectal Cancer	Irinotecan		Predictive	Supports	B	Sensitivity/Response	19775480	accepted
PRKAA2	T172 PHOSPHORYLATION	Cancer	ACLY SiRNA		Predictive	Supports	E	Sensitivity/Response	23506848	accepted
HSPA5	EXPRESSION	Colorectal Cancer	Fluorouracil		Predictive	Supports	B	Sensitivity/Response	23456958	accepted
PIK3CA	MUTATION	Colorectal Cancer	Anti-EGFR Monoclonal Antibody		Predictive	Supports	B	Resistance	23435830	accepted
EIF4EBP1	PHOSPHORYLATION	Gastric Adenocarcinoma	Everolimus		Predictive	Supports	D	Sensitivity/Response	23340172	accepted
KIT	MUTATION	Gastrointestinal Stromal Tumor	Pictilisib,Imatinib	Combination	Predictive	Supports	D	Sensitivity/Response	23231951	accepted
TUBB3	EXPRESSION	Cancer	Paclitaxel		Predictive	Supports	D	Resistance	21576762	accepted
TUBB3	EXPRESSION	Breast Cancer	Taxane Compound		Predictive	Supports	B	Sensitivity/Response	23218766	accepted
TYMS	EXPRESSION	Lung Non-small Cell Carcinoma	Pemetrexed		Predictive	Supports	B	Resistance	23060591	accepted
EGFR	Y1092 PHOSPHORYLATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	22901364	accepted
IGF1R	NUCLEAR EXPRESSION	Sarcoma	IGF1R Monoclonal Antibody		Predictive	Supports	B	Sensitivity/Response	22682017	accepted
CFLAR	EXPRESSION	Prostate Cancer	Bicalutamide		Predictive	Supports	D	Resistance	22623731	accepted
PROM1	EXPRESSION	Hepatocellular Carcinoma	Sorafenib		Predictive	Supports	B	Resistance	22596232	accepted
TIMP1	OVEREXPRESSION	Breast Cancer	Paclitaxel		Predictive	Supports	B	Resistance	22544540	accepted
FOXP3	EXPRESSION	Breast Cancer	Epirubicin		Predictive	Supports	B	Sensitivity/Response	22431701	accepted
TYMS	EXPRESSION	Gastric Adenocarcinoma	Raltitrexed		Predictive	Supports	B	Resistance	22422354	accepted
RPS6	PHOSPHORYLATION	Gastric Adenocarcinoma	Everolimus		Predictive	Supports	D	Sensitivity/Response	22343617	accepted
JAK1	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Enzastaurin		Predictive	Supports	D	Sensitivity/Response	22333600	accepted
EIF4EBP1	PHOSPHORYLATION	Colorectal Cancer	MTOR Kinase Inhibitor PP242,Dactolisib,WYE354	Substitutes	Predictive	Supports	D	Resistance	22262166	accepted
BRCA1	EXPRESSION	Malignant Mesothelioma	Vinorelbine		Predictive	Supports	D	Sensitivity/Response	22190288	accepted
DUSP6	EXPRESSION	Cancer	Trametinib		Predictive	Supports	D	Sensitivity/Response	22169769	accepted
KRAS	MUTATION	Cancer	Trametinib		Predictive	Supports	D	Sensitivity/Response	22169769	accepted
BRAF	MUTATION	Cancer	Trametinib		Predictive	Supports	D	Sensitivity/Response	22169769	accepted
KRAS	G12D	Pancreatic Carcinoma	Akt Inhibitor MK2206		Predictive	Supports	C	Sensitivity/Response	22025163	accepted
PTEN	LOSS	Pancreatic Carcinoma	Akt Inhibitor MK2206		Predictive	Supports	C	Sensitivity/Response	22025163	accepted
HSPB1	EXPRESSION	Pancreatic Ductal Adenocarcinoma	Gemcitabine		Predictive	Supports	D	Sensitivity/Response	22004109	accepted
NQO1	EXPRESSION	Lung Cancer	Amrubicin		Predictive	Supports	D	Resistance	21964527	accepted
NQO1	P187S	Lung Cancer	Amrubicin		Predictive	Supports	D	Sensitivity/Response	21964527	accepted
BRCA1	UNDEREXPRESSION	Ovarian Cancer	Taxane Compound,Platinum Compound	Combination	Predictive	Supports	B	Sensitivity/Response	21920589	accepted
KRAS	MUTATION	Colorectal Cancer	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	21890455	accepted
ABCB1	EXPRESSION	Lung Non-small Cell Carcinoma	Paclitaxel		Predictive	Supports	D	Resistance	21883677	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Pemetrexed		Predictive	Supports	B	Sensitivity/Response	21642865	accepted
DNMT1	EXPRESSION	Gastric Adenocarcinoma	Cisplatin		Predictive	Supports	B	Resistance	21458988	accepted
KRAS	MUTATION	Colorectal Cancer	Dasatinib,Cetuximab	Combination	Predictive	Supports	D	Sensitivity/Response	20956938	accepted
EGFR	AMPLIFICATION	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	20826716	accepted
CXCR4	EXPRESSION	Gastric Adenocarcinoma	Docetaxel		Predictive	Supports	B	Resistance	20651371	accepted
MAGEH1	EXPRESSION	Bile Duct Adenocarcinoma	Gemcitabine		Predictive	Supports	D	Resistance	20088962	accepted
ABCC3	AMPLIFICATION	Breast Cancer	Monomethyl Auristatin E,Paclitaxel	Substitutes	Predictive	Supports	D	Resistance	18593940	accepted
ABCC10	EXPRESSION	Lung Non-small Cell Carcinoma	Paclitaxel		Predictive	Supports	D	Resistance	18445659	accepted
ASNS	AMPLIFICATION	Ovarian Cancer	Asparaginase		Predictive	Supports	D	Resistance	17088436	accepted
EGFR	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	16707605	accepted
PTEN	EXPRESSION	Breast Cancer	Trastuzumab		Predictive	Supports	B	Sensitivity/Response	16404430	accepted
POU5F1	EXPRESSION	Colon Cancer	Oxaliplatin		Predictive	Supports	D	Resistance	26398480	accepted
ERBB2	KINASE DOMAIN MUTATION	Lung Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	22325357	accepted
ERBB2	Y772_A775DUP	Lung Non-small Cell Carcinoma	Sirolimus,Afatinib	Combination	Predictive	Supports	D	Sensitivity/Response	19122144	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib		Predictive	Supports	B	Sensitivity/Response	22418700	accepted
ERBB2	AMPLIFICATION	Pancreatic Adenocarcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	26668065	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib		Predictive	Supports	D	Sensitivity/Response	24893891	accepted
EGFR	C797S	Lung Non-small Cell Carcinoma	Osimertinib		Predictive	Supports	B	Resistance	25939061	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib		Predictive	Supports	B	Sensitivity/Response	25923549	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib		Predictive	Supports	B	Sensitivity/Response	26720284	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Rociletinib,Osimertinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	26515464	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	26515464	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	26515464	accepted
EGFR	VIII	Glioblastoma Multiforme	Rindopepimut		Predictive	Supports	B	Sensitivity/Response	25586468	accepted
ERBB2	SERUM LEVELS	Breast Cancer	Lapatinib		Predictive	Supports	B	Sensitivity/Response	26811533	accepted
NTRK1	NTRK1 FUSIONS	Colorectal Cancer	Larotrectinib		Predictive	Supports	D	Sensitivity/Response	26716414	accepted
IDH1	R132H	Anaplastic Oligodendroglioma	AGI-5198		Predictive	Supports	D	Sensitivity/Response	23558169	accepted
EGFR	EXON 19 DELETION	Lung Adenocarcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	24439929	accepted
EGFR	L858R	Lung Adenocarcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	24439929	accepted
EGFR	EXON 19 DELETION	Lung Adenocarcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	25589191	accepted
HLA-DRA	EXPRESSION	Skin Melanoma	Pembrolizumab,Atezolizumab,Nivolumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	26822383	accepted
MYD88	L265P	Waldenström's Macroglobulinemia	Ibrutinib		Predictive	Supports	B	Sensitivity/Response	25853747	accepted
KRAS	MUTATION	Colorectal Cancer	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Combination	Predictive	Supports	D	Sensitivity/Response	25199829	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Combination	Predictive	Supports	D	Sensitivity/Response	25199829	accepted
KRAS	MUTATION	Colorectal Cancer	Trametinib,Afatinib	Combination	Predictive	Supports	D	Sensitivity/Response	24685132	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Afatinib,Trametinib	Combination	Predictive	Supports	D	Sensitivity/Response	24685132	accepted
KRAS	EXON 2 MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	A	Resistance	18946061	accepted
BRAF	V600	Melanoma	MEK Inhibitor RO4987655		Predictive	Supports	B	Sensitivity/Response	24947927	accepted
BRAF	WILD TYPE	Melanoma	MEK Inhibitor RO4987655		Predictive	Supports	B	Sensitivity/Response	24947927	accepted
NRAS	MUTATION	Melanoma	MEK Inhibitor RO4987655		Predictive	Supports	B	Sensitivity/Response	24947927	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Combination	Predictive	Supports	B	Sensitivity/Response	23200175	accepted
BRAF	V600	Melanoma	Refametinib		Predictive	Supports	C	Resistance	23434733	accepted
NRAS	Q61K	Neuroblastoma	Binimetinib,Everolimus	Combination	Predictive	Supports	D	Sensitivity/Response	26821351	accepted
KRAS	MUTATION	Pancreatic Adenocarcinoma	SCH772984,PI3Kbeta Inhibitor AZD8186	Combination	Predictive	Supports	D	Sensitivity/Response	26725216	accepted
KRAS	MUTATION	Colorectal Cancer	Teprotumumab,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	21985784	accepted
BRAF	V600E	Melanoma	Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	26678033	accepted
ERBB2	AMPLIFICATION	Breast Cancer	Trastuzumab,Lapatinib	Combination	Predictive	Supports	D	Sensitivity/Response	16091755	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	22493419	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Lapatinib	Combination	Predictive	Supports	B	Sensitivity/Response	20124187	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib		Predictive	Supports	B	Sensitivity/Response	22418700	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib		Predictive	Supports	B	Sensitivity/Response	26596672	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Afatinib,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	25370464	accepted
MRE11	FRAMESHIFT MUTATION	Prostate Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	26510020	accepted
EGFR	VIII	Brain Glioma	Nimotuzumab		Predictive	Supports	D	Sensitivity/Response	26778701	accepted
NTRK1	NTRK1 FUSIONS	Lung Adenocarcinoma	Larotrectinib,Lestaurtinib,Crizotinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24162815	accepted
AREG	EXPRESSION	Colorectal Cancer	Panitumumab		Predictive	Supports	B	Sensitivity/Response	26867820	accepted
EREG	EXPRESSION	Colorectal Cancer	Panitumumab		Predictive	Supports	B	Sensitivity/Response	26867820	accepted
ERBB2	AMPLIFICATION	Gastric Adenocarcinoma	Trastuzumab		Predictive	Supports	B	Sensitivity/Response	20728210	accepted
ERBB2	AMPLIFICATION	Gastric Adenocarcinoma	Lapatinib		Predictive	Supports	B	Sensitivity/Response	24868024	accepted
KIT	EXPRESSION	Endometrial Cancer	Imatinib		Predictive	Supports	C	Sensitivity/Response	18607592	accepted
KIT	EXPRESSION	Endometrial Cancer	Imatinib		Predictive	Supports	C	Sensitivity/Response	16487996	accepted
ROS1	REARRANGEMENT	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	25667280	accepted
VHL	LOSS	Renal Carcinoma	Temsirolimus		Predictive	Supports	D	Sensitivity/Response	16341243	accepted
FLT3	D835	Acute Myeloid Leukemia	Ponatinib,Quizartinib	Substitutes	Predictive	Supports	D	Resistance	23430109	accepted
FLT3	D835	Acute Myeloid Leukemia	SU5614		Predictive	Supports	D	Resistance	19318574	accepted
FLT3	D835	Acute Myeloid Leukemia	Quizartinib,Sorafenib	Substitutes	Predictive	Supports	B	Resistance	22504184	accepted
FLT3	D835	Acute Myeloid Leukemia	Sorafenib		Predictive	Supports	B	Resistance	22368270	accepted
FLT3	ITD	Acute Myeloid Leukemia	Sorafenib		Predictive	Supports	B	Sensitivity/Response	22368270	accepted
ERBB2	KINASE DOMAIN MUTATION	Lung Adenocarcinoma	Trastuzumab		Predictive	Supports	C	Sensitivity/Response	26598547	accepted
ERBB2	AMPLIFICATION	Lung Small Cell Carcinoma	Irinotecan,Trastuzumab	Combination	Predictive	Supports	C	Sensitivity/Response	25601188	accepted
ERBB2	Y772_A775DUP	Lung Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	26559459	accepted
ERBB2	Y772_A775DUP	Lung Carcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	19122144	accepted
ERBB2	P780INS	Lung Adenocarcinoma	Dacomitinib		Predictive	Supports	C	Sensitivity/Response	25899785	accepted
ERBB2	AMPLIFICATION	Lung Non-small Cell Carcinoma	Trastuzumab Emtansine		Predictive	Supports	D	Sensitivity/Response	24898067	accepted
EGFR	G465R	Colorectal Cancer	Futuximab/Modotuximab Mixture		Predictive	Supports	C	Sensitivity/Response	26888827	accepted
EGFR	G465R	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	C	Resistance	26888827	accepted
ETS2	RS461155	Lung Non-small Cell Carcinoma	Cisplatin,Paclitaxel	Combination	Predictive	Supports	B	Sensitivity/Response	26893365	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pertuzumab,Trastuzumab,Docetaxel	Combination	Predictive	Supports	B	Sensitivity/Response	25693012	accepted
EGFR	S492R	Colorectal Cancer	Panitumumab		Predictive	Supports	C	Sensitivity/Response	22270724	accepted
EGFR	S492R	Colorectal Cancer	Panitumumab,Futuximab/Modotuximab Mixture	Substitutes	Predictive	Supports	D	Sensitivity/Response	26888827	accepted
EGFR	S492R	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	26888827	accepted
EGFR	R451C	Colorectal Cancer	Panitumumab,Cetuximab,Futuximab/Modotuximab Mixture	Substitutes	Predictive	Supports	D	Sensitivity/Response	26888827	accepted
EGFR	K467T	Colorectal Cancer	Panitumumab,Futuximab/Modotuximab Mixture	Substitutes	Predictive	Supports	D	Sensitivity/Response	26888827	accepted
EGFR	K467T	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	26888827	accepted
EGFR	P753S	Skin Squamous Cell Carcinoma	Sirolimus,Cetuximab	Combination	Predictive	Supports	C	Sensitivity/Response	24934779	accepted
PML	PML-RARA	Acute Promyelocytic Leukemia	Tretinoin,Arsenic Trioxide	Combination	Predictive	Supports	A	Sensitivity/Response	11704842	accepted
PML	B2 DOMAIN MUTATION	Acute Promyelocytic Leukemia	Tretinoin		Predictive	Supports	B	Resistance	23670176	accepted
PML	PML-RARA A216V	Acute Promyelocytic Leukemia	Tretinoin		Predictive	Supports	C	Resistance	21613260	accepted
PML	PML-RARA L218P	Acute Promyelocytic Leukemia	Tretinoin		Predictive	Supports	C	Resistance	21613260	accepted
MET	EXON 14 MUTATION and AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26729443	accepted
ERBB2	AMPLIFICATION	Endometrial Serous Adenocarcinoma	Trastuzumab		Predictive	Supports	C	Sensitivity/Response	18555254	accepted
SMO	D473H	Brain Medulloblastoma	Patidegib		Predictive	Supports	D	Sensitivity/Response	22550175	accepted
ROS1	CD74-ROS1 G2032R	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Resistance	23724914	accepted
ROS1	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Cabozantinib		Predictive	Supports	D	Sensitivity/Response	25351743	accepted
CEBPA	N-TERMINAL FRAME SHIFT	Acute Myeloid Leukemia	OICR-9429		Predictive	Supports	D	Sensitivity/Response	26167872	accepted
FGFR1	ZNF198-FGFR1	Chronic Myeloproliferative Disease	Midostaurin		Predictive	Supports	C	Sensitivity/Response	15448205	accepted
FGFR1	AMPLIFICATION	Breast Cancer	Afimoxifene		Predictive	Supports	D	Resistance	20179196	accepted
KDR	A1065T	Angiosarcoma	Sorafenib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	19723655	accepted
KDR	D717V	Angiosarcoma	Sunitinib,Sorafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	19723655	accepted
TSC2	Q1178*	Thyroid Gland Carcinoma	Everolimus		Predictive	Supports	C	Sensitivity/Response	25295501	accepted
MTOR	F2108L	Thyroid Gland Carcinoma	Everolimus		Predictive	Supports	C	Resistance	25295501	accepted
FLT3	ITD	Acute Promyelocytic Leukemia	Anthracycline Antineoplastic Antibiotic,Tretinoin	Combination	Predictive	Supports	B	Resistance	24981688	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Neratinib,Trastuzumab	Sequential	Predictive	Supports	A	Sensitivity/Response	26874901	accepted
ALDH1A2	UNDEREXPRESSION	Head And Neck Squamous Cell Carcinoma	Tretinoin		Predictive	Supports	D	Sensitivity/Response	26634247	accepted
CIP2A	UNDEREXPRESSION	Pancreatic Ductal Adenocarcinoma	Gemcitabine		Predictive	Supports	D	Sensitivity/Response	26894380	accepted
ALK	EML4-ALK	Lung Acinar Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	23181703	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	A	Sensitivity/Response	16236737	accepted
ERBB2	Y772_A775DUP	Lung Adenocarcinoma	Trastuzumab Emtansine		Predictive	Supports	C	Sensitivity/Response	25789838	accepted
EGFR	VIII	Glioblastoma Multiforme	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	16282176	accepted
PTEN	EXPRESSION	Glioblastoma Multiforme	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	16282176	accepted
KRAS	Q22*	Colon Mucinous Adenocarcinoma	Panitumumab		Predictive	Supports	C	Resistance	19661358	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Capecitabine,Lapatinib	Combination	Predictive	Supports	B	Sensitivity/Response	17192538	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Capecitabine	Combination	Predictive	Supports	B	Sensitivity/Response	19289619	accepted
DDX43	OVEREXPRESSION	Uveal Melanoma	Selumetinib,Trametinib,MEK Inhibitor PD0325901	Substitutes	Predictive	Supports	D	Resistance	24899684	accepted
KIT	RS3733542	Acute Myeloid Leukemia	Selumetinib		Predictive	Supports	B	Sensitivity/Response	24178622	accepted
FLT3	ITD	Acute Myeloid Leukemia	Selumetinib		Predictive	Supports	B	Resistance	24178622	accepted
TBK1	OVEREXPRESSION	Melanoma	AZ909,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	24962318	accepted
KRAS	MUTATION	Colorectal Cancer	Chemotherapy,Bevacizumab	Combination	Predictive	Supports	B	Resistance	23828442	accepted
KRAS	MUTATION	Cancer	G-573,MEK Inhibitor GDC-0623	Substitutes	Predictive	Supports	D	Sensitivity/Response	23934108	accepted
BRAF	V600E	Cancer	Cobimetinib		Predictive	Supports	D	Sensitivity/Response	23934108	accepted
KRAS	G12C	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Combination	Predictive	Supports	B	Sensitivity/Response	26125448	accepted
KRAS	G12V	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Combination	Predictive	Supports	B	Sensitivity/Response	26125448	accepted
STK11	LOSS	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	Combination	Predictive	Supports	D	Resistance	22425996	accepted
TP53	MUTATION	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Combination	Predictive	Supports	D	Sensitivity/Response	22425996	accepted
TP53	MUTATION	Lung Non-small Cell Carcinoma	Docetaxel		Predictive	Supports	D	Resistance	22425996	accepted
TP53	WILD TYPE	Lung Non-small Cell Carcinoma	Adjuvant Chemotherapy		Predictive	Supports	B	Sensitivity/Response	26899019	accepted
HAVCR2	OVEREXPRESSION	Lung Non-small Cell Carcinoma	PD1 Inhibitor		Predictive	Supports	C	Resistance	26883990	accepted
HAVCR2	OVEREXPRESSION	Lung Non-small Cell Carcinoma	PD1 Inhibitor,Anti-TIM-3 Monoclonal Antibody	Combination	Predictive	Supports	D	Sensitivity/Response	26883990	accepted
ERBB3	OVEREXPRESSION	Cancer	Selumetinib,Afatinib	Combination	Predictive	Supports	D	Sensitivity/Response	24685132	accepted
ERBB3	OVEREXPRESSION	Cancer	HER2 Inhibitor CP-724,714,Gefitinib,Selumetinib	Substitutes	Predictive	Supports	D	Resistance	24685132	accepted
CDKN2A	p16 EXPRESSION	Head And Neck Squamous Cell Carcinoma	Afatinib		Predictive	Supports	B	Resistance	25892145	accepted
MMP2	SERUM LEVELS	Inflammatory Breast Carcinoma	Bevacizumab		Predictive	Supports	B	Sensitivity/Response	26921265	accepted
MMP9	SERUM LEVELS	Inflammatory Breast Carcinoma	Bevacizumab		Predictive	Supports	B	Resistance	26921265	accepted
MMP2	SERUM LEVELS	Brain Glioma	Bevacizumab		Predictive	Supports	B	Sensitivity/Response	24327581	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	24793816	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	23020162	accepted
HSPH1	NUCLEAR EXPRESSION	Gastric Adenocarcinoma	Fluorouracil,Cisplatin	Substitutes	Predictive	Supports	D	Sensitivity/Response	26943774	accepted
HSPH1	T17 DELETION	Colorectal Cancer	Oxaliplatin,Fluorouracil	Combination	Predictive	Supports	B	Sensitivity/Response	24512910	accepted
CD274	EXPRESSION	Lung Non-small Cell Carcinoma	Avelumab,Pembrolizumab,Atezolizumab,Nivolumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	26918451	accepted
TP53	DELETERIOUS MUTATION	Sarcoma	Pazopanib		Predictive	Supports	B	Sensitivity/Response	26646755	accepted
PIK3CA	E545K	Lung Adenocarcinoma	Gefitinib		Predictive	Supports	D	Resistance	16906227	accepted
CD274	EXPRESSION	Lung Non-small Cell Carcinoma	Atezolizumab		Predictive	Supports	B	Sensitivity/Response	26970723	accepted
KRAS	G12C	Cancer	ARS-853,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	26739882	accepted
ERBB2	V842I	Colon Cancer	Trastuzumab,Neratinib,Lapatinib	Combination	Predictive	Supports	D	Sensitivity/Response	26243863	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	B	Sensitivity/Response	26973324	accepted
ERBB2	L755S	Colon Cancer	Trastuzumab,Lapatinib,Neratinib	Combination	Predictive	Supports	D	Sensitivity/Response	26243863	accepted
ERBB2	V777L	Colon Cancer	Trastuzumab,Neratinib,Lapatinib	Combination	Predictive	Supports	D	Sensitivity/Response	26243863	accepted
ERBB2	L866M	Colon Cancer	Trastuzumab,Neratinib,Lapatinib	Combination	Predictive	Supports	D	Sensitivity/Response	26243863	accepted
ERBB2	S310F/Y	Colon Cancer	Lapatinib,Neratinib,Trastuzumab	Combination	Predictive	Supports	D	Sensitivity/Response	26243863	accepted
KRAS	G13D	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	26371285	accepted
KRAS	G13D	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	26812186	accepted
KRAS	MUTATION	Colorectal Cancer	Ixazomib		Predictive	Supports	D	Resistance	26709701	accepted
KRAS	MUTATION	Cancer	AZD5438		Predictive	Supports	D	Sensitivity/Response	26881434	accepted
MET	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26729443	accepted
MET	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	Capmatinib		Predictive	Supports	C	Sensitivity/Response	25971938	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	A	Sensitivity/Response	20979469	accepted
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	WHI-P154		Predictive	Supports	D	Sensitivity/Response	17625570	accepted
ALK	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	20979469	accepted
ALK	EML4-ALK E2;A20	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	E	Sensitivity/Response	18927303	accepted
KDR	R961W	Colorectal Adenocarcinoma	Regorafenib		Predictive	Supports	C	Sensitivity/Response	27004155	accepted
ALK	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	2,4-pyrimidinediamine		Predictive	Supports	D	Sensitivity/Response	18593892	accepted
ALK	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	20979469	accepted
ALK	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	TAE684		Predictive	Supports	D	Sensitivity/Response	18451166	accepted
ALK	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Sensitivity/Response	22912387	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	A	Sensitivity/Response	23724913	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	A	Sensitivity/Response	25470694	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	24478318	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	27022118	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Retaspimycin Hydrochloride		Predictive	Supports	C	Sensitivity/Response	20940188	accepted
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Retaspimycin Hydrochloride,Crizotinib	Combination	Predictive	Supports	D	Sensitivity/Response	21258415	accepted
ALK	EML4-ALK E20;A20	Lung Non-small Cell Carcinoma	Alvespimycin,Crizotinib	Combination	Predictive	Supports	D	Sensitivity/Response	22912387	accepted
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Alvespimycin,Crizotinib	Combination	Predictive	Supports	D	Sensitivity/Response	22912387	accepted
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	20979469	accepted
KRAS	EXON 2 MUTATION	Colorectal Cancer	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Resistance	27037411	accepted
TP53	P47S	Cancer	Cisplatin		Predictive	Supports	E	Resistance	27034505	accepted
GNAQ	MUTATION	Uveal Melanoma	JQ1		Predictive	Supports	D	Sensitivity/Response	26397223	accepted
GNA11	MUTATION	Uveal Melanoma	JQ1		Predictive	Supports	D	Sensitivity/Response	26397223	accepted
PMS2	K706FS*19	Glioblastoma Multiforme	Nivolumab		Predictive	Supports	C	Sensitivity/Response	27001570	accepted
KRAS	G12C	Colorectal Cancer	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	23313110	accepted
KRAS	EXON 2 MUTATION	Pancreatic Cancer	Gemcitabine,Erlotinib	Combination	Predictive	Supports	B	Resistance	21862683	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Trametinib		Predictive	Supports	B	Sensitivity/Response	22805291	accepted
KIT	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Sensitivity/Response	16624552	accepted
KIT	MUTATION	Melanoma	Imatinib		Predictive	Supports	B	Sensitivity/Response	21690468	accepted
KIT	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	B	Sensitivity/Response	22439647	accepted
KIT	EXON 11 MUTATION	Melanoma	Sunitinib		Predictive	Supports	C	Sensitivity/Response	22261812	accepted
NRAS	MUTATION	Skin Melanoma	Docetaxel,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	25542057	accepted
NRAS	Q61	Skin Melanoma	Binimetinib		Predictive	Supports	B	Sensitivity/Response	23414587	accepted
GNA11	MUTATION	Uveal Melanoma	Trametinib		Predictive	Supports	C	Sensitivity/Response	22805292	accepted
GNAQ	MUTATION	Uveal Melanoma	Trametinib		Predictive	Supports	B	Sensitivity/Response	22805292	accepted
NRAS	MUTATION	Cancer	Trametinib,Metformin	Combination	Predictive	Supports	D	Sensitivity/Response	25504439	accepted
PTEN	DELETION	Prostate Cancer	Everolimus		Predictive	Supports	B	Sensitivity/Response	23582881	accepted
GNAQ	Q209	Uveal Melanoma	Refametinib		Predictive	Supports	C	Sensitivity/Response	23434733	accepted
BAP1	MUTATION	Uveal Melanoma	Vorinostat,Trichostatin A,Panobinostat,Valproic Acid	Substitutes	Predictive	Supports	D	Sensitivity/Response	22038994	accepted
BAP1	MUTATION	Malignant Mesothelioma	Vorinostat,Mocetinostat,MC1568	Substitutes	Predictive	Supports	E	Sensitivity/Response	25970771	accepted
FGFR2	MUTATION	Endometrial Cancer	Ponatinib		Predictive	Supports	D	Sensitivity/Response	26574622	accepted
ALK	MUTATION	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	B	Sensitivity/Response	24670165	accepted
ALK	NPM-ALK	Anaplastic Large Cell Lymphoma	Crizotinib		Predictive	Supports	D	Sensitivity/Response	18089725	accepted
ALK	ALK FUSIONS	Anaplastic Large Cell Lymphoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	21345110	accepted
ALK	NPM-ALK	Anaplastic Large Cell Lymphoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	23598171	accepted
ALK	ALK FUSIONS	Inflammatory Myofibroblastic Tumor	Crizotinib		Predictive	Supports	B	Sensitivity/Response	23598171	accepted
ALK	RANBP2-ALK	Inflammatory Myofibroblastic Tumor	Crizotinib		Predictive	Supports	C	Sensitivity/Response	20979472	accepted
ALK	EML4-ALK E20;A20	Cancer	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25408655	accepted
FGFR1	N546K	Ewing Sarcoma Of Bone	Ponatinib		Predictive	Supports	E	Sensitivity/Response	26179511	accepted
FGFR1	AMPLIFICATION	Ewing Sarcoma Of Bone	Ponatinib		Predictive	Supports	D	Sensitivity/Response	26179511	accepted
ROS1	REARRANGEMENT	Lung Adenocarcinoma	Ceritinib		Predictive	Supports	C	Sensitivity/Response	26917690	accepted
ROS1	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Cabozantinib,Foretinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	26372962	accepted
ROS1	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Brigatinib,Crizotinib,AZD3463,Ceritinib	Substitutes	Predictive	Supports	D	Resistance	26372962	accepted
ROS1	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Lorlatinib		Predictive	Supports	D	Sensitivity/Response	25733882	accepted
ROS1	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	25733882	accepted
ROS1	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	Lorlatinib		Predictive	Supports	D	Sensitivity/Response	25733882	accepted
ROS1	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	25688157	accepted
ROS1	CD74-ROS1 G2032R	Lung Non-small Cell Carcinoma	Foretinib		Predictive	Supports	D	Sensitivity/Response	25688157	accepted
ROS1	CD74-ROS1 L2155S	Lung Non-small Cell Carcinoma	Foretinib,TAE684,Crizotinib	Substitutes	Predictive	Supports	D	Resistance	25688157	accepted
ROS1	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	25688157	accepted
ROS1	CD74-ROS1 L2026M	Lung Non-small Cell Carcinoma	Foretinib		Predictive	Supports	D	Sensitivity/Response	25688157	accepted
ROS1	CD74-ROS1 G2101A	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	25688157	accepted
ROS1	CD74-ROS1 G2101A	Lung Non-small Cell Carcinoma	Foretinib		Predictive	Supports	D	Sensitivity/Response	25688157	accepted
ALK	CLTC-ALK	Diffuse Large B-cell Lymphoma	TAE684		Predictive	Supports	D	Sensitivity/Response	21494621	accepted
ALK	ALK FUSIONS	Diffuse Large B-cell Lymphoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	24330038	accepted
ALK	CLTC-ALK	Diffuse Large B-cell Lymphoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26221234	accepted
BRAF	DEL 485-490	Cancer	Pan-RAF Inhibitor LY3009120		Predictive	Supports	D	Sensitivity/Response	26732095	accepted
ALK	R1275Q	Neuroblastoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	23598171	accepted
ALK	R1275Q	Neuroblastoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	23598171	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	B	Sensitivity/Response	23639470	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	C	Sensitivity/Response	26938871	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	B	Sensitivity/Response	25153538	accepted
BCL2L11	DELETION POLYMORPHISM	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	B	Resistance	22426421	accepted
BCL2L11	DELETION POLYMORPHISM	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Resistance	22426421	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	A	Sensitivity/Response	26708155	accepted
ALK	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	C	Resistance	25228534	accepted
ALK	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	C	Sensitivity/Response	25228534	accepted
ALK	ALK FUSION I1171	Lung Non-small Cell Carcinoma	TAE684		Predictive	Supports	D	Sensitivity/Response	25228534	accepted
ALK	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	D	Resistance	25228534	accepted
ALK	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	25228534	accepted
ALK	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	25228534	accepted
ALK	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	D	Sensitivity/Response	25228534	accepted
ALK	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	TAE684		Predictive	Supports	D	Sensitivity/Response	25228534	accepted
ALK	EML4-ALK  V1180L	Lung Non-small Cell Carcinoma	Brigatinib		Predictive	Supports	D	Sensitivity/Response	25228534	accepted
SIRT1	OVEREXPRESSION	Pancreatic Cancer	Niacinamide		Predictive	Supports	D	Resistance	24088390	accepted
FLT3	TKD MUTATION	Acute Myeloid Leukemia	Midostaurin		Predictive	Supports	B	Sensitivity/Response	20733134	accepted
PIK3CA	MUTATION	Her2-receptor Positive Breast Cancer	Everolimus		Predictive	Supports	B	Sensitivity/Response	27091708	accepted
PTEN	LOSS	Her2-receptor Positive Breast Cancer	Everolimus		Predictive	Supports	B	Sensitivity/Response	27091708	accepted
ROS1	REARRANGEMENT	Colorectal Adenocarcinoma	Crizotinib		Predictive	Supports	E	Sensitivity/Response	24296758	accepted
PALB2	BIALLELIC INACTIVATION	Pancreatic Cancer	Mitomycin		Predictive	Supports	C	Sensitivity/Response	21135251	accepted
FANCC	LOSS-OF-FUNCTION	Pancreatic Cancer	Chlorambucil,Melphalan,Mitomycin,Cisplatin,Gemcitabine	Substitutes	Predictive	Supports	D	Sensitivity/Response	16243825	accepted
BRCA2	LOSS-OF-FUNCTION	Pancreatic Cancer	Mitomycin		Predictive	Supports	D	Sensitivity/Response	16243825	accepted
PDGFRA	I843DEL	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	D	Sensitivity/Response	14645423	accepted
PDGFRB	EBF1-PDGFRB	Acute Lymphoblastic Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	23835704	accepted
MLH1	METHYLATION	Stomach Carcinoma	Oxaliplatin		Predictive	Supports	B	Resistance	24748501	accepted
FLT3	T227M	Renal Cell Carcinoma	Sunitinib		Predictive	Supports	B	Adverse Response	19667267	accepted
MTOR	S2215Y	Endometrial Adenocarcinoma	Sirolimus		Predictive	Supports	D	Sensitivity/Response	24631838	accepted
MTOR	C1483Y	T-cell Acute Lymphoblastic Leukemia	Sirolimus		Predictive	Supports	D	Sensitivity/Response	24631838	accepted
MTOR	E1799K	Clear Cell Renal Cell Carcinoma	Sirolimus		Predictive	Supports	D	Sensitivity/Response	24631838	accepted
FGFR2	N550K	Endometrial Cancer	PD173074		Predictive	Supports	D	Sensitivity/Response	18757403	accepted
RB1	OVEREXPRESSION	Pancreatic Adenocarcinoma	Mitomycin,Gemcitabine,Doxorubicin,Fluorouracil	Substitutes	Predictive	Supports	D	Resistance	11792751	accepted
PPP1R15A	RS557806	Colorectal Cancer	FOLFIRI Regimen,Bevacizumab	Combination	Predictive	Supports	B	Sensitivity/Response	27177629	accepted
KRAS	EXON 2 MUTATION	Colorectal Cancer	Irinotecan,Selumetinib	Combination	Predictive	Supports	B	Sensitivity/Response	25322874	accepted
ALK	F1174L	Neuroblastoma	AZD3463		Predictive	Supports	D	Sensitivity/Response	26786851	accepted
ALK	F1174L	Neuroblastoma	Lorlatinib		Predictive	Supports	D	Sensitivity/Response	26554404	accepted
ALK	F1245C	Neuroblastoma	Lorlatinib		Predictive	Supports	D	Sensitivity/Response	26554404	accepted
ALK	R1275Q	Neuroblastoma	Lorlatinib		Predictive	Supports	D	Sensitivity/Response	26554404	accepted
ALK	EML4-ALK	Lung Non-small Cell Carcinoma	Lorlatinib		Predictive	Supports	D	Sensitivity/Response	26554404	accepted
ALK	F1245C	Neuroblastoma	Crizotinib		Predictive	Supports	C	Resistance	23598171	accepted
ALK	ALK FUSIONS	Colorectal Adenocarcinoma	Crizotinib		Predictive	Supports	E	Sensitivity/Response	19737969	accepted
ALK	ALK FUSIONS	Breast Cancer	Crizotinib		Predictive	Supports	E	Sensitivity/Response	19737969	accepted
ALK	DEL4-11	Neuroblastoma	Brigatinib		Predictive	Supports	D	Sensitivity/Response	27049722	accepted
ALK	ALK FUSION F1245C	Cancer	Crizotinib		Predictive	Supports	D	Resistance	22034911	accepted
ALK	ALK FUSION F1245C	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	C	Sensitivity/Response	26775591	accepted
ALK	ALK FUSION F1245C	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	26775591	accepted
ALK	EML4-ALK E6;A20	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	D	Sensitivity/Response	24675041	accepted
ALK	EML4-ALK L1196M	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	D	Sensitivity/Response	24675041	accepted
ALK	ALK FUSION G1269A	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	D	Sensitivity/Response	24675041	accepted
ALK	EML4-ALK S1206Y	Cancer	Ceritinib		Predictive	Supports	D	Sensitivity/Response	24675041	accepted
ALK	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	D	Sensitivity/Response	24675041	accepted
ALK	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	D	Resistance	24675041	accepted
ALK	EML4-ALK C1156Y	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Resistance	24675041	accepted
ALK	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	D	Resistance	22277784	accepted
ALK	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	TAE684		Predictive	Supports	D	Resistance	22277784	accepted
ALK	EML4-ALK T1151INST	Lung Non-small Cell Carcinoma	Tanespimycin		Predictive	Supports	D	Sensitivity/Response	22277784	accepted
ALK	ALK FUSION G1202R	Cancer	Alectinib		Predictive	Supports	D	Resistance	25727400	accepted
ALK	ALK FUSION G1202R	Cancer	Brigatinib		Predictive	Supports	D	Resistance	25727400	accepted
ALK	ALK FUSION G1202R	Lung Non-small Cell Carcinoma	Tanespimycin		Predictive	Supports	D	Sensitivity/Response	22277784	accepted
ALK	ALK FUSION G1269A	Cancer	Brigatinib		Predictive	Supports	D	Sensitivity/Response	25727400	accepted
ALK	ALK FUSION G1269A	Cancer	Alectinib		Predictive	Supports	D	Resistance	25727400	accepted
ALK	ALK FUSION G1269A	Cancer	Ceritinib		Predictive	Supports	D	Sensitivity/Response	25727400	accepted
ALK	NPM-ALK	Cancer	Crizotinib		Predictive	Supports	D	Sensitivity/Response	25727400	accepted
ALK	ALK FUSION G1202R	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Resistance	22277784	accepted
PIK3CA	MUTATION	Head And Neck Cancer	Dactolisib		Predictive	Supports	D	Sensitivity/Response	23619167	accepted
PIK3CA	H1047R	Head And Neck Cancer	Dactolisib		Predictive	Supports	D	Sensitivity/Response	25855885	accepted
PIK3CA	H1047R	Head And Neck Cancer	Dactolisib		Predictive	Supports	D	Sensitivity/Response	23619167	accepted
PIK3CA	H1047R	Head And Neck Cancer	Dactolisib,Cetuximab	Combination	Predictive	Supports	D	Sensitivity/Response	23619167	accepted
RET	M918T	Thyroid Gland Medullary Carcinoma	Sorafenib		Predictive	Supports	B	Sensitivity/Response	20368568	accepted
CDK4	AMPLIFICATION	Liposarcoma	Palbociclib		Predictive	Supports	B	Sensitivity/Response	23569312	accepted
ALK	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	C	Resistance	25736571	accepted
ALK	ALK FUSION I1171	Lung Non-small Cell Carcinoma	Ceritinib		Predictive	Supports	C	Sensitivity/Response	25736571	accepted
BRCA1	MUTATION	Cancer	Olaparib		Predictive	Supports	A	Sensitivity/Response	19553641	accepted
BRCA2	MUTATION	Cancer	Olaparib		Predictive	Supports	A	Sensitivity/Response	19553641	accepted
CDKN2A	LOSS	Skin Melanoma	Alvocidib		Predictive	Supports	D	Sensitivity/Response	12777976	accepted
CDKN2A	LOSS	Renal Cell Carcinoma	Palbociclib		Predictive	Supports	D	Sensitivity/Response	23898052	accepted
CDKN2B	LOSS	Renal Cell Carcinoma	Palbociclib		Predictive	Supports	D	Sensitivity/Response	23898052	accepted
CDKN2A	LOSS	Skin Melanoma	Palbociclib		Predictive	Supports	D	Sensitivity/Response	24495407	accepted
CDK4	R24C	Skin Melanoma	Palbociclib		Predictive	Supports	D	Sensitivity/Response	24495407	accepted
CDKN2A	LOSS	Ovarian Cancer	Palbociclib		Predictive	Supports	D	Sensitivity/Response	21278246	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pictilisib		Predictive	Supports	D	Sensitivity/Response	22802530	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	A66		Predictive	Supports	D	Sensitivity/Response	22802530	accepted
PTEN	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	D	Resistance	17936563	accepted
PIK3CA	MUTATION	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	B	Resistance	17936563	accepted
PTEN	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	B	Resistance	20813970	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Ponatinib		Predictive	Supports	B	Sensitivity/Response	23190221	accepted
EGFR	T790M	Lung Adenocarcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Resistance	23470965	accepted
MET	AMPLIFICATION	Lung Adenocarcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	C	Resistance	23470965	accepted
ERBB2	AMPLIFICATION	Lung Adenocarcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	C	Resistance	23470965	accepted
EGFR	S768I	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	25521405	accepted
EGFR	S768I	Lung Adenocarcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	20522446	accepted
EGFR	C797S	Lung Adenocarcinoma	Osimertinib		Predictive	Supports	C	Resistance	26181354	accepted
EGFR	T790M	Lung Adenocarcinoma	Osimertinib		Predictive	Supports	C	Sensitivity/Response	26181354	accepted
BRAF	V600E	Melanoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	24508103	accepted
BRAF	V600K	Melanoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	24508103	accepted
BRAF	V600K	Melanoma	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	26989536	accepted
PIK3CA	H1047R	Head And Neck Cancer	Alpelisib		Predictive	Supports	D	Sensitivity/Response	25550549	accepted
PIK3CA	MUTATION	Cancer	Alpelisib		Predictive	Supports	D	Sensitivity/Response	24608574	accepted
PIK3CA	AMPLIFICATION	Stomach Carcinoma	Alpelisib		Predictive	Supports	D	Sensitivity/Response	24608574	accepted
BRAF	V600	Melanoma	Dabrafenib		Predictive	Supports	B	Sensitivity/Response	22608338	accepted
BRAF	V600E	Colorectal Cancer	Gefitinib,Vemurafenib,Cetuximab	Combination	Predictive	Supports	D	Sensitivity/Response	22281684	accepted
BRAF	V600E	Skin Melanoma	Vemurafenib		Predictive	Supports	A	Sensitivity/Response	21639808	accepted
BRAF	V600E	Skin Melanoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	22356324	accepted
BRAF	V600	Skin Melanoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	A	Sensitivity/Response	25399551	accepted
BRAF	V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	24987354	accepted
BRAF	V600	Colorectal Cancer	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	26392102	accepted
BRAF	TRIM24-BRAF	Skin Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24345920	accepted
SF3B1	K700E	Breast Cancer	Spliceostatin A		Predictive	Supports	D	Sensitivity/Response	25424858	accepted
SF3B1	K666N	Breast Cancer	Spliceostatin A		Predictive	Supports	D	Sensitivity/Response	25424858	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	21933749	accepted
BRAF	V600E	Melanoma	Cobimetinib,Vemurafenib	Combination	Predictive	Supports	B	Sensitivity/Response	25265494	accepted
BRAF	V600	Melanoma	Cobimetinib,Vemurafenib	Combination	Predictive	Supports	B	Sensitivity/Response	25265494	accepted
KIT	M541L	Chronic Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	25015329	accepted
KIT	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	B	Sensitivity/Response	18955458	accepted
BRAF	V600E	Colorectal Cancer	GDC-0879,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	23549875	accepted
NRAS	MUTATION	Melanoma	Omipalisib,Trametinib	Combination	Predictive	Supports	D	Sensitivity/Response	23431193	accepted
BRAF	V600E	Gastrointestinal Neuroendocrine Tumor	Trametinib,Dabrafenib,Vemurafenib	Combination	Predictive	Supports	C	Sensitivity/Response	27048246	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	23382472	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pertuzumab,Docetaxel,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	22149875	accepted
MTOR	E2014K and E2419K	Urothelial Carcinoma	Pazopanib,Everolimus	Combination	Predictive	Supports	C	Sensitivity/Response	24625776	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab,Lapatinib	Combination	Predictive	Supports	B	Sensitivity/Response	22257673	accepted
RICTOR	AMPLIFICATION	Lung Adenocarcinoma	Sapanisertib,MTOR Kinase Inhibitor CC-223	Substitutes	Predictive	Supports	C	Sensitivity/Response	26370156	accepted
PDGFRA	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib		Predictive	Supports	B	Sensitivity/Response	14504092	accepted
ROS1	REARRANGEMENT	Bronchiolo-alveolar Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	22215748	accepted
ROS1	TFG-ROS1	Inflammatory Myofibroblastic Tumor	Crizotinib		Predictive	Supports	C	Sensitivity/Response	24875859	accepted
PDGFRA	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib		Predictive	Supports	A	Sensitivity/Response	12660384	accepted
PDGFRA	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib		Predictive	Supports	C	Resistance	12660384	accepted
PIK3CA	H1047R	Lung Adenocarcinoma	Dactolisib		Predictive	Supports	D	Sensitivity/Response	19029981	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Pilaralisib,Trastuzumab	Combination	Predictive	Supports	D	Sensitivity/Response	23204226	accepted
BIRC5	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	B	Resistance	23204226	accepted
PIK3CA	E545K	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	D	Resistance	18829560	accepted
BRAF	D594A	Skin Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,Sorafenib	Substitutes	Predictive	Supports	E	Sensitivity/Response	20141835	accepted
PTEN	LOSS	Her2-receptor Positive Breast Cancer	PI3K/BET Inhibitor LY294002,Trastuzumab	Combination	Predictive	Supports	D	Sensitivity/Response	15324695	accepted
BRAF	D594V	Skin Melanoma	Trametinib,Sorafenib	Substitutes	Predictive	Supports	E	Sensitivity/Response	20141835	accepted
BRAF	K483M	Skin Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,Sorafenib	Substitutes	Predictive	Supports	E	Sensitivity/Response	20141835	accepted
BRAF	L597R	Skin Melanoma	Vemurafenib,Trametinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	22798288	accepted
BRAF	L597S	Skin Melanoma	Trametinib,Vemurafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	22798288	accepted
BRAF	L597S	Skin Melanoma	MEK Inhibitor TAK-733		Predictive	Supports	C	Sensitivity/Response	22798288	accepted
BRAF	L597Q	Skin Melanoma	Vemurafenib,Trametinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	22798288	accepted
BRAF	K601E	Skin Melanoma	Trametinib,Vemurafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	22798288	accepted
BRAF	L597V	Skin Melanoma	Trametinib		Predictive	Supports	C	Sensitivity/Response	22805292	accepted
PIK3CA	AMPLIFICATION	Head And Neck Squamous Cell Carcinoma	Taselisib		Predictive	Supports	D	Sensitivity/Response	26589432	accepted
PIK3CA	H1047R	Head And Neck Squamous Cell Carcinoma	Taselisib		Predictive	Supports	D	Sensitivity/Response	26589432	accepted
KIT	AMPLIFICATION	Mucosal Melanoma	Imatinib		Predictive	Supports	B	Resistance	23775962	accepted
PTEN	MUTATION	Head And Neck Squamous Cell Carcinoma	Taselisib		Predictive	Supports	D	Resistance	26589432	accepted
NF1	MUTATION	Skin Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	23171796	accepted
NF1	MUTATION	Skin Melanoma	Sirolimus,MEK Inhibitor PD0325901	Combination	Predictive	Supports	D	Sensitivity/Response	23171796	accepted
NF1	MUTATION	Skin Melanoma	Vemurafenib		Predictive	Supports	C	Resistance	23288408	accepted
NF1	MUTATION	Skin Melanoma	VTX-11e,AZ628	Substitutes	Predictive	Supports	D	Sensitivity/Response	23288408	accepted
NRAS	MUTATION	Skin Melanoma	Binimetinib		Predictive	Supports	B	Sensitivity/Response	23414587	accepted
NRAS	Q61	Skin Melanoma	Selumetinib		Predictive	Supports	C	Sensitivity/Response	18390968	accepted
NRAS	Q61K	Skin Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	22194965	accepted
NRAS	Q61K	Skin Melanoma	Selumetinib		Predictive	Supports	D	Sensitivity/Response	22194965	accepted
NRAS	MUTATION	Skin Melanoma	Amuvatinib		Predictive	Supports	D	Sensitivity/Response	24950457	accepted
SMO	MUTATION	Basal Cell Carcinoma	Sonidegib,Vismodegib	Sequential	Predictive	Supports	B	Resistance	26546616	accepted
TP53	MUTATION	Chronic Lymphocytic Leukemia	Alemtuzumab		Predictive	Supports	B	Sensitivity/Response	14726385	accepted
CALR	EXON 9 FRAMESHIFT	Chronic Myeloproliferative Disease	Peginterferon Alfa-2a		Predictive	Supports	B	Sensitivity/Response	26486786	accepted
ALK	HIP1-ALK I1171N	Lung Non-small Cell Carcinoma	Alectinib,Crizotinib	Sequential	Predictive	Supports	C	Resistance	25393796	accepted
ALK	EML4-ALK I1171S	Lung Non-small Cell Carcinoma	Alectinib,Crizotinib	Sequential	Predictive	Supports	C	Resistance	25393796	accepted
PIK3CA	MUTATION	Head And Neck Squamous Cell Carcinoma	Taselisib,Radiation Therapy	Combination	Predictive	Supports	D	Sensitivity/Response	26589432	accepted
PTEN	MUTATION	Cancer	Ipatasertib		Predictive	Supports	D	Sensitivity/Response	23287563	accepted
PTEN	LOSS	Ovarian Cancer	Cisplatin		Predictive	Supports	D	Resistance	15790433	accepted
PTEN	LOSS	Stomach Carcinoma	Chemotherapy		Predictive	Supports	B	Resistance	15900596	accepted
EZH2	Y646	Skin Melanoma	GSK126		Predictive	Supports	D	Sensitivity/Response	26304929	accepted
CCND1	AMPLIFICATION	Skin Melanoma	Carboplatin,Paclitaxel,Sorafenib	Combination	Predictive	Supports	B	Sensitivity/Response	26307133	accepted
RAF1	AMPLIFICATION	Skin Melanoma	Carboplatin,Paclitaxel,Sorafenib	Combination	Predictive	Supports	B	Sensitivity/Response	26307133	accepted
KRAS	AMPLIFICATION	Skin Melanoma	Carboplatin,Docetaxel,Sorafenib	Combination	Predictive	Supports	B	Sensitivity/Response	26307133	accepted
PDGFRB	PDGFRB FUSIONS	Chronic Myeloproliferative Disease	Imatinib		Predictive	Supports	A	Sensitivity/Response	16960151	accepted
ERBB2	AMPLIFICATION	Gastric Adenocarcinoma	Trastuzumab		Predictive	Supports	A	Sensitivity/Response	20728210	accepted
PTEN	LOSS	Stomach Cancer	Capivasertib,Docetaxel	Combination	Predictive	Supports	D	Sensitivity/Response	24088382	accepted
PIK3CA	MUTATION	Stomach Cancer	Capivasertib		Predictive	Supports	D	Sensitivity/Response	24088382	accepted
PTEN	LOSS	Cancer	Capivasertib		Predictive	Supports	D	Sensitivity/Response	22294718	accepted
PIK3CA	MUTATION	Cancer	Capivasertib		Predictive	Supports	D	Sensitivity/Response	22294718	accepted
PIK3CA	MUTATION	Her2-receptor Positive Breast Cancer	Capivasertib		Predictive	Supports	D	Sensitivity/Response	22294718	accepted
PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	Capivasertib,Trastuzumab	Combination	Predictive	Supports	D	Sensitivity/Response	22294718	accepted
PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	Capivasertib,Lapatinib	Combination	Predictive	Supports	D	Sensitivity/Response	22294718	accepted
NRAS	MUTATION	Melanoma	Binimetinib		Predictive	Supports	D	Sensitivity/Response	24588908	accepted
CD274	EXPRESSION	Cancer	Nivolumab		Predictive	Supports	B	Sensitivity/Response	22658127	accepted
RET	OVEREXPRESSION	Papillary Adenocarcinoma	Sunitinib		Predictive	Supports	C	Sensitivity/Response	20696054	accepted
PML	PML-RARA	Acute Promyelocytic Leukemia	Tretinoin		Predictive	Supports	C	Sensitivity/Response	21505136	accepted
CTLA4	CTLA4-CD28	Sezary's Disease	Ipilimumab		Predictive	Supports	C	Sensitivity/Response	25802883	accepted
AR	MUTATION	Prostate Cancer	Flutamide,Nilutamide,Cyproterone Acetate,Bicalutamide	Substitutes	Predictive	Supports	B	Resistance	26000489	accepted
PTEN	MUTATION	Prostate Cancer	Alpelisib,Enzalutamide,PI3Kbeta Inhibitor AZD8186	Combination	Predictive	Supports	D	Sensitivity/Response	25544636	accepted
NOTCH1	LOSS-OF-FUNCTION	Head And Neck Squamous Cell Carcinoma	Porcupine Inhibitor WNT974		Predictive	Supports	D	Sensitivity/Response	24277854	accepted
CDK6	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Fulvestrant		Predictive	Supports	B	Resistance	27252418	accepted
CDK6	OVEREXPRESSION	Estrogen-receptor Positive Breast Cancer	Palbociclib,Fulvestrant	Combination	Predictive	Supports	D	Sensitivity/Response	27252418	accepted
FLT3	OVEREXPRESSION	Adult B-Lymphoblastic Leukemia	Sunitinib		Predictive	Supports	C	Sensitivity/Response	27181063	accepted
BRCA1	MUTATION	Ovarian Carcinoma	Platinum Compound		Predictive	Supports	B	Sensitivity/Response	24240112	accepted
BRCA2	MUTATION	Ovarian Carcinoma	Platinum Compound		Predictive	Supports	B	Sensitivity/Response	24240112	accepted
BRCA1	MUTATION	Ovarian Carcinoma	Platinum Compound		Predictive	Supports	B	Sensitivity/Response	24240112	accepted
BRCA2	MUTATION	Ovarian Carcinoma	Platinum Compound		Predictive	Supports	B	Sensitivity/Response	24240112	accepted
GNAQ	Q209P	Skin Melanoma	Vemurafenib		Predictive	Supports	C	Resistance	24504448	accepted
PTEN	V317FS	Skin Melanoma	MEK Inhibitor CI-1040,Akt Inhibitor MK2206	Combination	Predictive	Supports	D	Sensitivity/Response	24504448	accepted
RB1	LOSS-OF-FUNCTION	Breast Cancer	Palbociclib		Predictive	Supports	D	Resistance	20473330	accepted
GNAQ	Q209P	Skin Melanoma	PLX4720		Predictive	Supports	D	Resistance	24504448	accepted
ESR1	OVEREXPRESSION	Breast Cancer	Palbociclib,Letrozole	Combination	Predictive	Supports	B	Sensitivity/Response	25524798	accepted
MTOR	F2108L	Breast Cancer	Sirolimus		Predictive	Supports	D	Resistance	27279227	accepted
MTOR	M2327I	Breast Cancer	MTOR Kinase Inhibitor AZD8055		Predictive	Supports	D	Resistance	27279227	accepted
MTOR	A2034V	Breast Cancer	Sirolimus		Predictive	Supports	D	Resistance	27279227	accepted
PIK3CA	E542K	Head And Neck Squamous Cell Carcinoma	Apitolisib		Predictive	Supports	C	Sensitivity/Response	26787751	accepted
PIK3CA	E545K	Cancer	Apitolisib		Predictive	Supports	C	Sensitivity/Response	26787751	accepted
FLT3	ITD	Acute Myeloid Leukemia	Sorafenib		Predictive	Supports	C	Sensitivity/Response	23969938	accepted
FLT3	D835H	Acute Myeloid Leukemia	Sorafenib		Predictive	Supports	C	Resistance	23969938	accepted
FLT3	D835H/Y	Acute Myeloid Leukemia	Sorafenib		Predictive	Supports	D	Resistance	23969938	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Palbociclib,Trastuzumab	Combination	Predictive	Supports	D	Sensitivity/Response	19874578	accepted
CCND1	AMPLIFICATION	Breast Cancer	Palbociclib		Predictive	Supports	D	Sensitivity/Response	19874578	accepted
CCND1	OVEREXPRESSION	Mantle Cell Lymphoma	Palbociclib		Predictive	Supports	D	Sensitivity/Response	16690963	accepted
MET	AMPLIFICATION	Glioblastoma Multiforme	Crizotinib		Predictive	Supports	C	Sensitivity/Response	22162573	accepted
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	D	Sensitivity/Response	21716144	accepted
JAK1	Q503*	Skin Melanoma	Pembrolizumab		Predictive	Supports	C	Resistance	27433843	accepted
JAK2	c.1641+1dup	Skin Melanoma	Pembrolizumab		Predictive	Supports	C	Resistance	27433843	accepted
B2M	S14FS	Skin Melanoma	Pembrolizumab		Predictive	Supports	C	Resistance	27433843	accepted
BRAF	PPFIBP2-BRAF	Skin Melanoma	Trametinib		Predictive	Supports	C	Sensitivity/Response	26072686	accepted
BRAF	KIAA1549-BRAF	Skin Melanoma	Trametinib		Predictive	Supports	C	Sensitivity/Response	26072686	accepted
EGFR	EXPRESSION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Sensitivity/Response	18003960	accepted
PTGS2	OVEREXPRESSION	Colorectal Cancer	Aspirin		Predictive	Supports	B	Sensitivity/Response	17522398	accepted
BRAF	V600	Lung Non-small Cell Carcinoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	26287849	accepted
BRAF	V600	Langerhans-Cell Histiocytosis	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	26287849	accepted
BRAF	V600	Colorectal Cancer	Vemurafenib		Predictive	Supports	B	Resistance	26287849	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	26466010	accepted
BRAF	V600E	Hairy Cell Leukemia	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	26352686	accepted
KRAS	G12D	Hairy Cell Leukemia	Vemurafenib		Predictive	Supports	C	Resistance	26352686	accepted
MET	OVEREXPRESSION	Skin Melanoma	Vemurafenib		Predictive	Supports	B	Resistance	26359985	accepted
MET	OVEREXPRESSION	Uveal Melanoma	Crizotinib		Predictive	Supports	D	Sensitivity/Response	24140933	accepted
DNMT3A	MUTATION	Acute Myeloid Leukemia	Decitabine		Predictive	Supports	B	Sensitivity/Response	22124213	accepted
MET	AMPLIFICATION	Colorectal Cancer	Crizotinib,Vemurafenib	Combination	Predictive	Supports	C	Sensitivity/Response	27325282	accepted
BRAF	V600E	Colorectal Cancer	Panitumumab,Vemurafenib	Combination	Predictive	Supports	C	Sensitivity/Response	27325282	accepted
BRAF	V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	27460442	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib		Predictive	Supports	A	Sensitivity/Response	26729184	accepted
RB1	LOSS-OF-FUNCTION	Glioblastoma Multiforme	Palbociclib		Predictive	Supports	D	Resistance	20354191	accepted
RAD23B	EXPRESSION	Sarcoma	Vorinostat		Predictive	Supports	D	Sensitivity/Response	27499916	accepted
PIK3CA	MUTATION	Breast Cancer	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	25002028	accepted
RET	CCDC6-RET	Lung Non-small Cell Carcinoma	Nintedanib		Predictive	Supports	C	Sensitivity/Response	26787234	accepted
MAP2K1	C121S	Melanoma	Vemurafenib		Predictive	Supports	C	Resistance	21383288	accepted
FGFR3	S249C	Urothelial Carcinoma	Pazopanib		Predictive	Supports	C	Sensitivity/Response	25766722	accepted
FGFR1	AMPLIFICATION	Breast Cancer	Dovitinib		Predictive	Supports	B	Sensitivity/Response	23658459	accepted
FGFR2	AMPLIFICATION	Breast Cancer	Dovitinib		Predictive	Supports	B	Sensitivity/Response	23658459	accepted
FGF3	AMPLIFICATION	Breast Cancer	Dovitinib		Predictive	Supports	B	Sensitivity/Response	23658459	accepted
PIK3CA	MUTATION	Breast Cancer	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Combination	Predictive	Supports	D	Sensitivity/Response	25002028	accepted
VHL	R200W (c.598C>T)	Chuvash Polycythemia	Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	27518686	accepted
RB1	PHOSPHORYLATION	Breast Cancer	Alpelisib		Predictive	Supports	B	Resistance	25002028	accepted
PIK3CA	MUTATION	Breast Cancer	Everolimus,MTOR Kinase Inhibitor PP242	Substitutes	Predictive	Supports	D	Sensitivity/Response	21358673	accepted
PIK3R1	MUTATION	Breast Cancer	MTOR Kinase Inhibitor PP242		Predictive	Supports	D	Sensitivity/Response	21358673	accepted
ERBB2	AMPLIFICATION	Breast Cancer	MTOR Kinase Inhibitor PP242		Predictive	Supports	D	Sensitivity/Response	21358673	accepted
PTEN	LOSS	Endometrial Cancer	Temsirolimus		Predictive	Supports	D	Sensitivity/Response	23674493	accepted
PIK3CA	MUTATION	Endometrial Cancer	Pictilisib		Predictive	Supports	D	Sensitivity/Response	23674493	accepted
STK11	D194E	Pancreatic Cancer	Everolimus		Predictive	Supports	C	Sensitivity/Response	21189378	accepted
STK11	LOSS	Peutz-Jeghers Syndrome	Sirolimus		Predictive	Supports	D	Sensitivity/Response	18281551	accepted
STK11	LOSS	Peutz-Jeghers Syndrome	Sirolimus		Predictive	Supports	D	Sensitivity/Response	19541609	accepted
AKT2	AMPLIFICATION	Lung Adenocarcinoma	Everolimus,Vandetanib	Combination	Predictive	Supports	C	Sensitivity/Response	25982012	accepted
RET	KIF5B-RET	Lung Adenocarcinoma	Vandetanib,Everolimus	Combination	Predictive	Supports	C	Sensitivity/Response	25982012	accepted
PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	Everolimus,Fulvestrant	Combination	Predictive	Supports	C	Sensitivity/Response	27445490	accepted
PTEN	EXPRESSION	Her2-receptor Positive Breast Cancer	Fulvestrant,Everolimus	Combination	Predictive	Supports	C	Resistance	27445490	accepted
PIK3CA	H1047R	Thyroid Cancer	Perifosine,Temsirolimus	Substitutes	Predictive	Supports	D	Sensitivity/Response	19706758	accepted
PIK3CA	E542K	Thyroid Cancer	Perifosine,Temsirolimus	Substitutes	Predictive	Supports	D	Sensitivity/Response	19706758	accepted
PTEN	R130*	Thyroid Cancer	Perifosine,Temsirolimus	Substitutes	Predictive	Supports	D	Sensitivity/Response	19706758	accepted
FBXW7	LOSS-OF-FUNCTION	Renal Cell Carcinoma	Everolimus		Predictive	Supports	E	Sensitivity/Response	24253377	accepted
CCNE1	AMPLIFICATION	Estrogen-receptor Positive Breast Cancer	Palbociclib		Predictive	Supports	D	Resistance	27020857	accepted
RB1	M695FS*26	Estrogen-receptor Positive Breast Cancer	Palbociclib		Predictive	Supports	D	Resistance	27020857	accepted
FBXW7	MUTATION	Cancer	MTOR Inhibitor		Predictive	Supports	B	Sensitivity/Response	24586741	accepted
FBXW7	LOSS-OF-FUNCTION	Cancer	Sirolimus		Predictive	Supports	D	Sensitivity/Response	18787170	accepted
JUN	OVEREXPRESSION	Colorectal Adenocarcinoma	Irbesartan		Predictive	Supports	C	Sensitivity/Response	27022066	accepted
FOS	OVEREXPRESSION	Colon Adenocarcinoma	Irbesartan		Predictive	Supports	C	Sensitivity/Response	27022066	accepted
MYD88	L265P	Waldenström's Macroglobulinemia	IMG-2005-5,IRAK-1/4 Inhibitor	Substitutes	Predictive	Supports	D	Sensitivity/Response	22931316	accepted
KRAS	MUTATION	Hepatocellular Carcinoma	Refametinib,Sorafenib	Combination	Predictive	Supports	B	Sensitivity/Response	25294897	accepted
SMAD4	DELETION	Colorectal Cancer	Fluorouracil		Predictive	Supports	B	Resistance	12237773	accepted
ATRX	UNDEREXPRESSION	Astrocytoma	Procarbazine,Lomustine,Vincristine,Temozolomide	Substitutes	Predictive	Supports	B		23904111	accepted
AURKA	OVEREXPRESSION	Ovarian Serous Carcinoma	Platinum Compound		Predictive	Supports	B	Resistance	27209210	accepted
MET	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26845194	accepted
MET	D1228N	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	27343442	accepted
AURKA	EXPRESSION	Esophagus Squamous Cell Carcinoma	Fluorouracil,Cisplatin	Combination	Predictive	Supports	B	Sensitivity/Response	25924824	accepted
GAS6	EXPRESSION	Prostate Cancer	Docetaxel		Predictive	Supports	D	Resistance	27153245	accepted
STAG2	UNDEREXPRESSION	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	27500726	accepted
STAG3	UNDEREXPRESSION	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	27500726	accepted
MAP2K1	Q56_V60del	Ovarian Serous Carcinoma	Selumetinib		Predictive	Supports	C	Sensitivity/Response	26324360	accepted
BRAF	BRAF-CUL1	Ovarian Serous Carcinoma	Mitogen-Activated Protein Kinase Kinase Inhibitor		Predictive	Supports	C	Sensitivity/Response	26324360	accepted
BRAF	ZKSCAN1-BRAF	Melanoma	Trametinib		Predictive	Supports	C	Sensitivity/Response	26314551	accepted
BRAF	KIAA1549-BRAF	Sarcoma	Temsirolimus,Bevacizumab,Sorafenib	Combination	Predictive	Supports	C	Sensitivity/Response	24422672	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	18509184	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	18509184	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Erlotinib,Afatinib,Gefitinib	Substitutes	Predictive	Supports	B	Resistance	27304188	accepted
BRAF	L505H	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24112705	accepted
BRAF	L505H	Melanoma	Vemurafenib		Predictive	Supports	B	Resistance	25515853	accepted
PIK3CA	E545K	Lung Adenocarcinoma	Afatinib,Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Resistance	27304188	accepted
NF2	MUTATION	Acoustic Neuroma	Everolimus		Predictive	Supports	B	N/A	25567352	accepted
BRCA1	MUTATION	Ovarian Cancer	Cediranib,Olaparib	Combination	Predictive	Supports	B	Sensitivity/Response	25218906	accepted
BRCA2	MUTATION	Ovarian Cancer	Cediranib,Olaparib	Combination	Predictive	Supports	B	Sensitivity/Response	25218906	accepted
BRCA1	MUTATION	Triple-receptor Negative Breast Cancer	Cisplatin,Carboplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	25847936	accepted
BRCA2	MUTATION	Triple-receptor Negative Breast Cancer	Cisplatin,Carboplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	25847936	accepted
ERBB2	AMPLIFICATION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	22586653	accepted
ERBB2	AMPLIFICATION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	22586653	accepted
ERBB2	AMPLIFICATION	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	23348520	accepted
ERBB2	AMPLIFICATION	Colorectal Cancer	Trastuzumab,Lapatinib	Combination	Predictive	Supports	B	Sensitivity/Response	27108243	accepted
ROS1	REARRANGEMENT	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25922291	accepted
ALK	ALK FUSIONS	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25922291	accepted
MET	AMPLIFICATION	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25922291	accepted
ERBB2	AMPLIFICATION	Scrotum Paget's Disease	Trastuzumab		Predictive	Supports	C	Sensitivity/Response	25692060	accepted
ERBB2	MUTATION	Bladder Carcinoma	Platinum Compound		Predictive	Supports	C	Sensitivity/Response	25636205	accepted
BRAF	V600E	Multiple Myeloma	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	24997557	accepted
BRAF	V600E	Multiple Myeloma	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	24997557	accepted
KRAS	MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	22586653	accepted
NRAS	MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	22586653	accepted
BRAF	MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	22586653	accepted
PIK3CA	MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	22586653	accepted
MYCL	EXPRESSION	Multiple Myeloma	I-BET151,JQ1	Substitutes	Predictive	Supports	D	Sensitivity/Response	27276402	accepted
HGF	EXPRESSION	Glioblastoma Multiforme	MET Tyrosine Kinase Inhibitor SGX523		Predictive	Supports	D	Sensitivity/Response	22203985	accepted
EGFR	EXPRESSION	Colorectal Cancer	Panitumumab		Predictive	Supports	B	Sensitivity/Response	17470858	accepted
EGFR	EXPRESSION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Sensitivity/Response	14993230	accepted
SOX10	LOSS	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24670642	accepted
FGF2	EXPRESSION	Acute Myeloid Leukemia	Quizartinib		Predictive	Supports	D	Resistance	27671675	accepted
MET	AMPLIFICATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	27664533	accepted
MET	AMPLIFICATION	Cancer	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25232318	accepted
ERRFI1	E384*	Cholangiocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	24550739	accepted
KIT	D816V	Systemic Mastocytosis	Midostaurin		Predictive	Supports	B	Sensitivity/Response	27355533	accepted
ESR1	S463P	Estrogen-receptor Positive Breast Cancer	Aromatase Inhibitor		Predictive	Supports	D	Resistance	24185512	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	27083334	accepted
SGK1	OVEREXPRESSION	Breast Cancer	Alpelisib		Predictive	Supports	D	Resistance	27451907	accepted
SGK1	OVEREXPRESSION	Breast Cancer	Alpelisib		Predictive	Supports	B	Resistance	27451907	accepted
SGK1	OVEREXPRESSION	Breast Cancer	Alpelisib,SGK1-Inh	Combination	Predictive	Supports	D	Sensitivity/Response	27451907	accepted
CD274	EXPRESSION	Lung Non-small Cell Carcinoma	Pembrolizumab		Predictive	Supports	B	Sensitivity/Response	27718847	accepted
CCNE1	OVEREXPRESSION	Ovarian Cancer	CDK Inhibitor SNS-032		Predictive	Supports	D	Sensitivity/Response	26204491	accepted
CCNE1	AMPLIFICATION	Ovarian Serous Cystadenocarcinoma	Dinaciclib,Akt Inhibitor MK2206	Combination	Predictive	Supports	D	Sensitivity/Response	27663592	accepted
EGFR	G719S	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	26124334	accepted
BRAF	G596C	Lung Non-small Cell Carcinoma	Dabrafenib,Trametinib	Combination	Predictive	Supports	D	Sensitivity/Response	27577079	accepted
SMARCB1	UNDEREXPRESSION	Synovial Sarcoma	Tazemetostat		Predictive	Supports	D	Sensitivity/Response	27391784	accepted
SMARCB1	DELETION	Rhabdoid Cancer	Tazemetostat		Predictive	Supports	D	Sensitivity/Response	23620515	accepted
NF2	LOSS	Thyroid Gland Carcinoma	Selumetinib		Predictive	Supports	D	Sensitivity/Response	26359368	accepted
NF1	LOSS	Malignant Peripheral Nerve Sheath Tumor	JQ1 Compound		Predictive	Supports	D	Sensitivity/Response	24373973	accepted
ERBB3	V104M	Urothelial Carcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	27044931	accepted
ERBB3	R103G	Urothelial Carcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	27044931	accepted
ERBB3	G284R	Urothelial Carcinoma	Afatinib		Predictive	Supports	B	Sensitivity/Response	27044931	accepted
BRAF	V600E	Melanoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	20818844	accepted
BRAF	V600	Melanoma	Trametinib		Predictive	Supports	B	Sensitivity/Response	22663011	accepted
MTHFR	A222V	Rectum Cancer	Fluorouracil		Predictive	Supports	B	Sensitivity/Response	26693073	accepted
EGFR	D761Y	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	C	Resistance	17085664	accepted
ERBB2	AMPLIFICATION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	21172893	accepted
CDKN2A	LOSS	Her2-receptor Negative Breast Cancer	Palbociclib,Letrozole	Combination	Predictive	Supports	C	Sensitivity/Response	26715889	accepted
CRBN	MUTATION	Multiple Myeloma	Lenalidomide,Pomalidomide	Substitutes	Predictive	Supports	C	Resistance	23480694	accepted
FGFR1	AMPLIFICATION	Estrogen-receptor Positive Breast Cancer	Ponatinib		Predictive	Supports	D	Sensitivity/Response	22238366	accepted
BTK	C481S	Chronic Lymphocytic Leukemia	Ibrutinib		Predictive	Supports	B	Resistance	26182309	accepted
PDGFRA	AMPLIFICATION	Lung Non-small Cell Carcinoma	Sunitinib		Predictive	Supports	D	Sensitivity/Response	19366796	accepted
BRCA1	MUTATION	Ovarian Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	21862407	accepted
BRCA2	MUTATION	Ovarian Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	21862407	accepted
PDGFRA	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib		Predictive	Supports	C	Sensitivity/Response	24456122	accepted
BRCA1	MUTATION	Triple-receptor Negative Breast Cancer	Olaparib		Predictive	Supports	B	Resistance	21862407	accepted
PDGFRA	FIP1L1-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Ponatinib		Predictive	Supports	D	Sensitivity/Response	24407160	accepted
PDGFRA	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Ponatinib		Predictive	Supports	D	Sensitivity/Response	24407160	accepted
EGFR	G719	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	B	Sensitivity/Response	26773740	accepted
BRD4	BRD4-NUTM1	NUT Midline Carcinoma	JQ1		Predictive	Supports	D	Sensitivity/Response	20871596	accepted
EGFR	S720	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	26773740	accepted
EGFR	K757R	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	26773740	accepted
EGFR	E746G	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	26773740	accepted
UGT1A1	UGT1A1*28	Cancer	Belinostat		Predictive	Supports	A	Adverse Response	26313268	accepted
UGT1A1	UGT1A1*60	Cancer	Belinostat		Predictive	Supports	B	Adverse Response	26313268	accepted
EGFR	V769_770insASV	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	26773740	accepted
DPYD	DPYD*2A HOMOZYGOSITY	Cancer	Capecitabine,Tegafur,Fluorouracil	Substitutes	Predictive	Supports	A	Adverse Response	23988873	accepted
DPYD	DPYD*13 HOMOZYGOSITY	Cancer	Fluorouracil,Tegafur,Capecitabine	Substitutes	Predictive	Supports	A	Adverse Response	23988873	accepted
DPYD	RS67376798 HOMOZYGOSITY	Cancer	Capecitabine,Fluorouracil,Tegafur	Substitutes	Predictive	Supports	A	Adverse Response	23988873	accepted
EGFR	EXON 20 INSERTION	Lung Adenocarcinoma	Afatinib		Predictive	Supports	B	Resistance	26051236	accepted
PDGFRA	TNKS2-PDGFRA	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib		Predictive	Supports	C	Sensitivity/Response	25658984	accepted
SLCO1B1	RS4149056	Cancer	Methotrexate		Predictive	Supports	B	Adverse Response	23652803	accepted
SLCO1B1	N130D	Cancer	Methotrexate		Predictive	Supports	B	Adverse Response	23652803	accepted
TYMS	RS34743033	Cancer	Methotrexate		Predictive	Supports	B	Adverse Response	23652803	accepted
ERBB3	V855A	Lung Non-small Cell Carcinoma	Afatinib,Pertuzumab	Substitutes	Predictive	Supports	D	Sensitivity/Response	26689995	accepted
FGFR2	FGFR2-BICC1	Cholangiocarcinoma	PD173074,Infigratinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24122810	accepted
FGFR2	FGFR2-AHCYL1	Cholangiocarcinoma	PD173074,Infigratinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24122810	accepted
PTPRD	V253I	Ewing Sarcoma Of Bone	Teprotumumab,Cixutumumab	Substitutes	Predictive	Supports	C	Sensitivity/Response	23800680	accepted
RRM1	OVEREXPRESSION	Pancreatic Cancer	Gemcitabine		Predictive	Supports	D	Resistance	17224927	accepted
RRM2	OVEREXPRESSION	Pancreatic Cancer	Gemcitabine		Predictive	Supports	D	Resistance	17224927	accepted
POLE	MUTATION	Glioblastoma Multiforme	Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	27683556	accepted
POLE	MUTATION	Endometrial Cancer	Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	27159395	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	B	Resistance	24035188	accepted
MET	D1228V	Lung Non-small Cell Carcinoma	Cabozantinib		Predictive	Supports	C	Sensitivity/Response	27694386	accepted
MET	D1228V	Lung Non-small Cell Carcinoma	Savolitinib		Predictive	Supports	C	Resistance	27694386	accepted
RB1	MUTATION	Lung Small Cell Carcinoma	Chemotherapy		Predictive	Supports	B	Sensitivity/Response	26802149	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib		Predictive	Supports	A	Sensitivity/Response	27959700	accepted
NTRK1	SQSTM1-NTRK1	Lung Non-small Cell Carcinoma	Entrectinib		Predictive	Supports	C	Sensitivity/Response	26565381	accepted
NTRK3	ETV6-NTRK3	Salivary Gland Carcinoma	Entrectinib		Predictive	Supports	C	Sensitivity/Response	26884591	accepted
NTRK3	ETV6-NTRK3 G623R	Breast Cancer	Entrectinib		Predictive	Supports	C	Resistance	26884591	accepted
MSH2	LOSS	Urothelial Carcinoma	Durvalumab,Anti-PD-1 Monoclonal Antibody MEDI0680	Combination	Predictive	Supports	C	Sensitivity/Response	26674132	accepted
MSH6	LOSS	Urothelial Carcinoma	Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab	Combination	Predictive	Supports	C	Sensitivity/Response	26674132	accepted
CDKN2A	LOSS	Ewing Sarcoma	Linsitinib,Palbociclib	Substitutes	Predictive	Supports	D	Sensitivity/Response	27286459	accepted
CDKN2B	LOSS	Ewing Sarcoma	Palbociclib,Linsitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	27286459	accepted
CDKN2A	LOSS	Dermatofibrosarcoma Protuberans	Palbociclib		Predictive	Supports	D	Sensitivity/Response	25852058	accepted
ERBB2	Y772_A775DUP	Lung Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	22325357	accepted
ERBB2	G776L	Lung Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	22325357	accepted
ERBB2	G778_P780DUP	Lung Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	22325357	accepted
ERBB2	G778_P780DUP	Lung Non-small Cell Carcinoma	Dacomitinib		Predictive	Supports	C	Sensitivity/Response	25899785	accepted
ERBB2	M774DELINSWLV	Lung Non-small Cell Carcinoma	Dacomitinib		Predictive	Supports	C	Sensitivity/Response	25899785	accepted
PTPRB	LOSS-OF-FUNCTION	Angiosarcoma	Sunitinib		Predictive	Supports	D	Sensitivity/Response	24633157	accepted
BRCA1	MUTATION	Ovarian Cancer	Rucaparib		Predictive	Supports	B	Sensitivity/Response	27908594	accepted
KRAS	G12D	Colorectal Cancer	Therapeutic Tumor Infiltrating Lymphocytes		Predictive	Supports	C	Sensitivity/Response	27959684	accepted
HLA-C	COPY-NEUTRAL LOSS OF HETEROZYGOSITY	Colorectal Cancer	Therapeutic Tumor Infiltrating Lymphocytes		Predictive	Supports	C	Resistance	27959684	accepted
JAK1	S703I	Hepatocellular Carcinoma	Ruxolitinib		Predictive	Supports	D	Sensitivity/Response	26701727	accepted
BRAF	V600E	Colorectal Cancer	Cetuximab,Vemurafenib,Irinotecan	Combination	Predictive	Supports	B	Sensitivity/Response	27729313	accepted
ARAF	S490T	Colorectal Cancer	Cetuximab,Vemurafenib,Irinotecan	Combination	Predictive	Supports	C	Resistance	27729313	accepted
GNAS	R201C	Colorectal Cancer	Vemurafenib,Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	27729313	accepted
ATM	MUTATION	Mantle Cell Lymphoma	Olaparib		Predictive	Supports	D	Sensitivity/Response	20124459	accepted
FGFR1	AMPLIFICATION	Lung Squamous Cell Carcinoma	Infigratinib		Predictive	Supports	B	Sensitivity/Response	27870574	accepted
FGFR3	MUTATION	Bladder Carcinoma	Infigratinib		Predictive	Supports	B	Sensitivity/Response	27870574	accepted
FGFR2	MUTATION	Cholangiocarcinoma	Infigratinib		Predictive	Supports	C	Sensitivity/Response	27870574	accepted
FGFR2	FUSION	Cholangiocarcinoma	Infigratinib		Predictive	Supports	C	Sensitivity/Response	27870574	accepted
FGFR2	FGFR2-BICC1	Urothelial Carcinoma	Erdafitinib		Predictive	Supports	C	Sensitivity/Response	26324363	accepted
FGFR2	FUSION	Cancer	Erdafitinib		Predictive	Supports	B	Sensitivity/Response	26324363	accepted
FGFR3	FGFR3-TACC3	Cancer	Erdafitinib		Predictive	Supports	B	Sensitivity/Response	26324363	accepted
FGFR2	FGFR2-BICC1	Endometrial Cancer	Erdafitinib		Predictive	Supports	C	Sensitivity/Response	26324363	accepted
AKT3	OVEREXPRESSION	Breast Cancer	Akt Inhibitor MK2206		Predictive	Supports	D	Resistance	27297869	accepted
AKT3	OVEREXPRESSION	Triple-receptor Negative Breast Cancer	Pan-AKT Kinase Inhibitor GSK690693		Predictive	Supports	E	Sensitivity/Response	24335962	accepted
BRCA1	LOSS-OF-FUNCTION	Breast Cancer	Quarfloxin,Pol I Inhibitor CX5461	Substitutes	Predictive	Supports	D	Sensitivity/Response	28211448	accepted
BRCA2	LOSS-OF-FUNCTION	Breast Cancer	Quarfloxin,Pol I Inhibitor CX5461	Substitutes	Predictive	Supports	D	Sensitivity/Response	28211448	accepted
ALK	ALTERNATIVE TRANSCRIPT (ATI)	Skin Melanoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26444240	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	20022809	accepted
GNA11	MUTATION	Uveal Melanoma	MEK Inhibitor PD0325901,Sotrastaurin Acetate	Combination	Predictive	Supports	D	Sensitivity/Response	24141786	accepted
GNAQ	MUTATION	Uveal Melanoma	MEK Inhibitor PD0325901,Sotrastaurin Acetate	Combination	Predictive	Supports	D	Sensitivity/Response	24141786	accepted
NF1	MUTATION	Plexiform Neurofibroma	Selumetinib		Predictive	Supports	B	Sensitivity/Response	28029918	accepted
ATM	MUTATION	Prostate Cancer	Olaparib		Predictive	Supports	C	Sensitivity/Response	26510020	accepted
PALB2	BIALLELIC INACTIVATION	Prostate Cancer	Olaparib		Predictive	Supports	C	Sensitivity/Response	26510020	accepted
MET	AMPLIFICATION	Colorectal Cancer	Anti-EGFR Monoclonal Antibody		Predictive	Supports	D	Resistance	23729478	accepted
PDGFRA	P577S	Melanoma	Imatinib,Crenolanib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24132921	accepted
PDGFRA	R841K	Melanoma	Imatinib,Crenolanib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24132921	accepted
PDGFRA	H845Y	Melanoma	Crenolanib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24132921	accepted
PDGFRA	G853D	Melanoma	Crenolanib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	24132921	accepted
MET	AMPLIFICATION	Colorectal Cancer	Cetuximab,Crizotinib	Combination	Predictive	Supports	D	Sensitivity/Response	23729478	accepted
MTAP	Underexpression	Breast Cancer	Pyrimidine Antagonist		Predictive	Supports	D	Sensitivity/Response	26751376	accepted
VPS37A	UNDEREXPRESSION	Ovarian Cancer	Cetuximab		Predictive	Supports	D	Resistance	22016507	accepted
EGFR	EXPRESSION	Chordoma	Lapatinib		Predictive	Supports	B	Sensitivity/Response	23559153	accepted
BTK	T316A	Chronic Lymphocytic Leukemia	Ibrutinib		Predictive	Supports	C	Resistance	27626698	accepted
ERBB2	T862A	Stomach Carcinoma	Lapatinib		Predictive	Supports	D	Sensitivity/Response	22046346	accepted
ERBB2	V773A	Head And Neck Squamous Cell Carcinoma	Lapatinib		Predictive	Supports	D	Sensitivity/Response	22046346	accepted
ERBB2	N857S	Ovarian Cancer	Lapatinib		Predictive	Supports	D	Sensitivity/Response	22046346	accepted
ERBB2	H878Y	Hepatocellular Carcinoma	Lapatinib		Predictive	Supports	D	Sensitivity/Response	22046346	accepted
FGFR2	AMPLIFICATION	Stomach Carcinoma	FGFR Inhibitor AZD4547		Predictive	Supports	B	Sensitivity/Response	27179038	accepted
FGFR1	AMPLIFICATION	Breast Cancer	FGFR Inhibitor AZD4547		Predictive	Supports	C	Sensitivity/Response	27179038	accepted
ERBB2	OVEREXPRESSION	Head And Neck Squamous Cell Carcinoma	Lapatinib		Predictive	Supports	C	Sensitivity/Response	28061634	accepted
ERBB2	AMPLIFICATION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	28223103	accepted
GNAS	T393C	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Resistance	24758907	accepted
KRAS	G12V	Colorectal Cancer	Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	22392911	accepted
KRAS	G12A	Colorectal Cancer	Panitumumab		Predictive	Supports	C	Resistance	18316791	accepted
KRAS	G12A	Lung Cancer	Gefitinib		Predictive	Supports	B	Resistance	17409929	accepted
KRAS	G12A	Multiple Myeloma	Melphalan		Predictive	Supports	B	Resistance	19284554	accepted
KRAS	G12A	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	11050000	accepted
KRAS	G12A	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	12483530	accepted
KRAS	G12A	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	16497971	accepted
IDH1	R132	Malignant Glioma	Bevacizumab,Sunitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	22199315	accepted
PIK3CA	E545K	Breast Cancer	Pictilisib Bismesylate		Predictive	Supports	D	Sensitivity/Response	20453058	accepted
PTEN	LOSS	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	B	Resistance	21594665	accepted
PIK3CA	E545K	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	26920887	accepted
PIK3CA	E545K	Lung Non-small Cell Carcinoma	PI103		Predictive	Supports	D	Sensitivity/Response	19513541	accepted
PTEN	LOSS	Breast Cancer	Trastuzumab		Predictive	Supports	B	Resistance	21594665	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	21258250	accepted
PIK3CA	MUTATION	Breast Cancer	Trastuzumab		Predictive	Supports	B	Resistance	21594665	accepted
PIK3CA	MUTATION	Her2-receptor Positive Breast Cancer	Trastuzumab		Predictive	Supports	B	Resistance	21594665	accepted
PIK3CA	H1047R	Breast Cancer	Trastuzumab		Predictive	Supports	D	Resistance	20453058	accepted
PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	26920887	accepted
BRAF	V600E	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	B	Resistance	19001320	accepted
BRAF	V600E	Colorectal Cancer	Oxaliplatin		Predictive	Supports	B	Resistance	19603024	accepted
BRAF	V600E	Colorectal Cancer	Irinotecan		Predictive	Supports	B	Resistance	19603024	accepted
BRAF	V600E	Colorectal Cancer	Bevacizumab		Predictive	Supports	B	Resistance	19571295	accepted
BRAF	V600E	Melanoma	Trametinib		Predictive	Supports	B	Sensitivity/Response	22663011	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	19692680	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	22452896	accepted
EGFR	Ex19 del L858R	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	24755888	accepted
EGFR	T790M	Lung Adenocarcinoma	Osimertinib		Predictive	Supports	C	Sensitivity/Response	26269204	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Resistance	15737014	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Resistance	17020982	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Lapatinib		Predictive	Supports	D	Resistance	18408761	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Dacomitinib		Predictive	Supports	D	Sensitivity/Response	18089823	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Neratinib		Predictive	Supports	D	Sensitivity/Response	16818618	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	18408761	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	21732342	accepted
EGFR	T790M	Lung Non-small Cell Carcinoma	Canertinib		Predictive	Supports	D	Sensitivity/Response	18408761	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	15930265	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Resistance	19075254	accepted
KRAS	G13D	Colorectal Cancer	Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	22392911	accepted
NRAS	Q61K	Colorectal Cancer	Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	22392911	accepted
KRAS	A146T	Colorectal Cancer	Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	22392911	accepted
KRAS	A146V	Colorectal Cancer	Selumetinib,Dactolisib	Combination	Predictive	Supports	D	Sensitivity/Response	22392911	accepted
KRAS	G12C	Colorectal Cancer	Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	22392911	accepted
KRAS	G12D	Colorectal Cancer	Dactolisib,Selumetinib	Combination	Predictive	Supports	D	Sensitivity/Response	22392911	accepted
ATM	T2666A	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	MUTATION	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	R3008C	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	c.902-1G>T	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
KRAS	A146P	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	19603018	accepted
KRAS	G13D	Colorectal Cancer	Panitumumab		Predictive	Supports	C	Resistance	18316791	accepted
KRAS	G12V	Colorectal Cancer	Panitumumab		Predictive	Supports	C	Resistance	18316791	accepted
KRAS	G12D	Colorectal Cancer	Panitumumab		Predictive	Supports	C	Resistance	18316791	accepted
KRAS	G12D	Lung Cancer	Gefitinib		Predictive	Supports	B	Resistance	17409929	accepted
KRAS	G12D	Multiple Myeloma	Melphalan		Predictive	Supports	B	Resistance	19284554	accepted
KRAS	G12D	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	11050000	accepted
KRAS	G12D	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	12483530	accepted
KRAS	G12D	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	16497971	accepted
KRAS	G12C	Colorectal Cancer	Panitumumab		Predictive	Supports	C	Resistance	18316791	accepted
KRAS	G12C	Lung Cancer	Gefitinib		Predictive	Supports	B	Resistance	17409929	accepted
KRAS	G12C	Multiple Myeloma	Melphalan		Predictive	Supports	B	Resistance	19284554	accepted
KRAS	G12C	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	11050000	accepted
KRAS	G12C	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	12483530	accepted
KRAS	G12C	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	16497971	accepted
KRAS	G12R	Colorectal Cancer	Panitumumab		Predictive	Supports	C	Resistance	18316791	accepted
KRAS	G12V	Lung Cancer	Gefitinib		Predictive	Supports	C	Resistance	17409929	accepted
KRAS	G12S	Colorectal Cancer	Panitumumab		Predictive	Supports	C	Resistance	18316791	accepted
KRAS	G12S	Lung Cancer	Gefitinib		Predictive	Supports	B	Resistance	17409929	accepted
KRAS	G12S	Multiple Myeloma	Melphalan		Predictive	Supports	B	Resistance	19284554	accepted
KRAS	G12S	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	11050000	accepted
KRAS	G12S	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	12483530	accepted
KRAS	G12S	Multiple Myeloma	Melphalan		Predictive	Supports	D	Resistance	16497971	accepted
TP53	R273L	Ovarian Cancer	Cisplatin,Carboplatin	Substitutes	Predictive	Supports	C	Resistance	11595686	accepted
TP53	Y220C	Stomach Carcinoma	Cisplatin,Mitomycin,Etoposide	Combination	Predictive	Supports	C	Sensitivity/Response	14514923	accepted
TP53	R175H	Stomach Carcinoma	EAP Protocol		Predictive	Supports	C	Sensitivity/Response	14514923	accepted
IDH1	R132C	Brain Glioma	Temozolomide		Predictive	Supports	B	Sensitivity/Response	20975057	accepted
IDH1	R132C	Malignant Glioma	AGI-5198		Predictive	Supports	D	Sensitivity/Response	23558169	accepted
IDH1	R132	Malignant Glioma	Bevacizumab		Predictive	Supports	B	Sensitivity/Response	22199315	accepted
IDH1	R132C	Acute Myeloid Leukemia	Ivosidenib		Predictive	Supports	B	Sensitivity/Response	25583779	accepted
IDH1	R132C	Acute Myeloid Leukemia	BPTES		Predictive	Supports	D	Sensitivity/Response	24333121	accepted
PIK3CA	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Resistance	21258250	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Resistance	21258250	accepted
KIT	T417_D419delinsY	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Sensitivity/Response	18955451	accepted
KIT	D816V	Cancer	Imatinib		Predictive	Supports	D	Resistance	14645423	accepted
PDGFRA	D842V	Cancer	Imatinib		Predictive	Supports	D	Resistance	14645423	accepted
KIT	K484_G487DEL	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Sensitivity/Response	18955451	accepted
KIT	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Sensitivity/Response	14645423	accepted
KIT	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Sensitivity/Response	18955451	accepted
PDGFRA	V561D	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Sensitivity/Response	18955451	accepted
KIT	EXON 13 MUTATION	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Sensitivity/Response	14645423	accepted
KIT	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Reduced Sensitivity	18955451	accepted
PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Resistance	14645423	accepted
KIT	EXPRESSION	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	B	Sensitivity/Response	18955451	accepted
KIT	D579DEL	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Sensitivity/Response	14645423	accepted
BRAF	V600K	Melanoma	Dabrafenib		Predictive	Supports	B	Sensitivity/Response	21343559	accepted
BRAF	V600K	Melanoma	Trametinib		Predictive	Supports	B	Sensitivity/Response	22663011	accepted
EGFR	G719A	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	20038723	accepted
EGFR	WILDTYPE	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C		19692680	accepted
EGFR	E746_A750del	Bronchiolo-alveolar Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	15329413	accepted
EGFR	EXON 19 DELETION	Lung Adenocarcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	22370314	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	15329413	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	20038723	accepted
EGFR	L858R	Lung Adenocarcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	15329413	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	D	Sensitivity/Response	24893891	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Lapatinib		Predictive	Supports	D	Sensitivity/Response	18408761	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Dacomitinib		Predictive	Supports	D	Sensitivity/Response	18089823	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Neratinib		Predictive	Supports	D	Sensitivity/Response	16818618	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	D	Sensitivity/Response	18408761	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Canertinib		Predictive	Supports	D	Sensitivity/Response	18408761	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	15329413	accepted
EGFR	L858R	Lung Adenocarcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	22370314	accepted
ABL1	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	15930265	accepted
ABL1	BCR-ABL L248V	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL L248V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib,Dasatinib	Substitutes	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	15930265	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL Q252H	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Sensitivity/Response	19075254	accepted
ABL1	BCR-ABL Y253H	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	Y253F	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	Y253F	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	15930265	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	15930265	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL D276G	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL D276G	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Sensitivity/Response	19075254	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	15930265	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	15930265	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	15930265	accepted
ABL1	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Sensitivity/Response	19075254	accepted
ABL1	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	15930265	accepted
ABL1	BCR-ABL M351T	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Sensitivity/Response	19075254	accepted
ABL1	BCR-ABL H396R	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL H396R	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	15930265	accepted
TP53	Y234C	Ovarian Cancer	Cisplatin,Carboplatin	Substitutes	Predictive	Supports	C	Resistance	11595686	accepted
TP53	ALTERATION	Ovarian Cancer	Cisplatin,Carboplatin	Substitutes	Predictive	Supports	B	Resistance	11595686	accepted
TP53	DNA BINDING DOMAIN MUTATION	Breast Cancer	Tamoxifen		Predictive	Supports	B	Resistance	10786679	accepted
TP53	MUTATION	Breast Cancer	Tamoxifen		Predictive	Supports	C	Resistance	10786679	accepted
TP53	OVEREXPRESSION	Stomach Cancer	Mitomycin,Etoposide,Cisplatin	Combination	Predictive	Supports	B	Sensitivity/Response	14514923	accepted
TP53	R282L	Stomach Carcinoma	EAP Protocol		Predictive	Supports	C	Sensitivity/Response	14514923	accepted
TP53	R213P	Stomach Carcinoma	EAP Protocol		Predictive	Supports	C	Sensitivity/Response	14514923	accepted
TP53	MUTATION	Stomach Carcinoma	Etoposide,Doxorubicin,Cisplatin	Combination	Predictive	Supports	C	Sensitivity/Response	14514923	accepted
ABL1	BCR-ABL F486S	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Sensitivity/Response	19075254	accepted
ATM	c.7089+1del	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	c.7515+1_2del	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	K293*	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	F1025L	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	D1930V	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	E2187*	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	L2427P	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	F2732V	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	D1682H	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	A2062V	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ATM	C2488Y	Chronic Lymphocytic Leukemia	Doxorubicin		Predictive	Supports	D	Resistance	23585524	accepted
ABL1	BCR-ABL E255V	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Resistance	19075254	accepted
ABL1	BCR-ABL E255V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL E292V	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL F359C	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL L384M	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL V299L	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Sensitivity/Response	19075254	accepted
ABL1	BCR-ABL L387F	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL G398R	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Sensitivity/Response	19075254	accepted
BRCA1	M1V	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	M1I	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	C61G	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	C64Y	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	R71G	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	R71K	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	R1495M	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	E1559K	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	D1692N	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	R1443*	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA1	Q1467*	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA2	M1R	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA2	M1I	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA2	V159M	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA2	V211L	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA2	V211I	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA2	R2336P	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
BRCA2	R2336H	Ovarian Cancer	Rucaparib		Predictive	Supports	C	Sensitivity/Response	27908594	accepted
KIT	D820Y	Melanoma	Imatinib		Predictive	Supports	C	Resistance	21642685	accepted
KIT	D820Y	Melanoma	Sunitinib		Predictive	Supports	D		19035443	accepted
KIT	K642E	Mucosal Melanoma	Imatinib		Predictive	Supports	C	Sensitivity/Response	18510589	accepted
GNAS	T393C	Esophageal Cancer	Cisplatin,Fluorouracil	Combination	Predictive	Supports	B	Resistance	19274060	accepted
MGMT	UNDEREXPRESSION	Glioblastoma Multiforme	Temozolomide		Predictive	Supports	B	Sensitivity/Response	17442989	accepted
MGMT	UNDEREXPRESSION	Malignant Glioma	Temozolomide		Predictive	Supports	B	Sensitivity/Response	21365007	accepted
MGMT	UNDEREXPRESSION	Oligodendroglioma	Temozolomide		Predictive	Supports	B	Sensitivity/Response	16541434	accepted
MGMT	UNDEREXPRESSION	Glioblastoma Multiforme	Temozolomide		Predictive	Supports	B	Sensitivity/Response	21331613	accepted
MGMT	UNDEREXPRESSION	Neuroendocrine Tumor	Temozolomide		Predictive	Supports	B	Sensitivity/Response	19118063	accepted
RRM1	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Cisplatin,Gemcitabine	Combination	Predictive	Supports	B	Sensitivity/Response	24595080	accepted
NRAS	Q61K	Lung Non-small Cell Carcinoma	Selumetinib,Trametinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	23515407	accepted
FGFR1	EXPRESSION	Sarcoma	FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074,FGFR Inhibitor AZD4547,Infigratinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	27535980	accepted
KIT	N822K	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Resistance	16954519	accepted
KIT	Y823D	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Resistance	16954519	accepted
KIT	C809G	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Resistance	16954519	accepted
KIT	D820A	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Resistance	16954519	accepted
KIT	D820G	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Resistance	16954519	accepted
KIT	D816H	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Resistance	16954519	accepted
KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Resistance	16954519	accepted
DNMT3A	MUTATION	Cancer	Nivolumab,Pembrolizumab,Atezolizumab	Substitutes	Predictive	Supports	B	Resistance	28351930	accepted
BRAF	AMPLIFICATION	Colorectal Cancer	Panitumumab,Dabrafenib	Combination	Predictive	Supports	C	Resistance	25673644	accepted
NRAS	MUTATION	Skin Melanoma	Ribociclib,Binimetinib	Combination	Predictive	Supports	B	Sensitivity/Response	26987942	accepted
IDH1	MUTATION	Brain Glioma	Olaparib		Predictive	Supports	D	Sensitivity/Response	28148839	accepted
ROS1	G2032R	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Resistance	23724914	accepted
MAP2K1	K57N	Lung Adenocarcinoma	Selumetinib		Predictive	Supports	D	Sensitivity/Response	18632602	accepted
NRAS	MUTATION	Skin Melanoma	Binimetinib		Predictive	Supports	B	Sensitivity/Response	28284557	accepted
EGFR	MUTATION	Lung Cancer	Gefitinib		Predictive	Supports	B	Sensitivity/Response	17409929	accepted
CTAG1B	OVEREXPRESSION	Multiple Myeloma	Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794		Predictive	Supports	B	Sensitivity/Response	26193344	accepted
CTAG2	OVEREXPRESSION	Multiple Myeloma	Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794		Predictive	Supports	B	Sensitivity/Response	26193344	accepted
KRAS	A146T	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	20570890	accepted
NTRK1	NTRK1 FUSIONS	Lung Non-small Cell Carcinoma	Entrectinib		Predictive	Supports	C	Sensitivity/Response	26565381	accepted
NTRK1	NTRK1 FUSIONS	Cancer	Entrectinib		Predictive	Supports	B	Sensitivity/Response	28183697	accepted
NTRK3	NTRK3 FUSIONS	Cancer	Entrectinib		Predictive	Supports	B	Sensitivity/Response	28183697	accepted
NTRK1	SQSTM1-NTRK1	Lung Non-small Cell Carcinoma	Entrectinib		Predictive	Supports	C	Sensitivity/Response	28183697	accepted
ROS1	REARRANGEMENT	Cancer	Entrectinib		Predictive	Supports	B	Sensitivity/Response	28183697	accepted
ALK	ALK FUSIONS	Cancer	Entrectinib		Predictive	Supports	B	Sensitivity/Response	28183697	accepted
NTRK1	NTRK1 FUSIONS	Cancer	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	26603524	accepted
NTRK1	LMNA-NTRK1	Sarcoma	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	26216294	accepted
NTRK1	NTRK1 FUSIONS	Sarcoma	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	26216294	accepted
NTRK1	AMPLIFICATION	Cancer	Entrectinib		Predictive	Supports	B	Resistance	28183697	accepted
NTRK3	AMPLIFICATION	Cancer	Entrectinib		Predictive	Supports	B	Resistance	28183697	accepted
NTRK1	LMNA-NTRK1	Colorectal Adenocarcinoma	Entrectinib		Predictive	Supports	C	Sensitivity/Response	26546295	accepted
NTRK1	LMNA-NTRK1 G595R and G667C	Colorectal Adenocarcinoma	Entrectinib		Predictive	Supports	C	Resistance	26546295	accepted
TP53	WILD TYPE	Cancer	Nutlin-3a		Predictive	Supports	D	Sensitivity/Response	17671205	accepted
TP53	WILD TYPE	Cancer	AMGMDS3		Predictive	Supports	D	Sensitivity/Response	25730903	accepted
TP53	WILD TYPE	Leukemia	RG7112		Predictive	Supports	B	Sensitivity/Response	26459177	accepted
TP53	DELETERIOUS MUTATION	Leukemia	RG7112		Predictive	Supports	B	Resistance	26459177	accepted
TP53	DELETERIOUS MUTATION	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	DELETERIOUS MUTATION	Cancer	Nutlin-3a		Predictive	Supports	D	Resistance	17671205	accepted
ARID1A	LOSS-OF-FUNCTION	Ovarian Clear Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	27364904	accepted
ARID1A	LOSS-OF-FUNCTION	Ovarian Clear Cell Carcinoma	GSK126		Predictive	Supports	D	Sensitivity/Response	25686104	accepted
PIK3CA	E545K	Cervix Carcinoma	Pictilisib		Predictive	Supports	D	Sensitivity/Response	27489350	accepted
PIK3CA	E545K	Cervix Carcinoma	Cisplatin		Predictive	Supports	D	Resistance	27489350	accepted
ALK	F1245V	Neuroblastoma	Entrectinib		Predictive	Supports	C	Sensitivity/Response	28183697	accepted
CTNNB1	ACTIVATING MUTATION	Melanoma	Anti-CTLA-4 Monoclonal Antibody,Anti-PD-L1 Monoclonal Antibody	Substitutes	Predictive	Supports	D	Resistance	25970248	accepted
MERTK	OVEREXPRESSION	Melanoma	UNC1062		Predictive	Supports	D	Sensitivity/Response	23585477	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	A	Sensitivity/Response	24868098	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	A	Sensitivity/Response	24868098	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	A	Sensitivity/Response	23982599	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Afatinib		Predictive	Supports	A	Sensitivity/Response	23982599	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	Combination	Predictive	Supports	A	Resistance	28492898	accepted
CD274	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Radiation Therapy		Predictive	Supports	B	Resistance	28476872	accepted
MYC	OVEREXPRESSION	Lung Small Cell Carcinoma	Prexasertib,Cisplatin,Olaparib	Combination	Predictive	Supports	D	Sensitivity/Response	28490518	accepted
FLT3	D835V	Acute Myeloid Leukemia	Tandutinib		Predictive	Supports	D	Resistance	15256420	accepted
FLT3	D835V	Acute Myeloid Leukemia	Sunitinib,Cytarabine	Combination	Predictive	Supports	D	Sensitivity/Response	15304385	accepted
FLT3	D835V	Acute Myeloid Leukemia	Sunitinib,Daunorubicin	Combination	Predictive	Supports	D	Sensitivity/Response	15304385	accepted
TP53	OVEREXPRESSION	Ovarian Cancer	Carboplatin,Cisplatin	Substitutes	Predictive	Supports	B	Resistance	11595686	accepted
EGFR	AMPLIFICATION	Lung Non-small Cell Carcinoma	Osimertinib,Rociletinib	Substitutes	Predictive	Supports	D	Resistance	28202511	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	20038723	accepted
BRAF	V600E	Lung Non-small Cell Carcinoma	Dabrafenib,Trametinib	Combination	Predictive	Supports	A	Sensitivity/Response	27283860	accepted
FGFR1	AMPLIFICATION	Lung Non-small Cell Carcinoma	Dovitinib		Predictive	Supports	B	Sensitivity/Response	27315356	accepted
KIT	V559D	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	C	Sensitivity/Response	22114577	accepted
KIT	V559D	Cancer	PD-180970,Sunitinib,Dasatinib,Imatinib,Tandutinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	16046538	accepted
FLT3	D835V	Acute Myeloid Leukemia	AS602868,Tyrphostin AG 1296	Substitutes	Predictive	Supports	D	Sensitivity/Response	17330097	accepted
MET	OVEREXPRESSION	Uveal Melanoma	Selumetinib,Trametinib	Substitutes	Predictive	Supports	D	Resistance	25952648	accepted
AKT1	E17K	Cancer	Capivasertib		Predictive	Supports	B	Sensitivity/Response	28489509	accepted
PIK3CA	MUTATION	Cancer	Capivasertib		Predictive	Supports	B	Sensitivity/Response	28489509	accepted
TP53	R248Q	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
GNAS	R201H	Follicular Thyroid Carcinoma	Radioactive Iodine		Predictive	Supports	C	Sensitivity/Response	26788326	accepted
GNA11	MUTATION	Uveal Melanoma	Cabozantinib		Predictive	Supports	B	Sensitivity/Response	28103611	accepted
NRAS	G12D	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	25666295	accepted
KRAS	MUTATION	Colorectal Cancer	Chemotherapy,Cetuximab	Combination	Predictive	Supports	B	Resistance	20619739	accepted
KRAS	G12A	Colorectal Cancer	Regorafenib		Predictive	Supports	D	Resistance	26161928	accepted
PIK3CA	E545K	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
PIK3CA	E545G	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
PIK3CA	H1047R	Colorectal Cancer	Vemurafenib		Predictive	Supports	D	Resistance	22180495	accepted
BRAF	V600E	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	25666295	accepted
BRAF	V600E	Melanoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	23569304	accepted
BRAF	V600E	Melanoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	26557775	accepted
BRAF	V600E	Melanoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	25524477	accepted
BRAF	V600E	Skin Melanoma	Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	25399551	accepted
BRAF	V600E	Ganglioglioma	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	25524464	accepted
BRAF	V600E	Ovarian Cystadenocarcinoma	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	26490654	accepted
EGFR	Ex19 del L858R	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	B	Sensitivity/Response	22285168	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	B	Sensitivity/Response	15329413	accepted
EGFR	L861Q	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	21531810	accepted
EGFR	T790M	Cancer	Erlotinib		Predictive	Supports	D		19147750	accepted
EGFR	L858R	Cancer	Multikinase Inhibitor AEE788,Erlotinib,Gefitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	19147750	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Reduced Sensitivity	17264298	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Resistance	16775234	accepted
HRAS	G13D	Skin Squamous Cell Carcinoma	Vemurafenib		Predictive	Supports	C	Resistance	22256804	accepted
HRAS	G13D	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	26561417	accepted
KRAS	A146T	Colorectal Cancer	FOLFOX-4 Regimen,Cetuximab	Combination	Predictive	Supports	B	Resistance	25666295	accepted
KRAS	Q61H	Colorectal Cancer	Chemotherapy,Cetuximab	Combination	Predictive	Supports	C	Resistance	20619739	accepted
KRAS	Q61H	Colorectal Cancer	Cetuximab		Predictive	Supports	C	Resistance	22722830	accepted
KRAS	Q61L	Colorectal Cancer	Chemotherapy,Cetuximab	Combination	Predictive	Supports	C	Resistance	20619739	accepted
KRAS	Q61R	Colorectal Cancer	Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	20619739	accepted
KRAS	Q61K	Colorectal Cancer	Chemotherapy,Cetuximab	Combination	Predictive	Supports	C	Resistance	20619739	accepted
KRAS	G13D	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	22722830	accepted
KRAS	G13D	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	25666295	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	B	Resistance	21969500	accepted
KRAS	Q61	Colorectal Cancer	Chemotherapy,Cetuximab	Combination	Predictive	Supports	B	Resistance	20619739	accepted
KRAS	G12V	Colorectal Cancer	Regorafenib		Predictive	Supports	D	Resistance	26161928	accepted
KRAS	G12D	Colorectal Cancer	Regorafenib		Predictive	Supports	D	Resistance	26161928	accepted
KRAS	G12D	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
KRAS	G12D	Ovarian Cancer	Cetuximab		Predictive	Supports	D	Resistance	22246397	accepted
KRAS	G12C	Colorectal Cancer	Regorafenib		Predictive	Supports	D	Resistance	26161928	accepted
KRAS	G12R	Colorectal Cancer	Cetuximab		Predictive	Supports	D	Resistance	22722830	accepted
KRAS	G12R	Colorectal Cancer	Regorafenib		Predictive	Supports	D	Resistance	26161928	accepted
KRAS	G12S	Colorectal Cancer	Regorafenib		Predictive	Supports	D	Resistance	26161928	accepted
FLT3	D835V	Acute Myeloid Leukemia	Sunitinib		Predictive	Supports	C	Sensitivity/Response	15459012	accepted
AKT1	E17K	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
PDGFRA	D842V	Cancer	Sunitinib		Predictive	Supports	D	Resistance	18955458	accepted
KIT	V560_L576DEL	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	K550_K558del	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	C	Resistance	18955458	accepted
KIT	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	B	Resistance	18955458	accepted
KIT	W557_K558DELWK	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	C	Resistance	18955458	accepted
KIT	W557_K558DELWK	Gastrointestinal Stromal Tumor	Ponatinib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	W557_K558DELWK	Gastrointestinal Stromal Tumor	Sunitinib,Regorafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	K558_V559del	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	C	Resistance	18955458	accepted
KIT	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	C	Reduced Sensitivity	27371698	accepted
KIT	V560D	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	C	Resistance	18955458	accepted
KIT	P551_E554delPMYE	Gastrointestinal Stromal Tumor	Ponatinib		Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	V560D	Gastrointestinal Stromal Tumor	Sunitinib,Regorafenib,Ponatinib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	L576P	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	C	Resistance	18955458	accepted
KIT	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	B	Reduced Sensitivity	22614970	accepted
KIT	L576P	Cancer	Dasatinib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25317746	accepted
KIT	D579DEL	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	C	Resistance	18955458	accepted
KIT	WILDTYPE	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	B	Sensitivity/Response	27371698	accepted
KIT	K642E	Melanoma	Dasatinib		Predictive	Supports	C	Sensitivity/Response	21523734	accepted
KIT	N822K	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	D	Resistance	25239608	accepted
BRAF	V600K	Melanoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	25524477	accepted
BRAF	V600K	Skin Melanoma	Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	25399551	accepted
EGFR	R108K	Malignant Glioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	17177598	accepted
EGFR	T263P	Malignant Glioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	17177598	accepted
EGFR	A289V	Malignant Glioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	17177598	accepted
EGFR	G719	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	21531810	accepted
EGFR	G719S	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	19147750	accepted
EGFR	V742A	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	19147750	accepted
EGFR	E746_A750del	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	15329413	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	21969500	accepted
EGFR	E746_T751>I	Lung Adenocarcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	15329413	accepted
EGFR	G719D	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	C	Sensitivity/Response	21531810	accepted
EGFR	V774A	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	21531810	accepted
EGFR	V834I	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	21531810	accepted
EGFR	L838P	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	21531810	accepted
EGFR	V851I	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	21531810	accepted
EGFR	L858R	Cancer	Erlotinib		Predictive	Supports	D	Sensitivity/Response	17877814	accepted
EGFR	L747_P753delinsS	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	19147750	accepted
EGFR	S768I	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	22895145	accepted
EGFR	S768I	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	D	Resistance	19147750	accepted
EGFR	D770_N771insSVD	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Resistance	24353160	accepted
EGFR	H773_V774insH	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Resistance	24353160	accepted
EGFR	R831H	Malignant Mesothelioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	20942962	accepted
EGFR	L838V	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Resistance	19147750	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	18408761	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	21132006	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	24353160	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	27612423	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Resistance	22235099	accepted
EGFR	L858R	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	27032107	accepted
EGFR	L858R	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	27102076	accepted
EGFR	L858R	Lung Adenocarcinoma	Cetuximab		Predictive	Supports	D	Sensitivity/Response	27102076	accepted
EGFR	L858R	Malignant Glioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	17177598	accepted
EGFR	L861	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	21531810	accepted
EGFR	L861Q	Malignant Glioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	17177598	accepted
EGFR	E868G	Malignant Mesothelioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	20942962	accepted
ABL1	BCR-ABL L248V	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Reduced Sensitivity	22371878	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Reduced Sensitivity	17264298	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL Q252H	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	Y253F	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Reduced Sensitivity	17264298	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL D276G	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Resistance	21865346	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	B	Resistance	19779040	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	C	Sensitivity/Response	25686603	accepted
ABL1	BCR-ABL T315I	Acute Lymphoblastic Leukemia	Dasatinib		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Reduced Sensitivity	22371878	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL M351T	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Reduced Sensitivity	22371878	accepted
ABL1	BCR-ABL M351T	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Reduced Sensitivity	17264298	accepted
ABL1	BCR-ABL H396R	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL H396R	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL	Acute Lymphoblastic Leukemia	Dasatinib		Predictive	Supports	C	Sensitivity/Response	16775234	accepted
ABL1	BCR-ABL F486S	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL E255V	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL E255V	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Reduced Sensitivity	22371878	accepted
KIT	V559D	Gastrointestinal Stromal Tumor	Ponatinib,Regorafenib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25239608	accepted
EGFR	R776C	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	19147750	accepted
BRAF	D594G	Colorectal Cancer	Irinotecan,Cetuximab	Combination	Predictive	Supports	C	Resistance	26989027	accepted
ARID1A	Q456*	Ovarian Clear Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	27364904	accepted
BRAF	V600D	Melanoma	Vemurafenib		Predictive	Supports	D	Sensitivity/Response	18287029	accepted
BRAF	V600D	Melanoma	Vemurafenib		Predictive	Supports	D	Sensitivity/Response	20551065	accepted
EGFR	H773_V774insNPH	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	24353160	accepted
EGFR	D770_N771insGL	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	24353160	accepted
EGFR	A864T	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	19147750	accepted
EGFR	N826S	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Resistance	19147750	accepted
EGFR	A763_Y764insFQEA	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	24353160	accepted
AKT1	Q79K	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
EGFR	VIII	Malignant Glioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	17177598	accepted
KIT	T670I	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	D	Resistance	25239608	accepted
AKT3	E17K	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
ABL1	BCR-ABL L384M	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Resistance	19779040	accepted
ABL1	BCR-ABL M343T	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL F317V	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL V299L	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Reduced Sensitivity	22371878	accepted
ABL1	BCR-ABL V299L	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Resistance	19779040	accepted
ABL1	BCR-ABL L387F	Chronic Myeloid Leukemia	Bosutinib		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL G398R	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Sensitivity/Response	19075254	accepted
KIT	K550_W557del	Gastrointestinal Stromal Tumor	Sunitinib,Ponatinib,Regorafenib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	D820Y	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	C	Sensitivity/Response	22614970	accepted
KIT	K558NP	Gastrointestinal Stromal Tumor	Sunitinib,Ponatinib,Regorafenib,Imatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	N822K	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	C	Sensitivity/Response	22614970	accepted
PDGFRA	D842V	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	C	Resistance	18955458	accepted
KIT	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	B	Sensitivity/Response	23177515	accepted
KIT	V569_L576DEL	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	B	Sensitivity/Response	26772734	accepted
BRAF	EXON 15 MUTATION	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	C	Resistance	22614970	accepted
BRCA1	W1815X	Ovarian Cancer	Olaparib		Predictive	Supports	D	Sensitivity/Response	23415752	accepted
KIT	EXON 9 MUTATION	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	B	Sensitivity/Response	23177515	accepted
KIT	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	B	Sensitivity/Response	22614970	accepted
KIT	D816E	Gastrointestinal Stromal Tumor	Sunitinib,Imatinib	Substitutes	Predictive	Supports	D	Resistance	25239608	accepted
EGFR	D770_N771insGT	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	23371856	accepted
EGFR	EXON 20 INSERTION	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	22895145	accepted
SMO	L412F	Basal Cell Carcinoma	Vismodegib		Predictive	Supports	D	Resistance	25759020	accepted
SMO	L412F	Basal Cell Carcinoma	Vismodegib		Predictive	Supports	C	Resistance	26822128	accepted
EGFR	W731L	Malignant Mesothelioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	20942962	accepted
EGFR	E734Q	Malignant Mesothelioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	20942962	accepted
EGFR	T785A	Malignant Mesothelioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	20942962	accepted
EGFR	C797Y	Malignant Mesothelioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	20942962	accepted
EGFR	Y801H	Malignant Mesothelioma	Erlotinib		Predictive	Supports	D	Sensitivity/Response	20942962	accepted
EGFR	A767_V769dupASV	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	24353160	accepted
EGFR	L747_S752delinsQ	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	15329413	accepted
EGFR	L861R	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	C	Sensitivity/Response	21531810	accepted
ABL1	BCR-ABL	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Sensitivity/Response	16775234	accepted
ABL1	BCR-ABL E255K	Acute Lymphoblastic Leukemia	Dasatinib		Predictive	Supports	C	Resistance	16775234	accepted
EGFR	RARE Exon 18-21 Mutation	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	21531810	accepted
EGFR	Ex19 del L858R	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	21531810	accepted
EGFR	EXON 19 DELETION	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	27566387	accepted
POLD1	C284Y	Lung Adenocarcinoma	Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	25765070	accepted
POLD1	E374K	Lung Non-small Cell Carcinoma	Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	25765070	accepted
PIK3R2	N561D	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
PIK3CA	D350G	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
NRAS	Q179X	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	25666295	accepted
MET	EXON 14 SKIPPING MUTATION	Lung Adenocarcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25769807	accepted
ABL1	R351W	Lung Non-small Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	26758680	accepted
ABL1	G340L	Lung Non-small Cell Carcinoma	Imatinib Mesylate,Dasatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	26758680	accepted
KIT	S628N	Cancer	Imatinib,Dasatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25317746	accepted
EGFR	M766_A767insAI	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Resistance	24353160	accepted
EGFR	Y764_V765insHH	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	D	Resistance	24353160	accepted
EGFR	D770_N771insGY	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	24353160	accepted
EGFR	P772_H773insYNP	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	C	Resistance	24353160	accepted
EGFR	P772_V774insPHV	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Resistance	24353160	accepted
JAK2	F547 SPLICE SITE MUTATION	Melanoma	Pembrolizumab		Predictive	Supports	C	Resistance	27433843	accepted
ARID1A	P1175FS*5	Ovarian Clear Cell Carcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	27364904	accepted
VHL	MUTATION	Renal Cell Carcinoma	Anti-VEGF Monoclonal Antibody		Predictive	Supports	B	Resistance	28103578	accepted
IDH2	MUTATION	Acute Myeloid Leukemia	Enasidenib		Predictive	Supports	D	Sensitivity/Response	28193778	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Brigatinib		Predictive	Supports	B	Sensitivity/Response	28475456	accepted
BRCA1	LOSS-OF-FUNCTION	Breast Cancer	Talazoparib		Predictive	Supports	B	Sensitivity/Response	28242752	accepted
BRCA2	LOSS-OF-FUNCTION	Breast Cancer	Talazoparib		Predictive	Supports	B	Sensitivity/Response	28242752	accepted
ERBB2	OVEREXPRESSION	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	28526536	accepted
CDK4	AMPLIFICATION	Liposarcoma	Palbociclib		Predictive	Supports	B	Sensitivity/Response	27124835	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Abemaciclib		Predictive	Supports	B	Sensitivity/Response	27217383	accepted
RET	RET FUSIONS	Lung Non-small Cell Carcinoma	Cabozantinib		Predictive	Supports	B	Sensitivity/Response	27825636	accepted
RET	RET FUSIONS	Lung Non-small Cell Carcinoma	Vandetanib		Predictive	Supports	B	Sensitivity/Response	27803005	accepted
RET	RET FUSIONS	Lung Non-small Cell Carcinoma	Vandetanib		Predictive	Supports	B	Sensitivity/Response	27825616	accepted
RET	RET FUSIONS	Lung Non-small Cell Carcinoma	Alectinib		Predictive	Supports	B	Sensitivity/Response	27544060	accepted
CD274	EXPRESSION	Lung Non-small Cell Carcinoma	Durvalumab,Atezolizumab,Avelumab,Pembrolizumab,Nivolumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	28472902	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Alectinib,Crizotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	28586279	accepted
EGFR	EXON 19 DELETION	Lung Non-small Cell Carcinoma	Dacomitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	26768165	accepted
EGFR	L858R	Lung Non-small Cell Carcinoma	Dacomitinib		Predictive	Supports	B	Sensitivity/Response	26768165	accepted
FGFR3	FGFR3 FUSIONS	Adrenal Carcinoma	Erdafitinib		Predictive	Supports	C	Sensitivity/Response	26324363	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Pemetrexed,Docetaxel,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	27876675	accepted
KRAS	MUTATION	Lung Non-small Cell Carcinoma	Atezolizumab,Nivolumab	Substitutes	Predictive	Supports	B	Sensitivity/Response	28525386	accepted
KRAS	MUTATION	Colorectal Cancer	Binimetinib,Palbociclib	Combination	Predictive	Supports	D	Sensitivity/Response	27167191	accepted
CDK4	EXPRESSION	Sarcoma	Palbociclib		Predictive	Supports	D	Sensitivity/Response	26528855	accepted
CHEK1	OVEREXPRESSION	Lung Small Cell Carcinoma	Prexasertib,Cisplatin,Olaparib	Combination	Predictive	Supports	D	Sensitivity/Response	28490518	accepted
BRCA2	LOSS-OF-FUNCTION	Ovarian Cancer	Talazoparib		Predictive	Supports	B	Sensitivity/Response	28242752	accepted
BRCA1	LOSS-OF-FUNCTION	Ovarian Cancer	Talazoparib		Predictive	Supports	B	Sensitivity/Response	28242752	accepted
EGFR	EXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	12748244	accepted
TP53	R248W	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	R175H	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	R273C	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	R273H	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	G245S	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	Y220C	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	M237I	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	R158H	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	V157F	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	R249S	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	R280K	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	R280T	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
TP53	R158L	Cancer	AMGMDS3		Predictive	Supports	D	Resistance	25730903	accepted
BRAF	L597Q	Skin Melanoma	Trametinib		Predictive	Supports	C	Sensitivity/Response	24933606	accepted
EGFR	Gain-of-function	Lung Non-small Cell Carcinoma	Gefitinib		Predictive	Supports	B	Sensitivity/Response	15118073	accepted
GNAQ	MUTATION	Uveal Melanoma	Cabozantinib		Predictive	Supports	B	Sensitivity/Response	28103611	accepted
IDH2	MUTATION	Acute Myeloid Leukemia	Enasidenib		Predictive	Supports	B	Sensitivity/Response	28588020	accepted
ATM	UNDEREXPRESSION	Stomach Cancer	Olaparib,Paclitaxel	Combination	Predictive	Supports	B		26282658	accepted
FLT3	MUTATION	Acute Myeloid Leukemia	Midostaurin		Predictive	Supports	A	Sensitivity/Response	28546144	accepted
VHL	MUTATION	Renal Cell Carcinoma	Everolimus		Predictive	Supports	B	Sensitivity/Response	26951309	accepted
ERBB2	MUTATION	Breast Cancer	Neratinib		Predictive	Supports	B	Sensitivity/Response	28679771	accepted
BAP1	MUTATION	Renal Cell Carcinoma	Everolimus,Sunitinib	Sequential	Predictive	Supports	B	Resistance	27751729	accepted
NRAS	MUTATION	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	A	Resistance	28275037	accepted
KRAS	MUTATION	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	A	Resistance	28275037	accepted
PDGFRA	D842V	Cancer	Imatinib Mesylate		Predictive	Supports	D	Resistance	18955458	accepted
KIT	V560D	Cancer	Imatinib Mesylate		Predictive	Supports	D	Sensitivity/Response	18955458	accepted
MYC	OVEREXPRESSION	Multiple Myeloma	JQ-1		Predictive	Supports	D	Sensitivity/Response	21889194	accepted
RRM1	UNDEREXPRESSION	Pancreatic Cancer	Gemcitabine		Predictive	Supports	B	Sensitivity/Response	19543324	accepted
RRM1	UNDEREXPRESSION	Pancreatic Cancer	Gemcitabine		Predictive	Supports	B	Sensitivity/Response	17131328	accepted
RRM1	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Docetaxel,Gemcitabine,Vinorelbine	Substitutes	Predictive	Supports	B	Sensitivity/Response	24647522	accepted
RRM1	UNDEREXPRESSION	Lung Non-small Cell Carcinoma	Vinorelbine,Gemcitabine,Paclitaxel	Substitutes	Predictive	Supports	B	Sensitivity/Response	23038758	accepted
CD274	EXPRESSION	Lung Non-small Cell Carcinoma	Pembrolizumab		Predictive	Supports	B	Sensitivity/Response	25891174	accepted
BRCA1	LOSS-OF-FUNCTION	Her2-receptor Negative Breast Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	28578601	accepted
BRCA2	LOSS-OF-FUNCTION	Her2-receptor Negative Breast Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	28578601	accepted
RAD50	L1237F	Ureter Small Cell Carcinoma	Checkpoint Kinase Inhibitor AZD7762,Irinotecan	Combination	Predictive	Supports	C	Sensitivity/Response	24934408	accepted
BRCA1	MUTATION	Breast Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	28792849	accepted
BRCA2	MUTATION	Breast Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	28792849	accepted
NRG1	ATP1B1-NRG1	Cholangiocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	28950338	accepted
NRG1	SDC4-NRG1	Lung Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	28950338	accepted
BRAF	V600E	Cholangiocarcinoma	Trametinib Dimethyl Sulfoxide,Dabrafenib	Combination	Predictive	Supports	C	Sensitivity/Response	28480077	accepted
BRAF	V600E	Cholangiocarcinoma	Trametinib Dimethyl Sulfoxide,Dabrafenib	Combination	Predictive	Supports	C	Sensitivity/Response	28078132	accepted
BRAF	V600E	Cholangiocarcinoma	Dabrafenib,Trametinib Dimethyl Sulfoxide	Combination	Predictive	Supports	C	Sensitivity/Response	25435907	accepted
BRAF	V600	Cholangiocarcinoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	26287849	accepted
BRAF	V600E	Cholangiocarcinoma	Vemurafenib,Panitumumab,Irinotecan	Combination	Predictive	Supports	C	Sensitivity/Response	26687137	accepted
FGFR2	FGFR2 fusions	Cholangiocarcinoma	Infigratinib		Predictive	Supports	B	Sensitivity/Response	29182496	accepted
EGFR	EGFR-RAD51	Lung Adenocarcinoma	Erlotinib		Predictive	Supports	C	Sensitivity/Response	29290255	accepted
FGFR2	FGFR2 mutations	Cholangiocarcinoma	Infigratinib		Predictive	Supports	B	Sensitivity/Response	29182496	accepted
BRCA2	MUTATION	Pancreatic Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	25366685	accepted
BRCA1	MUTATION	Pancreatic Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	25366685	accepted
BRCA1	MUTATION	Pancreatic Cancer	Oxaliplatin,Cisplatin	Substitutes	Predictive	Supports	B	Sensitivity/Response	25072261	accepted
BRCA2	MUTATION	Pancreatic Cancer	Platinum Compound		Predictive	Supports	B	Sensitivity/Response	25072261	accepted
EGFR	MUTATION	Peritoneal Mesothelioma	Cytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy	Combination	Predictive	Supports	B	Sensitivity/Response	20942962	accepted
EGFR	COPY NUMBER VARIATION	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	20826716	accepted
EGFR	COPY NUMBER VARIATION	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Substitutes	Predictive	Supports	B	Sensitivity/Response	27664271	accepted
BAP1	ALTERNATIVE TRANSCRIPT (ATI)	Malignant Mesothelioma	Apitolisib,Olaparib	Combination	Predictive	Supports	D	Sensitivity/Response	28389374	accepted
BRCA1	MUTATION	Pancreatic Cancer	Veliparib,Cisplatin,Gemcitabine	Combination	Predictive	Supports	B	Sensitivity/Response	29338080	accepted
BRCA2	MUTATION	Pancreatic Cancer	Gemcitabine,Cisplatin,Veliparib	Combination	Predictive	Supports	B	Sensitivity/Response	29338080	accepted
BRCA2	MUTATION	Pancreatic Cancer	Iniparib		Predictive	Supports	C	Sensitivity/Response	21508395	accepted
ALK	STRN-ALK	Colon Adenocarcinoma	Ceritinib		Predictive	Supports	C	Sensitivity/Response	26933125	accepted
ALK	ALK FUSIONS	Anaplastic Thyroid Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	24687827	accepted
BRAF	V600E	Lung Non-small Cell Carcinoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	29320312	accepted
BRAF	V600E	Ovarian Cancer	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	29320312	accepted
BRAF	V600E	Colorectal Cancer	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	29320312	accepted
BRAF	V600E	Anaplastic Thyroid Carcinoma	Pertuzumab,Vemurafenib	Combination	Predictive	Supports	C	Sensitivity/Response	29320312	accepted
BRAF	V600E	Laryngeal Squamous Cell Carcinoma	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	29320312	accepted
BRAF	CUX1-BRAF	Pancreatic Cancer	Vemurafenib		Predictive	Supports	C	Sensitivity/Response	29320312	accepted
PTCH1	MUTATION	Cancer	Vismodegib		Predictive	Supports	B	Sensitivity/Response	29320312	accepted
ERBB2	MUTATION	Lung Non-small Cell Carcinoma	Pertuzumab,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	29320312	accepted
ERBB2	AMPLIFICATION	Colorectal Cancer	Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	29320312	accepted
ERBB2	AMPLIFICATION	Bladder Carcinoma	Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	29320312	accepted
ERBB2	AMPLIFICATION	Biliary Tract Cancer	Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	29320312	accepted
ERBB2	AMPLIFICATION	Salivary Gland Carcinoma	Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	29320312	accepted
ERBB2	AMPLIFICATION	Pancreatic Cancer	Trastuzumab,Pertuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	29320312	accepted
ASS1	LOSS	Sarcoma	Pegargiminase,Chloroquine	Combination	Predictive	Supports	D	Sensitivity/Response	27735949	accepted
ASS1	LOSS	Ovarian Cancer	Platinum Compound		Predictive	Supports	D	Resistance	19533750	accepted
RASA1	LOSS-OF-FUNCTION	Lung Non-small Cell Carcinoma	Trametinib		Predictive	Supports	D	Sensitivity/Response	29127119	accepted
TLK2	AMPLIFICATION	Breast Cancer	Go6983,GF109203X	Substitutes	Predictive	Supports	D	Sensitivity/Response	27694828	accepted
BRAF	D594G	Skin Melanoma	Sorafenib		Predictive	Supports	D	Sensitivity/Response	18794803	accepted
BRAF	D594G	Skin Melanoma	U0126		Predictive	Supports	D	Resistance	18794803	accepted
BRAF	G469E	Skin Melanoma	Sorafenib		Predictive	Supports	D	Sensitivity/Response	18794803	accepted
BRAF	G469E	Skin Melanoma	U0126		Predictive	Supports	D		18794803	accepted
ALK	ALK FUSIONS	Vagina Sarcoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26942346	accepted
ALK	ALK FUSIONS	Epithelioid Inflammatory Myofibroblastic Sarcoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25028698	accepted
BRAF	V600	Melanoma	Cobimetinib,Vemurafenib	Combination	Predictive	Supports	A	Sensitivity/Response	27480103	accepted
BRAF	V600E	Anaplastic Thyroid Carcinoma	Vemurafenib		Predictive	Supports	B	Sensitivity/Response	26287849	accepted
BRAF	V600	Colorectal Cancer	Cetuximab,Encorafenib	Combination	Predictive	Supports	B	Sensitivity/Response	28363909	accepted
BRAF	V600	Colorectal Cancer	Encorafenib,Cetuximab,Alpelisib	Combination	Predictive	Supports	B	Sensitivity/Response	28363909	accepted
BRCA1	LOSS-OF-FUNCTION	Pancreatic Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	25366685	accepted
BRCA2	LOSS-OF-FUNCTION	Pancreatic Cancer	Olaparib		Predictive	Supports	B	Sensitivity/Response	25366685	accepted
NTRK2	STRN-NTRK2	Sarcoma	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	29606586	accepted
NTRK3	ETV6-NTRK3	Pediatric Fibrosarcoma	Larotrectinib		Predictive	Supports	B	Sensitivity/Response	29606586	accepted
NTRK1	LMNA-NTRK1	Sarcoma	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	29606586	accepted
NTRK1	TMP3-NTRK1	Sarcoma	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	29606586	accepted
NTRK1	PDE4DIP-NTRK1	Sarcoma	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	29606586	accepted
NTRK1	SQSTM1-NTRK1	Pediatric Fibrosarcoma	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	29606586	accepted
BRAF	V600E	Colorectal Cancer	Dabrafenib,Panitumumab,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	29431699	accepted
ERBB2	OVEREXPRESSION	Salivary Gland Cancer	Paclitaxel,Trastuzumab	Combination	Predictive	Supports	C	Sensitivity/Response	23826550	accepted
ERBB2	OVEREXPRESSION	Salivary Gland Cancer	Capecitabine,Trastuzumab,Zoledronic Acid	Combination	Predictive	Supports	C	Sensitivity/Response	20504363	accepted
BRAF	V600E	Melanoma	Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	28891408	accepted
BRAF	V600K	Melanoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	28891408	accepted
BRAF	V600	Melanoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	28891408	accepted
ABL1	BCR-ABL T315A	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib Mesylate,Dasatinib	Combination	Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate,Dasatinib	Combination	Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Nilotinib,Dasatinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL Y253H	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	C	Resistance	19652056	accepted
ABL1	BCR-ABL F317V	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL L248R	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL V299L	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL F317I	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL F317S	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL Q252H	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	15705718	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	C	Resistance	19652056	accepted
ABL1	BCR-ABL F359C	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	C	Resistance	19652056	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib Mesylate,Dasatinib	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Dasatinib,Nilotinib	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL L248V	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL F311L	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL F359C	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL H396P	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL V299L	Chronic Myeloid Leukemia	Dasatinib,Imatinib Mesylate	Combination	Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL L248R	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL Q252H	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL D276G	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL V299L	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL F317C	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL F317I	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL F317V	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL E355G	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL V379I	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL H396R	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
AKT1	Q79K	Melanoma	Dabrafenib		Predictive	Supports	C	Resistance	24265155	accepted
AKT3	OVEREXPRESSION	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
BRAF	V600E/K and AMPLIFICATION	Melanoma	Dabrafenib,Vemurafenib	Substitutes	Predictive	Supports	B	Resistance	24265155	accepted
NRAS	MUTATION	Melanoma	Dabrafenib,Vemurafenib	Substitutes	Predictive	Supports	B	Resistance	24265155	accepted
KRAS	MUTATION	Melanoma	Vemurafenib,Dabrafenib	Substitutes	Predictive	Supports	B	Resistance	24265155	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Nilotinib		Predictive	Supports	D	Resistance	16772610	accepted
PREX2	R172I	Melanoma	Vemurafenib		Predictive	Supports	C	Resistance	24265155	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	16772610	accepted
PTEN	LOSS	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
NRG1	NRG1 FUSIONS	Pancreatic Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	29802158	accepted
ABL1	BCR-ABL Q252H	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	D	Resistance	16772610	accepted
PIK3CA	AMPLIFICATION	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	D	Resistance	16772610	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Nilotinib,Dasatinib,Imatinib Mesylate	Substitutes	Predictive	Supports	D	Resistance	16772610	accepted
KRAS	G12/G13	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	19603024	accepted
PIK3CA	MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	19603024	accepted
BRAF	MUTATION	Colorectal Cancer	Oxaliplatin		Predictive	Supports	B	Resistance	19603024	accepted
BRAF	MUTATION	Colorectal Cancer	Irinotecan		Predictive	Supports	B	Resistance	19603024	accepted
BRAF	MUTATION	Colorectal Cancer	Bevacizumab		Predictive	Supports	B	Resistance	19603024	accepted
BRAF	MUTATION	Colorectal Cancer	Cetuximab		Predictive	Supports	B	Resistance	19603024	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	B	Resistance	19779040	accepted
KRAS	G13V	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	19223544	accepted
KRAS	G12S	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	C	Resistance	19223544	accepted
PTEN	LOSS	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	B	Resistance	19223544	accepted
KRAS	G12D	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	19223544	accepted
KRAS	AMPLIFICATION	Melanoma	Vemurafenib		Predictive	Supports	D	Resistance	24265155	accepted
KRAS	G12A	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	19223544	accepted
KRAS	G13D	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	19223544	accepted
KRAS	G12V	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	C	Resistance	19223544	accepted
PIK3CA	MUTATION	Colorectal Cancer	Cetuximab,Panitumumab	Substitutes	Predictive	Supports	B	Resistance	19223544	accepted
KRAS	G12/G13	Colorectal Cancer	Panitumumab,Cetuximab	Substitutes	Predictive	Supports	B	Resistance	19223544	accepted
PIK3CA	MUTATION	Colorectal Cancer	Aspirin		Predictive	Supports	B	Sensitivity/Response	23094721	accepted
ABL1	R351W	Lung Non-small Cell Carcinoma	Imatinib		Predictive	Supports	D	Sensitivity/Response	26758680	accepted
KIT	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	Regorafenib		Predictive	Supports	B	Sensitivity/Response	27371698	accepted
CSF3R	T618I	Chronic Neutrophilic Leukemia	Ruxolitinib		Predictive	Supports	D	Sensitivity/Response	24081659	accepted
CSF3R	T618I	Chronic Neutrophilic Leukemia	Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	25180155	accepted
NTRK1	NTRK1-TRIM63	Melanoma	Larotrectinib		Predictive	Supports	E	Sensitivity/Response	29683819	accepted
NTRK1	NTRK1-DDR2	Melanoma	Larotrectinib		Predictive	Supports	E	Sensitivity/Response	29683819	accepted
NTRK1	NTRK1-GON4L	Melanoma	Larotrectinib		Predictive	Supports	E	Sensitivity/Response	29683819	accepted
NTRK2	ETV6-NTRK2	Acute Myeloid Leukemia	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	29920189	accepted
BRAF	intron 10 rearrangement	Melanoma	Vemurafenib,Dabrafenib	Substitutes	Predictive	Supports	B	Resistance	24265155	accepted
BRAF	intron 9 rearrangement	Melanoma	Dabrafenib,Vemurafenib	Substitutes	Predictive	Supports	B	Resistance	24265155	accepted
BRAF	D594K	Colorectal Cancer	Irinotecan		Predictive	Supports	B	Resistance	19603024	accepted
BRAF	D594K	Colorectal Cancer	Oxaliplatin		Predictive	Supports	B	Resistance	19603024	accepted
FGFR3	FGFR3-TACC3	Urothelial Carcinoma	Infigratinib		Predictive	Supports	B	Sensitivity/Response	29848605	accepted
IDH1	R132	Intrahepatic Cholangiocarcinoma	Dasatinib		Predictive	Supports	D	Sensitivity/Response	27231123	accepted
STK11	MUTATION	Lung Adenocarcinoma	Pembrolizumab,Nivolumab,Atezolizumab	Substitutes	Predictive	Supports	B	Resistance	29773717	accepted
NTRK3	ETV6-NTRK3	Congenital Fibrosarcoma	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	27093299	accepted
NTRK3	ETV6-NTRK3	Breast Secretory Carcinoma	Larotrectinib	Substitutes	Predictive	Supports	C	Sensitivity/Response	29623306	accepted
NTRK1	NTRK1 FUSIONS	Cancer	Larotrectinib		Predictive	Supports	B	Sensitivity/Response	29466156	accepted
NTRK3	NTRK3 FUSIONS	Cancer	Larotrectinib		Predictive	Supports	B	Sensitivity/Response	29466156	accepted
NTRK1	NTRK1 FUSIONS	Cancer	Larotrectinib		Predictive	Supports	B	Sensitivity/Response	29606586	accepted
NTRK3	ETV6-NTRK3	Pediatric B-lymphoblastic Leukemia	Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate,Larotrectinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	29880614	accepted
BRAF	V600	Melanoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	25265492	accepted
BRAF	V600E	Melanoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	25265492	accepted
BRAF	V600E	Melanoma	Dabrafenib,Trametinib	Combination	Predictive	Supports	B	Sensitivity/Response	23020132	accepted
BRAF	V600K	Melanoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	25265494	accepted
BRAF	V600	Melanoma	Vemurafenib,Cobimetinib	Combination	Predictive	Supports	B	Sensitivity/Response	25037139	accepted
ABL1	ETV6-ABL1	Precursor B Lymphoblastic Lymphoma/leukemia	Dasatinib		Predictive	Supports	C	Sensitivity/Response	25207766	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate,Nilotinib	Substitutes	Predictive	Supports	C	Resistance	19652056	accepted
ABL1	BCR-ABL E255V	Chronic Myeloid Leukemia	Nilotinib,Imatinib Mesylate	Substitutes	Predictive	Supports	C	Resistance	19652056	accepted
BRAF	V600E	Anaplastic Thyroid Carcinoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Sensitivity/Response	29072975	accepted
PDGFRB	EBF1-PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	24186319	accepted
ABL1	C475V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL N336S	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL E453A	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL L387F	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL V299L	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	B	Resistance	22371878	accepted
ABL1	BCR-ABL Q300R	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL F359I	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL F359C	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL E255V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL F486S	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL H396R	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	22371878	accepted
PARP1	OVEREXPRESSION	Malignant Peripheral Nerve Sheath Tumor	Olaparib		Predictive	Supports	D	Sensitivity/Response	26650448	accepted
BRD4	BRD4-NUTM1	NUT Midline Carcinoma	Birabresib		Predictive	Supports	C	Sensitivity/Response	26976114	accepted
PDGFRA	FIP1L1-PDGFRA T674I	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib		Predictive	Supports	C	Resistance	21818111	accepted
JAK2	JAK2 F694L	Pediatric B-cell Acute Lymphoblastic Leukemia	Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	27860260	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Erlotinib		Predictive	Supports	B	Sensitivity/Response	21783417	accepted
PDGFRB	EBF1-PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	26872634	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Dasatinib		Predictive	Supports	C	Reduced Sensitivity	17264298	accepted
ABL1	BCR-ABL V379I	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL A397P	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL F359C	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL E355G	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL E255K	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	B	Resistance	17264298	accepted
ABL1	BCR-ABL G250E	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	B	Resistance	17264298	accepted
ABL1	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL L248V	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL F317L	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
ABL1	BCR-ABL E459K	Chronic Myeloid Leukemia	Imatinib Mesylate		Predictive	Supports	C	Resistance	17264298	accepted
PDGFRB	EBF1-PDGFRB	Pediatric B-lymphoblastic Leukemia	Dasatinib,Imatinib	Substitutes	Predictive	Supports	C	Sensitivity/Response	25207766	accepted
ABL1	SNX2-ABL1	Pediatric B-cell Acute Lymphoblastic Leukemia	Dasatinib		Predictive	Supports	C	Resistance	24215620	accepted
FGFR1	AMPLIFICATION	Breast Cancer	Pazopanib		Predictive	Supports	C	Sensitivity/Response	29223982	accepted
ABL1	ABL1-RCSD	Pediatric B-cell Acute Lymphoblastic Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	25207766	accepted
ABL1	ABL1-RCSD1	Pediatric B-cell Acute Lymphoblastic Leukemia	Dasatinib		Predictive	Supports	D	Sensitivity/Response	25207766	accepted
ABL2	ABL2 fusions	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	Dasatinib		Predictive	Supports	D	Sensitivity/Response	25207766	accepted
JAK2	SSBP2-JAK2	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	25207766	accepted
MET	EXON 14 SKIPPING MUTATION	Lung Non-small Cell Carcinoma	Tepotinib		Predictive	Supports	B	Sensitivity/Response	160289	accepted
IDH1	MUTATION	Acute Myeloid Leukemia	Ivosidenib		Predictive	Supports	A	Sensitivity/Response	29860938	accepted
FLT3	MUTATION	Acute Myeloid Leukemia	Gilteritinib		Predictive	Supports	B	Sensitivity/Response	28645776	accepted
ALK	ALK FUSIONS	Lung Non-small Cell Carcinoma	Lorlatinib		Predictive	Supports	B	Sensitivity/Response	30413378	accepted
BRAF	V600	Melanoma	Binimetinib,Encorafenib	Combination	Predictive	Supports	A	Sensitivity/Response	29573941	accepted
KIT	V555_V559DEL	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	C	Resistance	18955458	accepted
ABL1	FOXP1-ABL1	Pediatric B-lymphoblastic Leukemia	Dasatinib		Predictive	Supports	C	Sensitivity/Response	30938769	accepted
ERBB2	AMPLIFICATION	Colorectal Cancer	Pertuzumab,Trastuzumab	Combination	Predictive	Supports	B	Sensitivity/Response	30857956	accepted
PIK3CA	MUTATION	Breast Cancer	Alpelisib,Fulvestrant	Combination	Predictive	Supports	A	Sensitivity/Response	31091374	accepted
EGFR	EGFR-RAD51	Lung Adenocarcinoma	Icotinib		Predictive	Supports	C	Sensitivity/Response	31064887	accepted
PIK3CA	E542K	Breast Cancer	Fulvestrant,Alpelisib	Combination	Predictive	Supports	A	Sensitivity/Response	31091374	accepted
BRAF	V600	Colorectal Cancer	Irinotecan,Vemurafenib,Cetuximab	Combination	Predictive	Supports	B	Sensitivity/Response	147167	accepted
EGFR	MUTATION	Lung Non-small Cell Carcinoma	Dacomitinib		Predictive	Supports	B	Sensitivity/Response	28958502	accepted
FLT3	ITD	Acute Myeloid Leukemia	Ponatinib		Predictive	Supports	D	Sensitivity/Response	21482694	accepted
PDGFRA	FIP1L1-PDGFRA	Acute Myeloid Leukemia	Sorafenib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	21482694	accepted
KIT	N822K	Acute Myeloid Leukemia	Ponatinib		Predictive	Supports	D	Sensitivity/Response	21482694	accepted
FGFR1	FGFR1OP2-FGFR1	Acute Myeloid Leukemia	Ponatinib		Predictive	Supports	D	Sensitivity/Response	21482694	accepted
FLT3	ITD	Leukemia	Sunitinib,Sorafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	21482694	accepted
KIT	A502_Y503insAY	Gastrointestinal Stromal Tumor	Sunitinib		Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	V560G	Gastrointestinal Stromal Tumor	Ponatinib,Imatinib,Regorafenib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	K642E	Gastrointestinal Stromal Tumor	Ponatinib,Sunitinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25239608	accepted
KIT	N822K	Gastrointestinal Stromal Tumor	Imatinib,Sunitinib	Substitutes	Predictive	Supports	D	Resistance	25239608	accepted
KIT	A829P	Gastrointestinal Stromal Tumor	Imatinib,Sunitinib	Substitutes	Predictive	Supports	D	Resistance	25239608	accepted
KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib		Predictive	Supports	D	Resistance	25239608	accepted
FGFR3	MUTATION	Urothelial Carcinoma	Erdafitinib		Predictive	Supports	A	Sensitivity/Response	31340094	accepted
TP53	R273H	Osteosarcoma	Doxorubicin,Methotrexate	Substitutes	Predictive	Supports	D	Resistance	17363498	accepted
NFE2L2	MUTATION	Lung Squamous Cell Carcinoma	Sapanisertib		Predictive	Supports	B	Sensitivity/Response	174406	accepted
IDH1	MUTATION	Cholangiocarcinoma	Ivosidenib		Predictive	Supports	B	Sensitivity/Response	31300360	accepted
KIT	D816V	Cancer	Dasatinib,Imatinib	Substitutes	Predictive	Supports	C	Resistance	25317746	accepted
RET	CCDC6-RET	Colorectal Cancer	Agerafenib		Predictive	Supports	C	Sensitivity/Response	29538669	accepted
ALK	CAD-ALK	Colorectal Cancer	Entrectinib		Predictive	Supports	C	Sensitivity/Response	26633560	accepted
ROS1	GOPC-ROS1	Glioblastoma Multiforme	Lorlatinib		Predictive	Supports	D	Sensitivity/Response	30171048	accepted
NRG1	ATP1B1-NRG1	Pancreatic Ductal Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	31068372	accepted
NRG1	APP-NRG1	Pancreatic Ductal Adenocarcinoma	Afatinib		Predictive	Supports	C	Sensitivity/Response	31068372	accepted
NTRK3	ETV6-NTRK3	Cancer	Larotrectinib		Predictive	Supports	B	Sensitivity/Response	30624546	accepted
MET	R1004G	Head And Neck Cancer	Crizotinib		Predictive	Supports	C	Sensitivity/Response	31391294	accepted
BRAF	G466V	Colorectal Cancer	Panitumumab,Irinotecan	Combination	Predictive	Supports	D	Sensitivity/Response	28783719	accepted
FGFR3	Mutations	Urinary Bladder Cancer	Gemcitabine,Cisplatin	Combination	Predictive	Supports	B	Sensitivity/Response	29941343	accepted
H3-3A	K27M	Glioma	Akt/ERK Inhibitor ONC201		Predictive	Supports	B	Sensitivity/Response	172409	accepted
BRAF	V600D	Melanoma	BRAF Inhibitor		Predictive	Supports	B	Sensitivity/Response	31580757	accepted
BRAF	V600D	Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor	Combination	Predictive	Supports	B	Sensitivity/Response	31580757	accepted
BRAF	V600_K601>E	Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor	Combination	Predictive	Supports	B	Sensitivity/Response	31580757	accepted
BRAF	G469	Melanoma	Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor	Combination	Predictive	Supports	B	Sensitivity/Response	31580757	accepted
FGF19	EXPRESSION	Hepatocellular Carcinoma	Fisogatinib		Predictive	Supports	B	Sensitivity/Response	31575541	accepted
ERBB2	AMPLIFICATION	Cholangiocarcinoma	Trastuzumab,Pertuzumab	Combination	Predictive	Supports	C	Sensitivity/Response	31453370	accepted
MET	EXON 14 SKIPPING MUTATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	B	Sensitivity/Response	123413	accepted
MET	EXON 14 SKIPPING MUTATION	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	C	Sensitivity/Response	26892698	accepted
ERBB2	AMPLIFICATION	Stomach Cancer	Trastuzumab Deruxtecan		Predictive	Supports	B	Sensitivity/Response	31047804	accepted
ABL1	SNX2-ABL1	Pediatric B-cell Acute Lymphoblastic Leukemia	Dasatinib,Imatinib		Predictive	Supports	D	Resistance	24367893	accepted
BRAF	AMPLIFICATION	Melanoma	Trametinib,Dabrafenib	Combination	Predictive	Supports	B	Resistance	25452114	accepted
RET	M918T	Thyroid Gland Medullary Carcinoma	Cabozantinib		Predictive	Supports	B	Sensitivity/Response	27525386	accepted
BRCA2	K3226*	Glioblastoma Multiforme	Olaparib,Temozolomide	Combination	Predictive	Supports	C	Sensitivity/Response	31619547	accepted
BRAF	N486_P490del	Pancreatic Cancer	Trametinib		Predictive	Supports	C	Sensitivity/Response	29903880	accepted
BRAF	D594G	Cancer	Trametinib		Predictive	Supports	D	Sensitivity/Response	28783719	accepted
BRAF	NRF1-BRAF	Urothelial Carcinoma	Trametinib		Predictive	Supports	C	Sensitivity/Response	31010895	accepted
ABL1	BCR-ABL T315V	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Sensitivity/Response	25686603	accepted
ABL1	BCR-ABL V299L	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Sensitivity/Response	25686603	accepted
ABL1	BCR-ABL T315A	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Sensitivity/Response	25686603	accepted
ABL1	BCR-ABL E279K	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Sensitivity/Response	25686603	accepted
ABL1	BCR-ABL F317R	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL L248R F359I	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL L248R	Chronic Myeloid Leukemia	Axitinib		Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL T315I	Acute Lymphoblastic Leukemia	Imatinib,Nilotinib,Dasatinib	Substitutes	Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL T315I	Chronic Myeloid Leukemia	Nilotinib,Dasatinib,Imatinib	Substitutes	Predictive	Supports	D	Resistance	25686603	accepted
ABL1	BCR-ABL E255K V299L	Chronic Myeloid Leukemia	Dasatinib,Ponatinib	Substitutes	Predictive	Supports	D	Sensitivity/Response	25686603	accepted
ABL1	ABL1-RCSD1	Pediatric B-lymphoblastic Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	27125982	accepted
DPYD	EXON 11-19 DELETION	Head And Neck Squamous Cell Carcinoma	Leucovorin,Fluorouracil	Combination	Predictive	Supports	C	Sensitivity/Response	31871216	accepted
MET	EXON 14 SKIPPING MUTATION	Histiocytic And Dendritic Cell Cancer	Crizotinib		Predictive	Supports	C	Sensitivity/Response	25971938	accepted
MET	EXON 14 SKIPPING MUTATION	Cancer	Capmatinib		Predictive	Supports	D	Sensitivity/Response	25971938	accepted
CDK4	EXPRESSION	Childhood B-cell Acute Lymphoblastic Leukemia	Ribociclib,Dexamethasone	Combination	Predictive	Supports	D	Sensitivity/Response	29408328	accepted
CDK6	OVEREXPRESSION	Glioblastoma Proneural Subtype	Palbociclib		Predictive	Supports	D	Sensitivity/Response	28903422	accepted
CDK6	EXPRESSION	Childhood B-cell Acute Lymphoblastic Leukemia	Ribociclib,Dexamethasone	Combination	Predictive	Supports	D	Sensitivity/Response	29408328	accepted
FGFR1	AMPLIFICATION	Adenosquamous Cell Lung Carcinoma	Pazopanib		Predictive	Supports	C	Sensitivity/Response	24302556	accepted
NT5C2	R367Q	Childhood Acute Lymphocytic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	C	Resistance	23377183	accepted
NT5C2	R238W	Childhood Acute Lymphocytic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	23377183	accepted
NT5C2	S445F	Childhood Acute Lymphocytic Leukemia	Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	23377183	accepted
ABL1	BCR-ABL D363G	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	16775234	accepted
ABL1	BCR-ABL E98G	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	16775234	accepted
ABL1	BCR-ABL M244V	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	16775234	accepted
NT5C2	R367Q	Childhood Acute Lymphocytic Leukemia	Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	23377183	accepted
PRPS1	T303S	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	L191F	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	D183E	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	K176N	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	N144S	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	S103I	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Thioguanine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	S103N	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	S103T	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	A190T	Childhood B-cell Acute Lymphoblastic Leukemia	Thioguanine,Mercaptopurine	Substitutes	Predictive	Supports	D	Resistance	25962120	accepted
PRPS1	N144S	Childhood B-cell Acute Lymphoblastic Leukemia	Cytarabine		Predictive	Supports	D	Sensitivity/Response	25962120	accepted
PRPS1	L191F	Childhood B-cell Acute Lymphoblastic Leukemia	Cytarabine		Predictive	Supports	D	Sensitivity/Response	25962120	accepted
PRPS1	A190T	Childhood B-cell Acute Lymphoblastic Leukemia	Mercaptopurine,Lometrexol	Combination	Predictive	Supports	D	Sensitivity/Response	25962120	accepted
ROS1	REARRANGEMENT	Lung Non-small Cell Carcinoma	Crizotinib		Predictive	Supports	A	Sensitivity/Response	29596029	accepted
IL6	OVEREXPRESSION	Rhabdomyosarcoma	Bazedoxifene		Predictive	Supports	D	Resistance	28672024	accepted
PDGFRA	OVEREXPRESSION	Rhabdomyosarcoma	Sunitinib		Predictive	Supports	D	Sensitivity/Response	19366796	accepted
PDGFRA	BCR-PDGFRA	B-cell Acute Lymphoblastic Leukemia	Imatinib		Predictive	Supports	C	Sensitivity/Response	12944919	accepted
PDGFB	COL1A1-PDGFB	Dermatofibrosarcoma Protuberans	Sunitinib		Predictive	Supports	C	Sensitivity/Response	29760553	accepted
PDGFRB	OVEREXPRESSION	Dermatofibrosarcoma Protuberans	Sunitinib		Predictive	Supports	C	Sensitivity/Response	29760553	accepted
NTRK3	ETV6-NTRK3	B-cell Adult Acute Lymphocytic Leukemia	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	31905241	accepted
NTRK3	ETV6-NTRK3	Acute Myeloid Leukemia	Entrectinib		Predictive	Supports	D	Sensitivity/Response	29237803	accepted
PIK3CA	V955I	Colorectal Cancer	Cetuximab		Predictive	Supports	C	Resistance	28424201	accepted
ABL1	Double Ph	Chronic Myeloid Leukemia	Imatinib		Predictive	Supports	C	Resistance	12623848	accepted
FLT3	D835Y	Acute Myeloid Leukemia	Gilteritinib		Predictive	Supports	D	Sensitivity/Response	27908881	accepted
PML	PML-RARA A216V	Acute Promyelocytic Leukemia	Arsenic Trioxide		Predictive	Supports	B	Resistance	26537301	accepted
PIK3CA	H1047R	Colorectal Cancer	Akt Inhibitor MK2206,Vemurafenib	Combination	Predictive	Supports	D	Sensitivity/Response	22180495	accepted
